Johnson & Johnson (JNJ) 10-K18 Feb 202019 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
Cover Page - USD ($) $ in Billions	Dec. 29, 2019	Feb. 10, 2020	Jun. 30, 2019
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 29, 2019
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	JOHNSON & JOHNSON
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Public Float			$ 368
Entity Common Stock, Shares Outstanding		2,634,721,257
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--12-29
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Document Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Document Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Document Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$ 17,305	$ 18,107
Marketable securities (Notes 1 and 2)	1,982	1,580
Accounts receivable trade, less allowances for doubtful accounts $226 (2018, $248)	14,481	14,098
Inventories (Notes 1 and 3)	9,020	8,599
Prepaid expenses and other receivables	2,392	2,699
Assets held for sale (Note 20)	94	950
Total current assets	45,274	46,033
Property, plant and equipment, net (Notes 1 and 4)	17,658	17,035
Intangible assets, net (Notes 1 and 5)	47,643	47,611
Goodwill (Notes 1 and 5)	33,639	30,453
Deferred taxes on income (Note 8)	7,819	7,640
Other assets	5,695	4,182
Total assets	157,728	152,954
Current liabilities:
Loans and notes payable (Note 7)	1,202	2,796
Accounts payable	8,544	7,537
Accrued liabilities	9,715	7,601
Accrued rebates, returns and promotions	10,883	9,380
Accrued compensation and employee related obligations	3,354	3,098
Accrued taxes on income (Note 8)	2,266	818
Total current liabilities	35,964	31,230
Long-term debt (Note 7)	26,494	27,684
Deferred taxes on income (Note 8)	5,958	7,506
Employee related obligations (Notes 9 and 10)	10,663	9,951
Long-term taxes payable (Note 8)	7,444	8,242
Other liabilities	11,734	8,589
Total liabilities	98,257	93,202
Shareholders' equity:
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 13)	(15,891)	(15,222)
Retained earnings	110,659	106,216
Stockholders' Equity before Treasury Stock	97,888	94,114
Less: common stock held in treasury, at cost (Note 12) (487,336,000 shares and 457,519,000 shares)	38,417	34,362
Total shareholders’ equity	59,471	59,752
Total liabilities and shareholders’ equity	$ 157,728	$ 152,954

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Current assets:
Allowances for doubtful accounts	$ 226	$ 248
Shareholders' equity:
Preferred par value	$ 0	$ 0
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares	487,336,000	457,519,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Statement [Abstract]
Sales to customers	$ 82,059	$ 81,581	$ 76,450
Cost of products sold	27,556	27,091	25,439
Gross profit	54,503	54,490	51,011
Selling, marketing and administrative expenses	22,178	22,540	21,520
Research and development expense	11,355	10,775	10,594
In-process research and development (Note 5)	890	1,126	408
Interest income	(357)	(611)	(385)
Interest expense, net of portion capitalized (Note 4)	318	1,005	934
Other (income) expense, net	2,525	1,405	(42)
Restructuring (Note 22)	266	251	309
Earnings before provision for taxes on income	17,328	17,999	17,673
Provision for taxes on income (Note 8)	2,209	2,702	16,373
Net earnings	$ 15,119	$ 15,297	$ 1,300
Net earnings per share (Notes 1 and 15)
Basic (in dollars per share)	$ 5.72	$ 5.70	$ 0.48
Diluted (in dollars per share)	$ 5.63	$ 5.61	$ 0.47
Average shares outstanding (Notes 1 and 15)
Basic (in shares)	2,645.1	2,681.5	2,692
Diluted (in shares)	2,684.3	2,728.7	2,745.3

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net earnings	$ 15,119	$ 15,297	$ 1,300
Other Comprehensive Income (Loss), net of tax
Foreign currency translation	164	(1,518)	1,696
Securities
Unrealized holding gain (loss) arising during period	0	(1)	159
Reclassifications to earnings	0	1	(338)
Net change	0	0	(179)
Employee benefit plans
Prior service credit (cost), net of amortization	(18)	(44)	2
Gain (loss), net of amortization	(714)	(56)	29
Effect of exchange rates	(1)	92	(201)
Net change	(733)	(8)	(170)
Derivatives & hedges
Unrealized gain (loss) arising during period	(107)	(73)	(4)
Reclassifications to earnings	7	(192)	359
Net change	(100)	(265)	355
Other comprehensive income (loss)	(669)	(1,791)	1,702
Comprehensive income	$ 14,450	$ 13,506	$ 3,002

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Foreign currency translation	$ 19	$ 236
Securities	0	0	$ (96)
Employee benefits	(222)	4	(83)
Derivatives & hedges	$ (27)	$ (70)	$ 191

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions		Total	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Jan. 01, 2017		$ 70,418	$ 110,551	$ (14,901)	$ 3,120	$ (28,352)
Net earnings		1,300	1,300
Cash dividends paid		(8,943)	(8,943)
Employee compensation and stock option plans		2,077	(1,079)			3,156
Repurchase of common stock		(6,358)				(6,358)
Other		(36)	(36)
Other comprehensive income (loss), net of tax		1,702		1,702
Ending Balance at Dec. 31, 2017		60,160	101,793	(13,199)	3,120	(31,554)
Cumulative adjustment	[1]	(486)	(254)	(232)
Net earnings		15,297	15,297
Cash dividends paid		(9,494)	(9,494)
Employee compensation and stock option plans		1,949	(1,111)			3,060
Repurchase of common stock		(5,868)				(5,868)
Other		(15)	(15)
Other comprehensive income (loss), net of tax		(1,791)		(1,791)
Ending Balance at Dec. 30, 2018		59,752	106,216	(15,222)	3,120	(34,362)
Net earnings		15,119	15,119
Cash dividends paid		(9,917)	(9,917)
Employee compensation and stock option plans		1,933	(758)			2,691
Repurchase of common stock		(6,746)				(6,746)
Other		(1)	(1)
Other comprehensive income (loss), net of tax		(669)		(669)
Ending Balance at Dec. 29, 2019		$ 59,471	$ 110,659	$ (15,891)	$ 3,120	$ (38,417)

[1]	(1) See Note 1 to Consolidated Financial Statements for additional details on the effect of cumulative adjustments to retained earnings.

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 3.75	$ 3.54	$ 3.32

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Cash flows from operating activities
Net earnings	$ 15,119	$ 15,297	$ 1,300
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	7,009	6,929	5,642
Stock based compensation	977	978	962
Asset write-downs	1,096	1,258	795
Gain on sale of assets/businesses	(2,154)	(1,217)	(1,307)
Deferred tax provision	(2,476)	(1,016)	2,406
Accounts receivable allowances	(20)	(31)	17
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(289)	(1,185)	(633)
(Increase)/Decrease in inventories	(277)	(644)	581
Increase in accounts payable and accrued liabilities	4,060	3,951	2,725
Increase in other current and non-current assets	(1,054)	(275)	(411)
Increase/(Decrease) in other current and non-current liabilities	1,425	(1,844)	8,979
Net cash flows from operating activities	23,416	22,201	21,056
Cash flows from investing activities
Additions to property, plant and equipment	(3,498)	(3,670)	(3,279)
Proceeds from the disposal of assets/businesses, net	3,265	3,203	1,832
Acquisitions, net of cash acquired (Note 20)	(5,810)	(899)	(35,151)
Purchases of investments	(3,920)	(5,626)	(6,153)
Sales of investments	3,387	4,289	28,117
Proceeds from credit support agreements	338	0	0
Other	44	(464)	(234)
Net cash used by investing activities	(6,194)	(3,167)	(14,868)
Cash flows from financing activities
Dividends to shareholders	(9,917)	(9,494)	(8,943)
Repurchase of common stock	(6,746)	(5,868)	(6,358)
Proceeds from short-term debt	39	80	869
Repayment of short-term debt	(100)	(2,479)	(1,330)
Proceeds from long-term debt, net of issuance costs	3	5	8,992
Repayment of long-term debt	(2,823)	(1,555)	(1,777)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	954	949	1,062
Other	575	(148)	(188)
Net cash used by financing activities	(18,015)	(18,510)	(7,673)
Effect of exchange rate changes on cash and cash equivalents	(9)	(241)	337
(Decrease)/Increase in cash and cash equivalents	(802)	283	(1,148)
Cash and cash equivalents, beginning of year (Note 1)	18,107	17,824	18,972
Cash and cash equivalents, end of year (Note 1)	17,305	18,107	17,824
Cash paid during the year for:
Interest	995	1,049	960
Interest, net of amount capitalized	925	963	866
Income taxes	4,191	4,570	3,312
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards	1,736	2,095	2,062
Conversion of debt	1	6	16
Acquisitions
Fair value of assets acquired	7,228	1,047	36,937
Fair value of liabilities assumed and noncontrolling interests	(1,418)	(148)	(1,786)
Net cash paid for acquisitions (Note 20)	$ 5,810	$ 899	$ 35,151

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 29, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Description of the Company and Business Segments The Company has approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. New Accounting Standards Recently Adopted Accounting Standards ASU 2016-02 : Leases The Company adopted this standard as of the beginning of fiscal year 2019, on a prospective basis. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements. The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet. ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. For additional disclosures see Note 16 to the Consolidated Financial Statements. ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings. The Company has elected not to reclassify the income tax effects of this standard and therefore this standard will not impact the Company's consolidated financial statements. ASU 2018-16 : Derivatives and Hedging (Topic ASC 815) This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments. Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned below: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 ) Recently Issued Accounting Standards Not Adopted as of December 29, 2019 ASU 2018-18 : Collaborative Arrangements This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements. ASU 2016-13 : Financial Instruments - Credit Losses This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities. Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.0 billion and $5.8 billion as of December 29, 2019 and December 30, 2018, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal reporting years 2019 , 2018 and 2017 . Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were approximately 2.0% of the total revenues and are included in sales to customers. See Note 18 to the Consolidated Financial Statements for further disaggregation of revenue. Shipping and Handling Shipping and handling costs incurred were $1.0 billion , $1.1 billion and $1.0 billion in 2019 , 2018 and 2017 , respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2019 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S. Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.2 billion , $2.6 billion and $2.5 billion in 2019 , 2018 and 2017 , respectively. Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of the global intangible low-taxed income (GILTI) in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). In fiscal 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.8 billion under current enacted tax laws and regulations and at current currency exchange rates. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes. Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks , and therefore includes additional shipping days, as was the case in 2015, and will be the case again in 2020. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Cash, Cash Equivalents and Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
Cash, Cash Equivalents and Current Marketable Securities	Dec. 29, 2019
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities At the end of the fiscal year 2019 and 2018 , cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2019 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,637 2,637 — Non-U.S. Sovereign Securities (1) 439 149 290 U.S. Reverse repurchase agreements 6,375 6,375 — Other Reverse repurchase agreements 375 375 — Corporate debt securities (1) 1,323 889 434 Money market funds 2,864 2,864 — Time deposits (1) 906 906 — Subtotal $ 14,919 14,195 724 U.S. Gov't Securities $ 4,102 3,095 1,007 Corporate debt securities 266 15 251 Subtotal available for sale (2) $ 4,368 3,110 1,258 Total cash, cash equivalents and current marketable securities $ 17,305 1,982 (Dollars in Millions) 2018 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,619 2,619 — U.S. Reverse repurchase agreements 3,009 3,009 — Other Reverse repurchase agreements 443 443 — Money market funds 3,397 3,397 — Time deposits (1) 485 485 — Subtotal $ 9,953 9,953 — Gov't Securities $ 9,474 8,144 1,330 Corporate debt securities 260 10 250 Subtotal available for sale (2) $ 9,734 8,154 1,580 Total cash, cash equivalents and current marketable securities $ 18,107 1,580 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs. In 2019 and 2018, the carrying amount was the same as the estimated fair value. The contractual maturities of the available for sale debt securities at December 29, 2019 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 4,322 4,322 Due after one year through five years 46 46 Due after five years through ten years — — Total debt securities $ 4,368 4,368 The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 29, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories At the end of 2019 and 2018 , inventories were comprised of: (Dollars in Millions) 2019 2018 Raw materials and supplies $ 1,117 1,114 Goods in process 1,832 2,109 Finished goods 6,071 5,376 Total inventories (1) $ 9,020 8,599 (1) See Note 20 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 29, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment At the end of 2019 and 2018 , property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2019 2018 Land and land improvements $ 854 807 Buildings and building equipment 11,877 11,176 Machinery and equipment 26,964 25,992 Construction in progress 3,637 3,876 Total property, plant and equipment, gross $ 43,332 41,851 Less accumulated depreciation 25,674 24,816 Total property, plant and equipment, net (1) $ 17,658 17,035 (1) See Note 20 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures. The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2019 , 2018 and 2017 was $70 million , $86 million and $94 million , respectively. Depreciation expense, including the amortization of capitalized interest in 2019 , 2018 and 2017 was $2.5 billion , $2.6 billion and $2.6 billion , respectively. Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
Intangible Assets and Goodwill	Dec. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill At the end of 2019 and 2018 , the gross and net amounts of intangible assets were: (Dollars in Millions) 2019 2018 Intangible assets with definite lives: Patents and trademarks — gross $ 36,634 35,194 Less accumulated amortization 13,154 9,784 Patents and trademarks — net $ 23,480 25,410 Customer relationships and other intangibles — gross $ 22,056 21,334 Less accumulated amortization 9,462 8,323 Customer relationships and other intangibles — net* $ 12,594 13,011 Intangible assets with indefinite lives: Trademarks $ 6,922 6,937 Purchased in-process research and development (1) 4,647 2,253 Total intangible assets with indefinite lives $ 11,569 9,190 Total intangible assets — net $ 47,643 47,611 *The majority is comprised of customer relationships (1) In the fiscal year 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion . Additionally, in the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter 2018 related to the development program of AL-8176. Goodwill as of December 29, 2019 and December 30, 2018 , as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Pharmaceutical Medical Devices Total Goodwill at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions 168 51 184 403 Goodwill, related to divestitures — — (1,348 ) (1) (1,348 ) Currency translation/other (373 ) (97 ) (38 ) (508 ) Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,188 75 2,018 3,281 Currency translation/other (122 ) 31 (4 ) (95 ) Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 (1) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business. Goodwill of $0.3 billion is related to the divestiture of the Advanced Sterilization Products business which closed in 2019, and was pending and classified as assets held for sale on the Consolidated Balance Sheet as of December 30, 2018. The weighted average amortization period for patents and trademarks is 12 years . The weighted average amortization period for customer relationships and other intangible assets is 21 years . The amortization expense of amortizable assets included in cost of products sold was $4.5 billion , $4.4 billion and $3.0 billion before tax, for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 , respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000 See Note 20 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December 29, 2019 , the total amount of cash collateral held by the Company under the credit support agreements (CSA) amounted to $255 million net, primarily related to net investment hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December 29, 2019 , the Company had notional amounts outstanding for forward foreign exchange contracts, and cross currency interest rate swaps of $45.3 billion , and $20.1 billion respectively. As of December 30, 2018 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $41.1 billion , $7.3 billion , and $0.5 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. The effect of which are immaterial for the fiscal years ended December 29, 2019 and December 30, 2018 . Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of December 29, 2019 , the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $295 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 29, 2019 and December 30, 2018 , net of tax: December 29, 2019 December 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 159 — — — — 56 — Amount of gain or (loss) recognized in AOCI — — — 159 — — — — 56 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (54 ) (321 ) (105 ) — 22 47 200 (220 ) — (24 ) Amount of gain or (loss) recognized in AOCI (20 ) (606 ) (94 ) — 39 (32 ) (17 ) (193 ) — (4 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 292 — — — — 133 — Amount of gain or (loss) recognized in AOCI $ — — — 415 — — — — 117 — For the fiscal years ended December 29, 2019 and December 30, 2018 , the following amounts were recorded on the Consolidated Balance Sheet Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) December 29, 2019 December 30, 2018 December 29, 2019 December 30, 2018 Current Portion of Long-term Debt $ — 494 — 5 The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended December 29, 2019 and December 30, 2018: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Recognized In Income on Derivative Derivatives Not Designated as Hedging Instruments December 29, 2019 December 30, 2018 Foreign Exchange Contracts Other (income) expense (144 ) (68 ) The following table is the effect of net investment hedges for the fiscal years ended December 29, 2019 and December 30, 2018: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) December 29, 2019 December 30, 2018 December 29, 2019 December 30, 2018 Debt $ 121 218 Interest (income) expense — — Cross Currency interest rate swaps $ 488 150 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments for the fiscal years ended December 29, 2019 and December 30, 2018 : December 30, 2018 December 29, 2019 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 533 104 1,148 1,148 Equity Investments without readily determinable value $ 681 (38 ) 69 712 712 December 31, 2017 December 30, 2018 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (247 ) 7 511 511 Equity Investments without readily determinable value $ 510 13 158 681 681 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For the fiscal years ended December 29, 2019 and December 30, 2018 for equity investments without readily determinable market values, $57 million and $54 million respectively, of the changes in fair value reflected in net income were the result of impairments. There were $19 million and $67 million respectively, of changes in fair value reflected in net income due to changes in observable prices. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended December 29, 2019 and December 30, 2018 were as follows: 2019 2018 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 209 — 209 501 Interest rate contracts (2)(4) — 693 — 693 161 Total — 902 — 902 662 Liabilities: Forward foreign exchange contracts — 426 — 426 548 Interest rate contracts (3)(4) — 193 — 193 292 Total — 619 — 619 840 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 23 — 23 32 Liabilities: Forward foreign exchange contracts — 33 — 33 32 Available For Sale Other Investments: Equity investments (5) 1,148 — — 1,148 511 Debt securities (6) $ — 4,368 — 4,368 9,734 Other Liabilities Contingent Consideration (7) 1,715 1,715 397 Gross to Net Derivative Reconciliation 2019 2018 (Dollars in Millions) Total Gross Assets $ 925 694 Credit Support Agreement (CSA) (841 ) (423 ) Total Net Asset 84 271 Total Gross Liabilities 652 872 Credit Support Agreement (CSA) (586 ) (605 ) Total Net Liabilities $ 66 267 Summarized information about changes in liabilities for contingent consideration is as follows: 2019 2018 2017 (Dollars in Millions) Beginning Balance 397 600 378 Changes in estimated fair value (8) 151 (156 ) 87 Additions 1,246 125 160 Payments (79 ) (172 ) (25 ) Ending Balance 1,715 397 600 (1) 2018 assets and liabilities are all classified as Level 2 with the exception of equity investments of $511 million , which are classified as Level 1 and contingent consideration of $397 million , classified as Level 3. (2) Includes $1 million and $6 million of non-current assets for the fiscal years ending December 29, 2019 and December 30, 2018 , respectively. (3) Includes $3 million of non-current liabilities for the fiscal years ending December 30, 2018 . (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. (6) Classified as cash equivalents and current marketable securities. (7) Includes $1,631 million (primarily related to Auris Health), $397 million and $600 million , classified as non-current other liabilities as of December 29, 2019 , December 30, 2018 and December 31, 2017 respectively. Includes $84 million classified as current liabilities as of December 29, 2019 . (8) Amounts are recorded primarily in Research and Development expense. See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
Borrowings	Dec. 29, 2019
Debt Disclosure [Abstract]
Borrowings	Borrowings The components of long-term debt are as follows: (Dollars in Millions) 2019 Effective Rate % 2018 Effective Rate % 4.75% Notes due 2019 (1B Euro 1.1096) (2) /(1B Euro 1.14) (3) $ — — 1,139 (2) 5.83 1.875% Notes due 2019 — — 494 1.93 0.89% Notes due 2019 — — 300 1.32 1.125% Notes due 2019 — — 699 1.13 3% Zero Coupon Convertible Subordinated Debentures due 2020 51 3.00 51 3.00 2.95% Debentures due 2020 549 3.15 548 3.15 1.950% Notes due 2020 500 1.99 499 1.99 3.55% Notes due 2021 449 3.67 449 3.67 2.45% Notes due 2021 349 2.48 349 2.48 1.65% Notes due 2021 999 1.65 998 1.65 0.250% Notes due 2022 (1B Euro 1.1096) (2) /(1B Euro 1.14) (3) 1,108 (2) 0.26 1,137 (3) 0.26 2.25% Notes due 2022 998 2.31 996 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 804 3.17 805 3.17 2.05% Notes due 2023 498 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.1096) (2) /(750MM Euro 1.14) (3) 829 (2) 0.68 851 (3) 0.68 5.50% Notes due 2024 (500MM GBP 1.2987) (2) /(500MM GBP 1.2636) (3) 645 (2) 6.75 627 (3) 6.75 2.625% Notes due 2025 748 2.63 748 2.63 2.45% Notes due 2026 1,993 2.47 1,992 2.47 2.95% Notes due 2027 996 2.96 996 2.96 1.150% Notes due 2028 (750MM Euro 1.1096) (2) /(750MM Euro 1.14) (3) 825 (2) 1.21 847 (3) 1.21 2.900% Notes due 2028 1,494 2.91 1,493 2.91 6.95% Notes due 2029 297 7.14 297 7.14 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 855 4.24 856 4.24 1.650% Notes due 2035 (1.5B Euro 1.1096) (2) /(1.5B Euro 1.14) (3) 1,649 (2) 1.68 1,693 (3) 1.68 3.55% Notes due 2036 989 3.59 988 3.59 5.95% Notes due 2037 992 5.99 991 5.99 3.625% Notes due 2037 1,487 3.64 1,486 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 991 3.42 990 3.42 4.50% Debentures due 2040 539 4.63 538 4.63 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 495 4.52 495 4.52 3.70% Notes due 2046 1,973 3.74 1,972 3.74 3.75% Notes due 2047 991 3.76 991 3.76 3.500% Notes due 2048 742 3.52 742 3.52 Other 18 — 24 — Subtotal 27,594 (4) 3.19 % (1) 30,320 (4) 3.19 (1 ) Less current portion 1,100 2,636 Total long-term debt $ 26,494 27,684 (1) Weighted average effective rate. (2) Translation rate at December 29, 2019 . (3) Translation rate at December 30, 2018 . (4) The excess of the fair value over the carrying value of debt was $3.0 billion in 2019 and $0.3 billion in 2018 . Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs. The Company has access to substantial sources of funds at numerous banks worldwide. In September 2019 , the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion , which expires on September 10, 2020 . Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate, London Interbank Offered Rates (LIBOR) or other applicable market rate as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material. Throughout 2019, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $1.2 billion at the end of 2019 , of which $1.1 billion is the current portion of the long-term debt, and the remainder principally represents local borrowing by international subsidiaries. Throughout 2018, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $2.8 billion at the end of 2018, of which $2.6 billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. Aggregate maturities of long-term debt obligations commencing in 2020 are: (Dollars in Millions) 2020 2021 2022 2023 2024 After 2024 $1,100 1,797 2,106 1,552 1,474 19,565

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 29, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for taxes on income consists of: (Dollars in Millions) 2019 2018 2017 Currently payable: U.S. taxes $ 1,941 1,284 12,095 International taxes 2,744 2,434 1,872 Total currently payable 4,685 3,718 13,967 Deferred: U.S. taxes (814 ) 1,210 (1) (1,956 ) International taxes (1,662 ) (2,226 ) 4,362 Total deferred (2,476 ) (1,016 ) 2,406 Provision for taxes on income $ 2,209 2,702 16,373 (1) Includes $1.4 billion of deferred tax expense for the adoption of the deferred method to account for GILTI. A comparison of income tax expense at the U.S. statutory rate of 21% in 2019 and 2018 and 35% in 2017 , to the Company’s effective tax rate is as follows: (Dollars in Millions) 2019 2018 2017 U.S. $ 3,543 5,575 4,865 International 13,785 12,424 12,808 Earnings before taxes on income: $ 17,328 17,999 17,673 Tax rates: U.S. statutory rate 21.0 % 21.0 35.0 International operations (1) (5.9 ) (3.7 ) (12.8 ) U.S. taxes on international income (2) 1.8 1.4 0.7 Tax benefits on share-based compensation (0.5 ) (1.5 ) (2.1 ) All other 0.2 (0.3 ) (1.5 ) TCJA and related impacts (3.9 ) (3) (1.9 ) (3) 73.3 (4) Effective Rate 12.7 % 15.0 92.6 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2017 amount also includes tax cost related to the revaluation of deferred tax balances related to the change in the Belgian statutory tax rate increasing the tax provision by approximately 3.4% . (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. (4) Includes U.S. state and local taxes provisionally recorded as part TCJA provisional charge which was approximately 0.6% of the total effective tax rate. The 2019 tax rate decreased by 2.3% compared to the fiscal year 2018 tax rate. In addition to the impact of Swiss tax reform discussed in more detail below, the primary drivers of the net decrease were as follows: • The Company reorganized the ownership structure of certain wholly-owned international subsidiaries in the fiscal fourth quarter of 2019, which resulted in a reduction of certain withholding and local taxes that it had previously recognized as part of the provisional Tax Cuts and Jobs Act (TCJA) tax charge in the fiscal year 2017 and finalized in the fiscal year 2018. Following the completion of this restructuring and approval by the applicable local authorities, the Company reversed a deferred tax liability of $0.6 billion and a related deferred tax asset of $0.2 billion for U.S. foreign tax credits, for a net deferred tax benefit of $0.4 billion decreasing the annual effective tax rate by 2.2% . This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. • The impact of the agreement in principle to settle opioid litigation for $4 billion (see Note 21 to the Consolidated Financial Statements) which reduced the U.S. earnings before taxes at an effective tax rate of 23.5% and decreased the Company’s annual effective tax rate by approximately 2.1% . • In December of fiscal year 2019, the U.S. Treasury issued final foreign tax credit regulations, which resulted in the Company revising the amount of foreign tax credits that were initially recorded in the fiscal year 2017 as part of the provisional TCJA tax charge. As a result, the Company recorded an increased deferred tax asset related to these foreign tax credits of approximately $0.3 billion or 1.7% to the annual effective tax rate. This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. • The Company reassessed its uncertain tax positions related to the current IRS audit and increased its unrecognized tax benefit by $0.3 billion liability which increased the annual effective tax rate by approximately 1.5% (see section on Unrecognized Tax Benefits for additional information). As these positions were related to uncertain tax regarding international transfer pricing, this expense has been classified as “International Operations” on the Company’s effective tax rate reconciliation. Subsequent to December 29, 2019, the Company received and agreed to Notices of Proposed Adjustments (NOPAs) from the IRS. The Company believes it is adequately reserved for potential exposures. • There were several one-time tax impacts that resulted in a cumulative net tax benefit to the 2018 annual effective tax rate of 1.2% . These items included the LifeScan divestiture, the adjustment to the 2017 provisional TCJA tax charge and the acceleration of certain tax deductions as part of the 2017 tax return. • More income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2018. On September 28, 2018 the Swiss Parliament approved the Federal Act on Tax Reform and AHV Financing (TRAF). On May 19, 2019 a public referendum was held in Switzerland that approved the federal reform proposals. In the fiscal third quarter of 2019, the Swiss Federal Council enacted TRAF which became effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust their tax basis adjustments to fair value (i.e., “step-up”) which is used for tax depreciation and amortization purposes resulting in a deduction over the transitional period. The subsequent adjustment to the Company’s asset tax basis will require review and approval by the tax authorities. TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF are also expected to allow companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons and enactment may not be uniform in both the substantive nature of the legislation and the timing of enactment. The Company recorded a net tax expense of $0.1 billion which increased the effective tax rate for the fiscal year 2019 by approximately 0.6% . This net tax expense related to federal and certain cantonal enactments in the fiscal year 2019 consisting of the following provisions: • approximately $0.6 billion tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred by December 29, 2019; this expense has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $0.9 billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $450 million of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. this benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. In the fiscal fourth quarter of 2019, the Swiss Federal Tax Administration issued authoritative guidance that required the Company to decrease the estimated value of the Federal tax basis step-up by approximately $0.3 billion from the determination made in the fiscal third quarter of 2019. Further authoritative guidance from the relevant Swiss tax authorities may be issued in the future and additional revisions may be required in the fiscal period that they are issued. The Company is currently assessing and applying for approval for the elective transition provisions in several cantons which includes discussions with local tax authorities on the application of the new law. The Company has recorded an estimated impact of the transitional provisions based on the best available information for cantons where enactment has occurred but the Company has not yet received a final tax ruling. As of December 29, 2019, the one canton where the Company maintains significant operations has not yet enacted TRAF legislation and the amounts recorded in the fiscal year 2019 do not include estimates for unenacted legislation. On February 9, 2020 a public referendum on the legislative change was held in this canton and the legislation was approved by the voters; formal enactment is expected in the fiscal first half of 2020. The Company has not yet elected the transitional provision in this canton. However, the net financial benefit is estimated to be between $0.2 billion and $0.5 billion in the fiscal first half of 2020. U.S. Tax Cuts and Jobs Act (TCJA) (2018 and 2017) In the fiscal year 2017, the United States enacted into law new U.S. tax legislation, the TCJA. This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21% , effective on January 1, 2018. This legislation also eliminated or reduced certain corporate income tax deductions as well as introduced new provisions that taxed certain foreign income not previously taxed by the United States. The TCJA also included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0% . This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the fiscal year 2019 was approximately $8.2 billion , of which $7.7 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. In the fourth quarter of 2017, the Company recorded a provisional tax cost of approximately $13.0 billion which consisted primarily of the following components: • a $10.1 billion charge on previously undistributed foreign earnings as of December 31, 2017 • a $4.5 billion deferred tax liability for foreign local and withholding taxes, offset by a $1.1 billion deferred tax asset for U.S. foreign tax credits, for repatriation of substantially all those earnings • a $0.6 billion tax benefit relating to the remeasurement of U.S. deferred tax assets and liabilities and the impact of the TCJA on unrecognized tax benefits • a $0.1 billion charge for U.S. state and local taxes on the repatriation of these foreign earnings In the fiscal year 2018, the Company completed its full assessment and finalized the accounting for the impact of the TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $0.2 billion . These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the facts and circumstances that existed as of the TCJA enactment date. This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the 2017 provisional charge. The TCJA also includes provisions for a tax on GILTI. GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In the fiscal year 2018, the Company elected to treat GILTI as a period expense under the deferred method and recorded a deferred tax cost of approximately $1.4 billion in the fiscal year 2018 related to facts and circumstances that existed on the date of TCJA enactment. See Note 1 for further information regarding income taxes accounting policies. During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $2.8 billion and a related deferred tax asset of $0.9 billion for U.S. foreign tax credits, for a net deferred tax benefit of $1.9 billion . This benefit has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. The 2018 effective tax rate decreased by 77.6% compared to 2017. The 2017 effective tax rate was primarily driven by the approximately $13 billion provisional tax charge recorded in the fourth quarter of 2017 and the impact of a Belgian statutory tax rate change which increased the 2017 effective rate by 3.4% . Additional drivers of the 2018 annual effective tax were: • the reduction of the U.S. statutory corporate tax rate including the effects of tax elections which resulted in the acceleration of certain deductions into the 2017 tax return. The impact of these accelerated deductions decreased the annual effective tax rate by approximately 1.7% • the impact of the adjustments to the 2017 provisional TCJA charge, including both Staff Accounting Bulletin (SAB) 118 adjustments and the internal restructuring, decreased the effective tax rate by approximately 1.9% • GILTI tax which increased the annual effective tax rate by approximately 1.6% , which excludes the impact of the SAB 118 adjustment for the adoption of the deferred method for GILTI • tax benefits received from stock-based compensation during fiscal 2018 and 2017, reduced the effective tax rate by 1.5% and 2.0% , respectively • in the fourth quarter of 2018, the Company completed the divestiture of its LifeScan business (See Note 20 to the Consolidated Financial Statements), which increased the Company's annual effective tax rate by approximately 0.8% • more income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2017 Temporary differences and carryforwards for 2019 and 2018 were as follows: 2019 Deferred Tax 2018 Deferred Tax (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,393 2,398 Stock based compensation 546 639 Depreciation & amortization 1,122 1,784 Non-deductible intangibles (5,752 ) (5,967 ) International R&D capitalized for tax 1,189 1,282 Reserves & liabilities 2,384 1,647 Income reported for tax purposes 1,605 1,104 Net operating loss carryforward international 838 786 Undistributed foreign earnings 765 (1,289 ) 693 (2,240 ) Global intangible low-taxed income (2,965 ) (2,971 ) Miscellaneous international 696 (81 ) 603 (93 ) Miscellaneous U.S. 410 469 Total deferred income taxes $ 11,948 (10,087 ) 11,405 (11,271 ) The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2019 2018 2017 Beginning of year $ 3,326 3,151 3,041 Increases related to current year tax positions 249 242 332 Increases related to prior period tax positions 408 145 232 Decreases related to prior period tax positions (105 ) (137 ) (416 ) (1) Settlements (9 ) (40 ) (2 ) Lapse of statute of limitations (16 ) (35 ) (36 ) End of year $ 3,853 3,326 3,151 (1) In 2017, $347 million of this decrease is related to the TCJA. The unrecognized tax benefits of $3.9 billion at December 29, 2019 , if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010-2012. The Company currently expects completion of this audit and settlement of the related tax liabilities in the fiscal year 2020. As of the December 29, 2019, the Company has classified unrecognized tax benefits and related interest of approximately $0.9 billion as a current liability on the “Accrued taxes on Income” line of the Consolidated Balance Sheet. This is the amount expected to be paid over the next 12 months with respect to the IRS audit. Subsequent to December 29, 2019, the Company made a payment for approximately $0.6 billion to the U.S. Treasury related to the estimated 2010-2012 tax audit liability in anticipation of the final settlement later in fiscal 2020. The completion of this tax audit may result in additional adjustments to the Company’s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities, except as previously noted on amounts related to the current United States IRS audit. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $50 million , $53 million and $60 million in 2019 , 2018 and 2017 , respectively. The total amount of accrued interest was $559 million and $503 million in 2019 and 2018 , respectively.

Employee Related Obligations

Employee Related Obligations	12 Months Ended
Employee Related Obligations	Dec. 29, 2019
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations At the end of 2019 and 2018 , employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2019 2018 Pension benefits $ 5,538 5,327 Postretirement benefits 2,297 2,283 Postemployment benefits 3,004 2,330 Deferred compensation 338 410 Total employee obligations 11,177 10,350 Less current benefits payable 514 399 Employee related obligations — non-current $ 10,663 9,951 Prepaid employee related obligations of $551 million and $475 million for 2019 and 2018 , respectively, are included in Other assets on the Consolidated Balance Sheets.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	12 Months Ended
Pensions and Other Benefit Plans	Dec. 29, 2019
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S. retired employees and their dependents. Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. Retirement plan benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last three to five years before retirement and the number of years of service. In 2014, the Company announced that the U.S. Defined Benefit Plan was amended to adopt a new benefit formula, effective for employees hired on or after January 1, 2015. The benefits are calculated using a new formula based on employee compensation over total years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. The Company does not typically fund retiree health care benefits in advance, but may do so at its discretion. The Company also has the right to modify these plans in the future. In 2019 and 2018 the Company used December 31, 2019 and December 31, 2018 , respectively, as the measurement date for all U.S. and international retirement and other benefit plans. Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2019 , 2018 and 2017 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2017 2019 2018 2017 Service cost $ 1,163 1,283 1,080 274 269 247 Interest cost 1,096 996 927 185 148 159 Expected return on plan assets (2,322 ) (2,212 ) (2,041 ) (6 ) (7 ) (6 ) Amortization of prior service cost (credit) 4 3 2 (31 ) (31 ) (30 ) Recognized actuarial losses 579 852 609 129 123 138 Curtailments and settlements 73 1 17 — — — Net periodic benefit cost $ 593 923 594 551 502 508 Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans: (Dollars in Millions) Amortization of net transition obligation $ — Amortization of net actuarial losses 1,022 Amortization of prior service credit 29 Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2019 2018 2017 2019 2018 2017 Net Periodic Benefit Cost Service cost discount rate 3.63 % 3.20 3.59 4.45 3.85 4.63 Interest cost discount rate 4.13 % 3.60 3.98 4.25 3.62 3.94 Rate of increase in compensation levels 3.99 % 3.98 4.01 4.29 4.29 4.31 Expected long-term rate of return on plan assets 8.31 % 8.46 8.43 Benefit Obligation Discount rate 2.91 % 3.76 3.30 3.39 4.40 3.78 Rate of increase in compensation levels 4.01 % 3.97 3.99 4.29 4.29 4.30 The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows. The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2019 2018 Health care cost trend rate assumed for next year 5.87 % 6.12 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.50 % 4.55 % Year the rate reaches the ultimate trend rate 2040 2038 A one-percentage-point change in assumed health care cost trend rates would have the following effect: One-Percentage- One-Percentage- (Dollars in Millions) Point Increase Point Decrease Health Care Plans Total interest and service cost $ 21 (17 ) Post-retirement benefit obligation $ 296 (246 ) The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2019 and 2018 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2019 2018 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 31,670 33,221 4,480 4,582 Service cost 1,163 1,283 274 269 Interest cost 1,096 996 185 148 Plan participant contributions 63 66 — — Amendments — 26 — — Actuarial (gains) losses 5,178 (2,326 ) 562 (119 ) Divestitures & acquisitions (278 ) (29 ) — — Curtailments, settlements & restructuring (172 ) (21 ) — — Benefits paid from plan assets * (1,555 ) (1,018 ) (431 ) (383 ) Effect of exchange rates 23 (528 ) 6 (17 ) Projected benefit obligation — end of year $ 37,188 31,670 5,076 4,480 Change in Plan Assets Plan assets at fair value — beginning of year $ 26,818 28,404 180 281 Actual return on plan assets 6,185 (1,269 ) 19 — Company contributions 908 1,140 347 282 Plan participant contributions 63 66 — — Settlements (16 ) (13 ) — — Divestitures & acquisitions (274 ) (17 ) — — Benefits paid from plan assets * (1,555 ) (1,018 ) (431 ) (383 ) Effect of exchange rates 72 (475 ) — — Plan assets at fair value — end of year $ 32,201 26,818 115 180 Funded status — end of year $ (4,987 ) (4,852 ) (4,961 ) (4,300 ) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 551 475 — — Current liabilities (113 ) (98 ) (397 ) (281 ) Non-current liabilities (5,425 ) (5,229 ) (4,564 ) (4,019 ) Total recognized in the consolidated balance sheet — end of year $ (4,987 ) (4,852 ) (4,961 ) (4,300 ) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 8,835 8,323 1,685 1,263 Prior service cost (credit) (8 ) 2 (75 ) (106 ) Unrecognized net transition obligation — — — — Total before tax effects $ 8,827 8,325 1,610 1,157 Accumulated Benefit Obligations — end of year $ 33,416 28,533 * In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2019 2018 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 593 923 551 502 Net actuarial (gain) loss 1,084 1,153 550 (111 ) Amortization of net actuarial loss (579 ) (852 ) (129 ) (123 ) Prior service cost (credit) — 26 — — Amortization of prior service (cost) credit (4 ) (3 ) 31 31 Effect of exchange rates 1 (114 ) 1 (3 ) Total loss/(income) recognized in other comprehensive income, before tax $ 502 210 453 (206 ) Total recognized in net periodic benefit cost and other comprehensive income $ 1,095 1,133 1,004 296 The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. In 2019 , the Company contributed $489 million and $419 million to its U.S. and international pension plans, respectively. The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2019 and December 31, 2018, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2019 2018 2019 2018 2019 2018 2019 2018 Plan Assets $ 21,398 17,725 — — 10,803 9,093 — — Projected Benefit Obligation 22,034 18,609 2,544 2,176 12,132 10,467 478 418 Accumulated Benefit Obligation 19,831 16,851 2,115 1,793 11,040 9,510 430 379 Over (Under) Funded Status Projected Benefit Obligation $ (636 ) (884 ) (2,544 ) (2,176 ) (1,329 ) (1,374 ) (478 ) (418 ) Accumulated Benefit Obligation 1,567 874 (2,115 ) (1,793 ) (237 ) (417 ) (430 ) (379 ) Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $4.3 billion , $5.2 billion and $0.9 billion , respectively, at the end of 2019 , and $7.5 billion , $8.8 billion and $4.3 billion , respectively, at the end of 2018 . The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2020 2021 2022 2023 2024 2025-2029 Projected future benefit payments Retirement plans $ 1,126 1,172 1,234 1,323 1,359 7,945 Other benefit plans $ 437 450 466 479 494 2,356 The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2020 2021 2022 2023 2024 2025-2029 Projected future contributions $ 103 107 113 118 127 749 Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. The Company’s retirement plan asset allocation at the end of 2019 and 2018 and target allocations for 2020 are as follows: Percent of Plan Assets Target Allocation 2019 2018 2020 Worldwide Retirement Plans Equity securities 74 % 71 % 69 % Debt securities 26 29 31 Total plan assets 100 % 100 % 100 % Determination of Fair Value of Plan Assets The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Valuation Hierarchy The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Following is a description of the valuation methodologies used for the investments measured at fair value. • Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2. • Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. • Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. • Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy. • Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price. • Insurance contracts — The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing. • Other assets — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2019 and December 31, 2018: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (a) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Short-term investment funds $ 119 122 405 529 — — — — 524 651 Government and agency securities — — 4,140 3,595 — — — — 4,140 3,595 Debt instruments — — 3,452 3,105 — — — — 3,452 3,105 Equity securities 12,483 11,298 2 4 — — — — 12,485 11,302 Commingled funds — — 3,338 2,304 181 133 7,580 5,201 11,099 7,638 Insurance contracts — — — — 19 193 — — 19 193 Other assets — — 9 33 — — 473 301 482 334 Investments at fair value $ 12,602 11,420 11,346 9,570 200 326 8,053 5,502 32,201 26,818 (a) The activity for the Level 3 assets is not significant for all years presented. The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $84 million and $72 million and U.S. short-term investment funds (Level 2) of $31 million and $108 million at December 31, 2019 and December 31, 2018, respectively. The fair value of Johnson & Johnson Common Stock directly held in plan assets was $984 million ( 3.1% of total worldwide plan assets) at December 31, 2019 and $876 million ( 3.3%

Savings Plan

Savings Plan	12 Months Ended
Savings Plan	Dec. 29, 2019
Savings Plan [Abstract]
Savings Plan	Savings Plan The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $235 million , $242 million and $214 million in 2019 , 2018 and 2017 , respectively.

Capital and Treasury Stock

Capital and Treasury Stock	12 Months Ended
Capital and Treasury Stock	Dec. 29, 2019
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at January 1, 2017 413,332 $ 28,352 Employee compensation and stock option plans (25,508 ) (3,156 ) Repurchase of common stock 49,494 6,358 Balance at December 31, 2017 437,318 31,554 Employee compensation and stock option plans (22,082 ) (3,060 ) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 34,362 Employee compensation and stock option plans (20,053 ) (2,691 ) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 $ 38,417 Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of 2019 , 2018 and 2017 . Cash dividends paid were $3.75 per share in 2019 , compared with dividends of $3.54 per share in 2018 , and $3.32 per share in 2017 . On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. This share repurchase program was completed as of September 29, 2019. On October 13, 2015, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $10.0 billion of the Company's shares of common stock. This share repurchase program was completed as of July 2, 2017.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
Accumulated Other Comprehensive Income (Loss)	Dec. 29, 2019
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total January 1, 2017 $ (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net 2017 changes 1,696 (179 ) (170 ) 355 1,702 December 31, 2017 (7,351 ) 232 (6,150 ) 70 (13,199 ) Cumulative adjustment to retained earnings — (232 ) (1) (232 ) Net 2018 changes (1,518 ) — (8 ) (265 ) (1,791 ) December 30, 2018 (8,869 ) — (6,158 ) (195 ) (15,222 ) Net 2019 changes 164 — (733 ) (100 ) (669 ) December 29, 2019 $ (8,705 ) — (6,891 ) (295 ) (15,891 ) (1) Per the adoption of ASU 2016-01- Financial Instruments Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International Currency Translat

International Currency Translation	12 Months Ended
International Currency Translation	Dec. 29, 2019
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years , or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. A rollforward of the changes during 2019 , 2018 and 2017 for foreign currency translation adjustments is included in Note 13. Net currency transaction gains and losses included in Other (income) expense were losses of $267 million , $265 million and $216 million in 2019 , 2018 and 2017 , respectively.

Earnings Per Share

Earnings Per Share	12 Months Ended
Earnings Per Share	Dec. 29, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 : (In Millions Except Per Share Amounts) 2019 2018 2017 Basic net earnings per share $ 5.72 5.70 0.48 Average shares outstanding — basic 2,645.1 2,681.5 2,692.0 Potential shares exercisable under stock option plans 136.3 139.0 139.7 Less: shares repurchased under treasury stock method (97.8 ) (92.5 ) (87.3 ) Convertible debt shares 0.7 0.7 0.9 Adjusted average shares outstanding — diluted 2,684.3 2,728.7 2,745.3 Diluted net earnings per share $ 5.63 5.61 0.47 The diluted net earnings per share calculation included the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $1 million after-tax for 2019, 2018 and 2017.

Lease Commitments

Lease Commitments	12 Months Ended
Lease Commitments	Dec. 29, 2019
Leases, Operating [Abstract]
Lease Commitments	Lease Commitments The Company primarily has operating leases for space, vehicles, manufacturing equipment and data processing equipment. Leases have remaining lease terms ranging from 1 year to 55 years , some of which could include options to extend the leases when they are reasonably certain. The operating lease costs were approximately $307 million , $332 million and $372 million in 2019 , 2018 and 2017 , respectively. Cash paid for amounts included in the measurement of lease liabilities in 2019 were $308 million . Commitments under finance leases are not significant. Other supplemental information related to these leases are as follows: The Weighted Average Remaining Lease Term and discount rate: Operating leases 5.8 years Weighted Average Discount Rate 3% Maturity of Lease Liabilities related to Operating Lease The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 29, 2019 are: (Dollars in Millions) Operating Leases 2020 $ 215 2021 254 2022 197 2023 141 2024 86 After 2024 201 Total lease payments 1,094 Less: Interest 109 Present Value of lease liabilities $ 985 Supplemental information for comparative periods: As of December 30, 2018, prior to the adoption of ASU 2016-02, the approximate future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year were: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896 Supplemental balance sheet information related to leases as of December 29, 2019 were as follows : (Dollars in Millions) Non-current operating lease right-of-use assets $ 957 Current operating lease liabilities 269 Non-current Operating lease liabilities 716 Total operating lease liabilities $ 985

Common Stock, Stock Option Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Dec. 29, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements At December 29, 2019 , the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 315 million at the end of 2019 . The compensation cost that has been charged against income for these plans was $977 million , $978 million and $962 million for 2019 , 2018 and 2017 , respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $227 million , $192 million and $275 million for 2019 , 2018 and 2017 , respectively. The total unrecognized compensation cost was $823 million , $827 million and $798 million for 2019 , 2018 and 2017 , respectively. The weighted average period for this cost to be recognized was 1.71 years, 1.73 years and 1.76 years for 2019 , 2018 , and 2017 , respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee benefit equity issuances. Stock Options Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years . All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2019, 2018 and 2017 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The average fair value of options granted was $17.80 , $17.98 and $13.38 , in 2019 , 2018 and 2017 , respectively. The fair value was estimated based on the weighted average assumptions of: 2019 2018 2017 Risk-free rate 2.56 % 2.77 % 2.25 % Expected volatility 16.27 % 15.77 % 15.30 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.80 % 2.70 % 2.90 % A summary of option activity under the Plan as of December 29, 2019 , December 30, 2018 and December 31, 2017 , and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Average Exercise Price Aggregate Intrinsic Value (Dollars in Millions) Shares at January 1, 2017 113,455 $ 83.16 $ 3,636 Options granted 19,287 115.67 Options exercised (18,975 ) 70.87 Options canceled/forfeited (2,461 ) 101.40 Shares at December 31, 2017 111,306 90.48 5,480 Options granted 17,115 129.51 Options exercised (16,228 ) 75.44 Options canceled/forfeited (2,541 ) 112.90 Shares at December 30, 2018 109,652 98.29 3,214 Options granted 19,745 131.94 Options exercised (14,785 ) 82.43 Options canceled/forfeited (2,975 ) 125.11 Shares at December 29, 2019 111,637 $ 105.63 $ 4,478 The total intrinsic value of options exercised was $807 million , $1,028 million and $1,060 million in 2019 , 2018 and 2017 , respectively. The following table summarizes stock options outstanding and exercisable at December 29, 2019 : (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Average Exercise Price Options Average Exercise Price $58.65-$66.07 7,752 1.3 $63.71 7,752 $63.71 $72.54-$90.44 23,837 3.6 $82.08 23,837 $82.08 $100.06-$101.87 29,586 5.6 $101.07 29,083 $101.05 $115.67-$129.51 31,810 7.6 $122.32 84 $120.76 $131.94-$141.06 18,652 9.1 $131.94 5 $131.94 111,637 6.0 $105.63 60,761 $88.88 (1) Average contractual life remaining in years. Stock options outstanding at December 30, 2018 and December 31, 2017 were 109,652 and an average life of 6.2 years and 111,306 and an average life of 6.3 years, respectively. Stock options exercisable at December 30, 2018 and December 31, 2017 were 54,862 at an average price of $82.03 and 52,421 at an average price of $73.61 , respectively. Restricted Share Units and Performance Share Units The Company grants restricted share units which vest over service periods that range from 6 months to 3 years . The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three -year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three -year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. The number of shares actually earned at the end of the three -year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted . In the fourth quarter of 2017, the Company modified the restricted share units that were scheduled to vest between January 1, 2018 and March 15, 2018. This modification guaranteed a minimum aggregate value, below the market value of the total expected payout amount, for all awards expected to vest during this period. The amount that was committed was not material to the Company’s overall financial position. A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2019 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 30, 2018 18,460 2,494 Granted 5,769 932 Issued (6,261 ) (996 ) Canceled/forfeited/adjusted (1,199 ) (256 ) Shares at December 29, 2019 16,769 2,174 The average fair value of the restricted share units granted was $121.31 , $119.67 and $107.69 in 2019 , 2018 and 2017 , respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $585.9 million , $613.7 million and $596.5 million in 2019 , 2018 and 2017 , respectively. The weighted average fair value of the performance share units granted was $124.67 , $120.64 and $114.13 in 2019 , 2018 and 2017 , calculated using the weighted average fair market value for each of the three component goals at the date of grant. The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. The fair value of performance share units issued was $119.1 million , $128.8 million and $132.5 million in 2019 , 2018 and 2017

Segments of Business and Geogra

Segments of Business and Geographic Areas	12 Months Ended
Segments of Business and Geographic Areas	Dec. 29, 2019
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of Business and Geographic Areas Sales to Customers % Change (Dollars in Millions) 2019 2018 2017 ’19 vs. ’18 ’18 vs. ’17 CONSUMER Baby Care U.S. $ 362 422 449 (14.2 )% (6.0 ) International 1,313 1,436 1,467 (8.6 ) (2.1 ) Worldwide 1,675 1,858 1,916 (9.9 ) (3.0 ) Beauty U.S. 2,392 2,403 2,335 (0.4 ) 2.9 International 2,201 1,979 1,865 11.2 6.1 Worldwide 4,593 4,382 4,200 4.8 4.3 Oral Care U.S. 621 637 616 (2.5 ) 3.4 International 906 918 915 (1.2 ) 0.3 Worldwide 1,528 1,555 1,531 (1.7 ) 1.6 OTC U.S. 2,010 1,850 1,716 8.6 7.8 International 2,434 2,484 2,410 (2.0 ) 3.1 Worldwide 4,444 4,334 4,126 2.5 5.0 Women's Health U.S. 12 13 12 (5.5 ) 8.3 International 974 1,036 1,038 (6.0 ) (0.2 ) Worldwide 986 1,049 1,050 (6.0 ) (0.1 ) Wound Care/Other U.S. 441 436 437 1.2 (0.2 ) International 230 239 342 (3.9 ) (30.1 ) Worldwide 671 675 779 (0.6 ) (13.4 ) TOTAL CONSUMER U.S. 5,839 5,761 5,565 1.4 3.5 International 8,059 8,092 8,037 (0.4 ) 0.7 Worldwide 13,898 13,853 13,602 0.3 1.8 PHARMACEUTICAL Immunology U.S. 9,641 9,073 8,871 6.3 2.3 International 4,309 4,047 3,373 6.5 20.0 Worldwide 13,950 13,120 12,244 6.3 7.2 REMICADE ® U.S. 3,079 3,664 4,525 (16.0 ) (19.0 ) U.S. Exports 294 436 563 (32.7 ) (22.6 ) International 1,007 1,226 1,227 (17.8 ) (0.1 ) Worldwide 4,380 5,326 6,315 (17.8 ) (15.7 ) SIMPONI / SIMPONI ARIA ® U.S. 1,159 1,051 954 10.2 10.2 International 1,029 1,033 879 (0.4 ) 17.5 Worldwide 2,188 2,084 1,833 5.0 13.7 STELARA ® U.S. 4,346 3,469 2,767 25.3 25.4 International 2,015 1,687 1,244 19.4 35.6 Worldwide 6,361 5,156 4,011 23.4 28.5 TREMFYA ® U.S. 764 453 62 68.5 * International 248 91 1 * * Worldwide 1,012 544 63 85.9 * OTHER IMMUNOLOGY U.S. — — — — — International 10 10 22 4.5 (54.5 ) Worldwide 10 10 22 4.5 (54.5 ) Infectious Diseases U.S. 1,597 1,378 1,358 15.9 1.5 International 1,815 1,926 1,796 (5.7 ) 7.2 Worldwide 3,413 3,304 3,154 3.3 4.8 EDURANT ® / rilpivirine U.S. 50 58 58 (13.7 ) 0.0 International 812 758 656 7.1 15.5 Worldwide 861 816 714 5.6 14.3 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,422 1,169 1,109 21.6 5.4 International 689 786 712 (12.3 ) 10.4 Worldwide 2,110 1,955 1,821 8.0 7.4 OTHER INFECTIOUS DISEASES U.S. 126 151 191 (16.5 ) (20.9 ) International 315 382 428 (17.6 ) (10.7 ) Worldwide 441 533 619 (17.3 ) (13.9 ) Neuroscience U.S. 2,919 2,574 2,630 13.4 (2.1 ) International 3,409 3,503 3,356 (2.7 ) 4.4 Worldwide 6,328 6,077 5,986 4.1 1.5 CONCERTA ® / Methylphenidate U.S. 233 229 384 1.7 (40.4 ) International 463 434 407 6.6 6.6 Worldwide 696 663 791 4.9 (16.2 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,107 1,791 1,590 17.6 12.6 International 1,224 1,137 979 7.7 16.1 Worldwide 3,330 2,928 2,569 13.7 14.0 RISPERDAL CONSTA ® U.S. 314 315 360 (0.3 ) (12.5 ) International 374 422 445 (11.4 ) (5.2 ) Worldwide 688 737 805 (6.7 ) (8.4 ) OTHER NEUROSCIENCE U.S. 266 239 296 11.4 (19.3 ) International 1,349 1,510 1,525 (10.7 ) (1.0 ) Worldwide 1,614 1,749 1,821 (7.7 ) (4.0 ) Oncology U.S. 4,299 4,331 3,098 (0.7 ) 39.8 International 6,393 5,513 4,160 16.0 32.5 Worldwide 10,692 9,844 7,258 8.6 35.6 DARZALEX ® U.S. 1,567 1,203 884 30.3 36.1 International 1,430 822 358 73.9 * Worldwide 2,998 2,025 1,242 48.0 63.0 IMBRUVICA ® U.S. 1,555 1,129 841 37.7 34.2 International 1,856 1,486 1,052 24.9 41.3 Worldwide 3,411 2,615 1,893 30.4 38.1 VELCADE ® U.S. — — — — — International 751 1,116 1,114 (32.7 ) 0.2 Worldwide 751 1,116 1,114 (32.7 ) 0.2 ZYTIGA ® / abiraterone acetate U.S. 810 1,771 1,228 (54.3 ) 44.2 International 1,985 1,727 1,277 15.0 35.2 Worldwide 2,795 3,498 2,505 (20.1 ) 39.6 OTHER ONCOLOGY U.S. 367 228 145 61.0 57.2 International 371 362 359 2.4 0.8 Worldwide 739 590 504 25.0 17.1 Pulmonary Hypertension U.S. 1,684 1,651 773 2.0 * International 939 922 554 1.9 66.4 Worldwide 2,623 2,573 1,327 1.9 93.9 OPSUMIT ® U.S. 766 700 320 9.4 * International 562 515 253 9.0 * Worldwide 1,327 1,215 573 9.2 * TRACLEER ® / bosentan U.S. 131 268 161 (51.1 ) 66.5 International 210 278 242 (24.3 ) 14.9 Worldwide 341 546 403 (37.5 ) 35.5 UPTRAVI ® U.S. 714 598 238 19.3 * International 105 65 25 62.4 * Worldwide 819 663 263 23.5 * OTHER U.S. 74 85 54 (13.7 ) 57.4 International 62 64 34 (3.7 ) 88.2 Worldwide 135 149 88 (9.4 ) 69.3 Cardiovascular / Metabolism / Other U.S. 3,734 4,279 4,744 (12.7 ) (9.8 ) International 1,458 1,537 1,543 (5.2 ) (0.4 ) Worldwide 5,192 5,816 6,287 (10.7 ) (7.5 ) XARELTO ® U.S. 2,313 2,477 2,500 (6.6 ) (0.9 ) International — — — — — Worldwide 2,313 2,477 2,500 (6.6 ) (0.9 ) INVOKANA ® / INVOKAMET ® U.S. 536 711 944 (24.6 ) (24.7 ) International 199 170 167 17.3 1.8 Worldwide 735 881 1,111 (16.5 ) (20.7 ) PROCRIT ® / EPREX ® U.S. 505 674 675 (25.1 ) (0.1 ) International 285 314 297 (9.2 ) 5.7 Worldwide 790 988 972 (20.0 ) 1.6 OTHER U.S. 380 417 625 (9.1 ) (33.3 ) International 974 1,053 1,079 (7.6 ) (2.4 ) Worldwide 1,353 1,470 1,704 (8.0 ) (13.7 ) TOTAL PHARMACEUTICAL U.S. 23,874 23,286 21,474 2.5 8.4 International 18,324 17,448 14,782 5.0 18.0 Worldwide 42,198 40,734 36,256 3.6 12.4 MEDICAL DEVICES Diabetes Care U.S. — 371 612 * (39.4 ) International — 638 1,003 * (36.4 ) Worldwide — 1,009 1,615 * (37.5 ) Diagnostics U.S. — — — — — International — — 1 — * Worldwide — — 1 — * Interventional Solutions U.S. 1,443 1,283 1,148 12.5 11.8 International 1,554 1,363 1,148 14.0 18.7 Worldwide 2,997 2,646 2,296 13.3 15.2 Orthopaedics U.S. 5,319 5,281 5,404 0.7 (2.3 ) International 3,520 3,604 3,654 (2.3 ) (1.4 ) Worldwide 8,839 8,885 9,058 (0.5 ) (1.9 ) HIPS U.S. 863 841 827 2.6 1.7 International 575 577 567 (0.3 ) 1.8 Worldwide 1,438 1,418 1,394 1.4 1.7 KNEES U.S. 889 911 948 (2.4 ) (3.9 ) International 591 591 575 0.0 2.8 Worldwide 1,480 1,502 1,523 (1.4 ) (1.4 ) TRAUMA U.S. 1,652 1,599 1,576 3.3 1.5 International 1,068 1,100 1,040 (2.9 ) 5.8 Worldwide 2,720 2,699 2,616 0.8 3.2 SPINE & OTHER U.S. 1,915 1,930 2,053 (0.8 ) (6.0 ) International 1,286 1,336 1,472 (3.8 ) (9.2 ) Worldwide 3,201 3,266 3,525 (2.0 ) (7.3 ) Surgery U.S. 3,828 4,125 4,085 (7.2 ) 1.0 International 5,673 5,776 5,474 (1.8 ) 5.5 Worldwide 9,501 9,901 9,559 (4.0 ) 3.6 ADVANCED U.S. 1,637 1,657 1,620 (1.2 ) 2.3 International 2,458 2,345 2,136 4.8 9.8 Worldwide 4,095 4,002 3,756 2.3 6.5 GENERAL U.S. 1,762 1,751 1,728 0.6 1.3 International 2,718 2,806 2,735 (3.1 ) 2.6 Worldwide 4,480 4,557 4,463 (1.7 ) 2.1 SPECIALTY U.S. 430 717 737 (40.1 ) (2.7 ) International 497 625 603 (20.5 ) 3.6 Worldwide 926 1,342 1,340 (31.0 ) 0.1 Vision U.S. 1,794 1,777 1,575 0.9 12.8 International 2,830 2,776 2,488 2.0 11.6 Worldwide 4,624 4,553 4,063 1.6 12.1 CONTACT LENSES / OTHER U.S. 1,304 1,237 1,122 5.4 10.2 International 2,088 2,065 1,914 1.1 7.9 Worldwide 3,392 3,302 3,036 2.7 8.8 SURGICAL U.S. 490 540 453 (9.4 ) 19.2 International 742 711 574 4.4 23.9 Worldwide 1,232 1,251 1,027 (1.6 ) 21.8 TOTAL MEDICAL DEVICES U.S. 12,384 12,837 12,824 (3.5 ) 0.1 International 13,579 14,157 13,768 (4.1 ) 2.8 Worldwide 25,963 26,994 26,592 (3.8 ) 1.5 WORLDWIDE U.S. 42,097 41,884 39,863 0.5 5.1 International 39,962 39,697 36,587 0.7 8.5 Worldwide $ 82,059 81,581 76,450 0.6 % 6.7 *Percentage greater than 100% or not meaningful Income Before Tax Identifiable Assets (Dollars in Millions) 2019 (3) 2018 (4) 2017 (5) 2019 2018 Consumer $ 2,061 2,320 2,524 $ 26,618 25,877 Pharmaceutical 8,816 12,568 11,083 56,292 56,636 Medical Devices 7,286 4,397 5,392 49,462 46,254 Total 18,163 19,285 18,999 132,372 128,767 Less: Expense not allocated to segments (1) 835 1,286 1,326 General corporate (2) 25,356 24,187 Worldwide total $ 17,328 17,999 17,673 $ 157,728 152,954 Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) 2019 2018 2017 2019 2018 2017 Consumer $ 328 438 485 $ 765 688 674 Pharmaceutical 950 1,012 936 3,910 3,802 2,416 Medical Devices 1,912 1,843 1,566 2,014 2,103 2,216 Segments total 3,190 3,293 2,987 6,689 6,593 5,306 General corporate 308 377 292 320 336 336 Worldwide total $ 3,498 3,670 3,279 $ 7,009 6,929 5,642 Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2019 2018 2017 2019 2018 United States $ 42,097 41,884 39,863 $ 41,528 37,117 Europe 18,466 18,753 17,126 48,015 51,433 Western Hemisphere excluding U.S. 5,941 6,113 6,041 2,862 2,752 Asia-Pacific, Africa 15,555 14,831 13,420 5,486 2,733 Segments total 82,059 81,581 76,450 97,891 94,035 General corporate 1,049 1,064 Other non long-lived assets 58,788 57,855 Worldwide total $ 82,059 81,581 76,450 $ 157,728 152,954 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In 2019, the Company utilized three wholesalers distributing products for all three segments that represented approximately 15.0% , 12.0% and 11.0% of the total consolidated revenues. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0% , 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) The Consumer segment includes a gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO, litigation expense of $0.4 billion and a restructuring charge of $0.1 billion . The Pharmaceutical segment includes litigation expense of $4.3 billion including $4.0 billion related to the agreement in principle to settle opioid litigation (see Note 21 to the Consolidated Financial Statements for additional information regarding the opioid litigation), an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, an unrealized gain on securities of $0.6 billion , Actelion acquisition related costs of $0.2 billion and a restructuring charge of $0.1 billion . The Medical Devices segment includes a gain of $2.0 billion from the divestiture of the ASP business, a restructuring related charge of $0.4 billion , litigation expense of $0.4 billion and Auris Health acquisition related costs of $0.1 billion . (4) The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL ® and litigation expense of $0.3 billion . The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion , Actelion acquisition related costs of $0.2 billion , unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion , a restructuring related charge of $0.6 billion , AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business. (5) The Pharmaceutical segment includes $0.8 billion for Actelion acquisition and integration related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion . The Medical Devices segment includes litigation expense of $1.1 billion , a restructuring related charge of $0.8 billion , an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED ® . (6) Long-lived assets include property, plant and equipment, net for 2019 , and 2018 of $17,658 and $17,035 , respectively, and intangible assets and goodwill, net for 2019 and 2018 of $81,282 and $78,064 , respectively.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
Selected Quarterly Financial Data (unaudited)	Dec. 29, 2019
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) Selected unaudited quarterly financial data for the years 2019 and 2018 are summarized below: 2019 2018 (Dollars in Millions Except Per Share Data) First Quarter (1) Second Quarter (2) Third Quarter (3) Fourth Quarter (4) First Quarter (5) Second Quarter (6) Third Quarter (7) Fourth Quarter (8) Segment sales to customers Consumer $ 3,318 3,544 3,469 3,567 3,398 3,504 3,415 3,536 Pharmaceutical 10,244 10,529 10,877 10,548 9,844 10,354 10,346 10,190 Medical Devices 6,459 6,489 6,383 6,632 6,767 6,972 6,587 6,668 Total sales 20,021 20,562 20,729 20,747 20,009 20,830 20,348 20,394 Gross profit 13,406 13,622 13,862 13,613 13,395 13,903 13,759 13,433 Earnings before provision for taxes on income 4,422 7,041 1,647 4,218 5,481 4,973 4,423 3,122 Net earnings 3,749 5,607 1,753 4,010 4,367 3,954 3,934 3,042 Basic net earnings per share $ 1.41 2.11 0.67 1.52 1.63 1.47 1.47 1.14 Diluted net earnings per share $ 1.39 2.08 0.66 1.50 1.60 1.45 1.44 1.12 (1) The first quarter of 2019 includes a gain of $0.3 billion after-tax ( $0.3 billion before-tax) related to the Company's previously held equity investment in DR. CI:LABO, an in-process research and development expense of $703 million after-tax ( $890 million before-tax) related to the Alios asset, a litigation expense of $342 million after-tax ( $423 million before-tax), an unrealized gain on securities of $125 million after-tax ( $158 million before-tax), a restructuring related charge of $75 million after-tax ( $90 million before-tax), and acquisition related costs of $60 million after-tax ( $67 million before-tax). (2) The second quarter of 2019 includes a gain of $1.5 billion after-tax ( $2.0 billion before-tax) from the divestiture of the ASP business, a litigation expense of $342 million after-tax ( $409 million before-tax), an unrealized gain on securities of $117 million after-tax ( $148 million before-tax), a restructuring related charge of $116 million after-tax ( $142 million before-tax) and acquisition related costs of $50 million after-tax ( $55 million before-tax). (3) The third quarter of 2019 includes a litigation expense of $3,080 million after-tax ( $4,000 million before-tax) related to the agreement in principle to settle opioid litigation, a restructuring related charge of $106 million after-tax ( $128 million before-tax), acquisition related costs of $88 million after-tax ( $107 million before-tax), a $391 million benefit after-tax from the impact of tax legislation, and an unrealized loss on securities of $71 million after-tax ( $89 million before-tax). (4) The fourth quarter of 2019 includes a litigation expense of $251 million after-tax ( $264 million before-tax), an unrealized gain on securities of $277 million after-tax ( $350 million before-tax), a restructuring related charge of $214 million after-tax ( $251 million before-tax), a $184 million benefit after-tax from the impact of tax legislation, and acquisition related costs of $82 million after-tax ( $90 million before-tax). (5) The first quarter of 2018 includes an Actelion acquisition related cost of $92 million after-tax ( $96 million before-tax) and a restructuring related charge of $81 million after-tax ( $107 million before-tax). (6) The second quarter of 2018 includes a litigation expense of $609 million after-tax ( $703 million before-tax) and a restructuring related charge of $152 million after-tax ( $176 million before-tax). (7) The third quarter of 2018 includes an in-process research and development expense of $859 million after-tax ( $1,126 million before-tax) related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $184 million after and before tax, a restructuring related charge of $162 million after-tax ( $190 million before-tax) and a $265 million benefit after-tax from the impact of tax legislation. (8) The fourth quarter of 2018 includes a litigation expense of $1,113 million after-tax ( $1,288 million before-tax), a restructuring related charge of $190 million after-tax ( $227 million before-tax) and a $137 million

Business Acquisitions and Dives

Business Acquisitions and Divestitures	12 Months Ended
Business Acquisitions and Divestitures	Dec. 29, 2019
Business Combinations [Abstract]
Business Combinations and Divestitures	and Divestitures Certain businesses were acquired for $5.8 billion in cash and $1.4 billion of liabilities assumed during 2019. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2019 acquisitions primarily included: DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products; Auris Health, Inc. a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures and Taris Biomedical LLC a company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases including cancer. The Company also acquired the assets of JointPoint, Inc., a privately held company, with navigation software to improve surgical outcomes in hip replacement. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $6.8 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. On January 17, 2019, the Company acquired DR. CI:LABO, a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion , which equates to approximately $2.1 billion , using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire the publicly held shares not already held by the Company for ¥5,900 per share. The Company previously held a 20% ownership in DR. CI:LABO. As of June 2019, the Company became the legal owner of DR. CI:LABO with the completion of the tender offer procedure in Japan. The acquired company was then delisted from the Tokyo Stock Exchange. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO. The Company treated this transaction as a business combination and included it in the Consumer segment. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. At December 29, 2019, the fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion , goodwill for $1.2 billion and liabilities of $0.4 billion subject to any subsequent valuation adjustments within the measurement period. The adjustments made since the date of acquisition were $0.1 billion to intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. On April 1, 2019 the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion , net of cash acquired. Additional contingent payments of up to $2.35 billion , in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D for $3.0 billion , goodwill for $2.0 billion , marketable securities of $0.2 billion and liabilities assumed of $1.8 billion , which includes the fair value of the contingent payments mentioned above, subject to any subsequent valuation adjustments within the measurement period. As of December 29, 2019 there were no valuation adjustments. The fair value of the contingent consideration was $1.1 billion . A probability of success factor ranging from 55% to 95% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied was approximately 10% . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. On December 20, 2019, the Company announced the agreement to acquire Verily's stake in Verb Surgical Inc. The transaction closed in the fiscal first quarter of 2020 and Verb Surgical Inc. is now a subsidiary of Johnson & Johnson. On December 30, 2019, subsequent to the fiscal year end, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion . XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. The transaction will be accounted for as a business combination and included in the Pharmaceutical segment. During 2018 certain businesses were acquired for $0.9 billion in cash and $0.1 billion of liabilities assumed during 2018. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2018 acquisitions primarily included: Zarbee’s, Inc., a privately held company that is a leader in naturally-based consumer healthcare products; BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies and Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. The Company also acquired the assets of Medical Enterprises Distribution LLC, a privately held healthcare technology firm focused on surgical procedure innovation. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $1.0 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. During 2017 certain businesses were acquired for $35.2 billion in cash and $1.8 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2017 acquisitions primarily included: Actelion Ltd, an established leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH); Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, which included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health; Neuravi Limited, a privately-held medical device company that develops and markets medical devices for neurointerventional therapy; TearScience Inc., a manufacturer of products dedicated to treating meibomian gland dysfunction; Sightbox, Inc., a privately-held company that developed a subscription vision care service that connects consumers with eye care professionals and a supply of contact lenses; Torax Medical, Inc., a privately-held medical device company that manufactures and markets the LINX™ Reflux Management System for the surgical treatment of gastroesophageal reflux disease and Megadyne Medical Products, Inc., a privately-held medical device company that develops, manufactures and markets electrosurgical tools. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $34.4 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1.1 billion has been identified as the value of IPR&D, primarily associated with the acquisition of Actelion Ltd. The value of the IPR&D was calculated using cash flow projections discounted for the inherent risk in the projects. During 2017, the Company completed the acquisition of Actelion Ltd through an all cash tender offer in Switzerland for $280 per share, amounting to $29.6 billion , net of cash acquired. As part of the transaction, immediately prior to the completion of the acquisition, Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia are listed on the SIX Swiss Exchange (SIX). In 2017 the Company held 9.9% of the shares of Idorsia and had rights to an additional 22.1% of Idorsia equity through a convertible loan with a principal amount of approximately $0.5 billion . As a result of Idorsia raising additional capital in July 2018, the Company currently holds 9.0% of the shares of Idorsia and has rights to an additional 20.8% of Idorsia equity through a convertible loan with a carrying value and a principal amount of approximately $0.5 billion . The convertible loan may be converted into 38,715,114 Idorsia shares, subject to certain restrictions, as follows: (i) up to an aggregate shareholding of 16% of Idorsia shares as a result of certain shareholders holding more than 20% of the issued Idorsia shares, and (ii) up to the balance of the remaining amount within 20 business days of the maturity date of the convertible loan, which has a 10 year term, or if Idorsia undergoes a change of control transaction. At the maturity of the loan, if the remaining amount has not yet been converted, Idorsia may elect to settle the remaining amount in cash or in ordinary shares of Idorsia. The equity investment in Idorsia and the convertible loan are recorded in Other assets in the Company's consolidated Balance Sheet. The Company also exercised the option acquired on ACT-132577, a product within Idorsia being developed for resistant hypertension currently in phase 3 of clinical development. The Company has also entered into an agreement to provide Idorsia with a Swiss franc denominated credit facility of approximately $250 million . As of December 29, 2019, Idorsia has not made any draw-downs under the credit facility. Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH) that are highly complementary to the existing portfolio of the Company. The addition of Actelion’s specialty in-market medicines and late-stage products is consistent with the Company's efforts to grow in attractive and complementary therapeutic areas and serve patients with serious illnesses and significant unmet medical need. During the fiscal second quarter of 2018, the Company finalized the purchase price allocation for Actelion to the individual assets acquired and liabilities assumed using the acquisition method. The following table presents the amounts recognized for assets acquired and liabilities assumed as of the acquisition date with adjustments made through the second quarter of 2018: (Dollars in Millions) Cash & Cash equivalents 469 Inventory (1) 759 Accounts Receivable 485 Other current assets 93 Property, plant and equipment 104 Goodwill 6,161 Intangible assets 25,010 Deferred Taxes 99 Other non-current assets 19 Total Assets Acquired 33,199 Current liabilities 956 Deferred Taxes 1,776 Other non-current liabilities 413 Total Liabilities Assumed 3,145 Net Assets Acquired 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value. The adjustments made since the date of acquisition were $0.2 billion to the deferred taxes and $0.4 billion to the current liabilities with the offset to goodwill. The assets acquired are recorded in the Pharmaceutical segment. The acquisition of Actelion resulted in approximately $6.2 billion of goodwill. The goodwill is primarily attributable to synergies expected to arise from the acquisition. The goodwill is not expected to be deductible for tax purposes. The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks* $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010 *Includes $0.4 billion related to VALCHLOR ® , one of the acquired products, which was divested in the fiscal second quarter of 2018. The patents and trademarks acquired are comprised of developed technology with a weighted average life of 9 years and was primarily based on the patent life of the marketed products. The intangible assets with definite lives were assigned asset lives ranging from 4 to 10 years . The in-process research and development intangible assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability adjusted cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 9% . The acquisition was accounted for using the acquisition method and, accordingly, the results of operations of Actelion were reported in the Company's financial statements beginning on June 16, 2017, the date of acquisition. For the year ended December 31, 2017, total sales and a net loss for Actelion from the date of acquisition were $1.4 billion and $1.4 billion , respectively. The following table provides pro forma results of operations for the fiscal year ended December 31, 2017, as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) 2017 Net Sales 77,681 Net Earnings 1,509 Diluted Net Earnings per Common Share 0.55 The Company recorded Actelion acquisition related costs before tax of approximately $0.2 billion , $0.2 billion and $0.8 billion in 2019, 2018 and 2017, respectively, which was recorded in Other (income)/expense and Cost of products sold. During 2017, the Company acquired Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.3 billion , net of cash acquired. The acquisition included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health. The net purchase price was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.7 billion . The weighted average life of total amortizable intangibles, the majority being customer relationships, is approximately 14.4 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not deductible for tax purposes. The intangible assets and goodwill amounts are based on the final purchase price allocation. The assets acquired were recorded in the Medical Devices segment. In 2012, the Company completed the acquisition of Synthes, Inc. for a purchase price of $20.2 billion in cash and stock. In connection with the acquisition of Synthes, Inc. the Company entered into two accelerated share repurchase (ASR) agreements. In 2013, the Company settled the remaining liabilities under the ASR agreements. While the Company believes that the transactions under each ASR agreement and a series of related internal transactions were consummated in a tax efficient manner in accordance with applicable law, it is possible that the Internal Revenue Service could assert one or more contrary positions to challenge the transactions from a tax perspective. If challenged, an amount up to the total purchase price for the Synthes shares could be treated as subject to applicable U.S. tax at approximately the statutory rate to the Company, plus interest. With the exception of the Actelion Ltd acquisition, supplemental pro forma information for 2019, 2018 and 2017 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position. Divestitures During 2019, the Company divested its Advanced Sterilization Products (ASP) business to Fortive Corporation for an aggregate value of approximately $2.8 billion , consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. As of December 30, 2018, the assets held for sale on the Consolidated Balance Sheet were $0.2 billion of inventory, $0.1 billion of property, plant and equipment, net and $0.3 billion of goodwill. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $2.0 billion . During 2018, the Company divested the LifeScan Inc business for approximately $2.1 billion and retained certain net liabilities. Other divestitures in 2018 included: NIZORAL ® , RoC ® and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $1.2 billion . In 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. The majority of the transfers were completed in 2019 with a minor amount remaining in 2020. As of December 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $0.1 billion of inventory and property, plant and equipment, net. As of December 30, 2018, the assets held for sale on the Consolidated Balance Sheet were $0.3 billion of inventory and $0.1 billion of property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 22 to the Consolidated Financial Statements. During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences Holdings Corporation and the divestiture of COMPEED ® to HRA Pharma. In 2017, the pre-tax gains on the divestitures were approximately $1.3 billion

Legal Proceedings

Legal Proceedings	12 Months Ended
Legal Proceedings	Dec. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of December 29, 2019 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of December 29, 2019 , in the United States there were approximately 1,100 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 10,300 with respect to the PINNACLE ® Acetabular Cup System; 17,600 with respect to pelvic meshes; 11,900 with respect to RISPERDAL ® ; 29,000 with respect to XARELTO ® ; 17,900 with respect to body powders containing talc; 400 with respect to INVOKANA ® ; and 3,300 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. Orders determining the damages amounts to be awarded to the three Lead Applicants are expected in the first quarter of 2020. With respect to other group members, there will be an individual case assessment process which will require proof of use and causally related loss. The class actions in Canada are expected to be discontinued in 2020 as a result of a settlement of a group of cases, subject to court approval of the discontinuance. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Along with ETHICON PHYSIOMESH ® lawsuits, there were a number of filings related to the PROCEED ® Mesh and PROCEED ® Ventral Patch products. In March 2019, the New Jersey Supreme Court entered an order consolidating all PROCEED ® and PROCEED ® Ventral Patch cases as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. The Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch products. In September 2019, plaintiffs’ attorney filed an application with the New Jersey Supreme Court seeking centralized management of 107 PROLENE™ Polypropylene Hernia System cases. The New Jersey Supreme Court granted plaintiffs application in January 2020 and those will be transferred to an MCL in Atlantic County Superior Court. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff which was subsequently reduced in January 2020 to $6.8 million by the trial judge. The Company will appeal the final judgment. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson (J&J); and JPI's collaboration partner for XARELTO ® Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and J&J announced an agreement in principle to the settle the XARELTO ® cases in the United States; the settlement agreement was executed in May 2019, and the settlement became final in December 2019. This will resolve the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, as well as outside the United States. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have moved to exclude experts, known as Daubert motions. The Court held Daubert hearings in mid-July 2019 and a final round of briefing has been submitted to the Court. The parties are awaiting a decision. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in July 2018 of $4.7 billion . The Company believes that it has strong grounds on appeal to overturn these verdicts. The Company has established an accrual primarily for defense costs in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’ potential liability for personal injury from exposure to talcum powder sold by Imerys (Talc Claims). In its bankruptcy filing, Imerys noted certain claims it alleges it has against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis have been remanded. The Company formally proposed to resolve Imerys' and the Company’s obligations arising out of the Talc Claims by agreeing to assume the defense of litigation of all Talc Claims involving the Company's products, lifting the automatic stay to enable the Talc Claims to proceed outside the bankruptcy forum with the Company agreeing to settle or pay any judgment against Imerys, and waiving the Company’s indemnification claims against Imerys. Discussions between Imerys and the Company on this issue remain ongoing. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to adequately disclose the alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In October 2018, a shareholder derivative lawsuit was filed against Johnson & Johnson as the nominal defendant and its current directors as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In June 2019, the shareholder filed an additional complaint initiating a summary proceeding in New Jersey state court for a books and records inspection. In August 2019, Johnson & Johnson responded to the books and records complaint and filed a cross motion to dismiss. In September 2019, Plaintiff replied and the Court heard oral argument. The Court has not yet ruled in the books and records action. In September 2019, the United States District Court for the District of New Jersey granted defendants’ motion to dismiss the shareholder derivative lawsuit, and dismissed the complaint without prejudice. In October 2019, the shareholder filed a notice of appeal with the United States Court of Appeals for the Third Circuit. In January 2020, the shareholder voluntarily dismissed his appeal, with prejudice. Four additional shareholder derivative lawsuits have been filed in New Jersey making similar allegations against the Company and its current directors and certain officers. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. Defendants have filed a motion to dismiss. A lawsuit is pending in the United States District Court for the Central District of California alleging violations of Proposition 65, California’s Unfair Competition Law and False Advertising Law concerning JOHNSON’S ® Baby Powder. In June 2019, plaintiffs filed a motion for voluntary dismissal of this Proposition 65 action and the Company opposed such motion to the extent it would allow plaintiffs’ counsel to refile such claims with new plaintiffs. The Court granted plaintiff’s motion conditioned upon payment of attorneys’ fees and costs. The Court entered its award of attorneys’ fees and costs in October 2019 and the case was dismissed without prejudice. Another lawsuit alleging violations of Proposition 65, California’s Consumer Legal Remedies Act relating to JOHNSON’S ® Baby Powder was filed in the Superior Court of California for the County of San Diego. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted, primarily on the basis that the plaintiffs failed to comply with Proposition 65’s mandatory pre-suit notice requirement, which applies even when a plaintiff asserts only an indirect Proposition 65 claim. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with government inquiries and continues to produce documents in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Although Johnson & Johnson has since sold Cordis, it has retained liability for this case. After the trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider Medinol’s motion for a new trial. In March 2019, the district court denied Medinol’s motion for a new trial. In April 2019, Medinol filed a notice of appeal. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In January 2019, the district court stayed the case pending a decision in the Inter Partes Review proceeding on the ’426 patent (see below). In December 2017, DePuy Synthes Products, Inc. filed a petition for Inter Partes Review with the United States Patent and Trademark Office (USPTO), seeking to invalidate the two claims of the ’426 patent asserted in the district court litigation, and in June 2018, the USPTO instituted review of those claims. A hearing was held in March 2019, an d in April 2019, the USPTO issued its decision upholding the validity of the patent. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ’426 patent. In November 2019, judgment was entered in favor of Depuy. In December 2019, MedIdea filed a notice of appeal. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (the ’310 patent); 9,084,608; 9,241,759 (the ’759 patent) and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. The parties have entered joint stipulations such that only the ’310 patent and the ’759 patent remain in dispute. Trial began in September 2019, and closing arguments will be heard in March 2020. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412 (the ’412 patent). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. In December 2016, Acclarent filed a petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO) challenging the validity of the ’412 patent. The USPTO instituted the IPR in July 2017. In July 2018, the USPTO ruled in favor of Albritton in the IPR, finding that Acclarent had not met its burden of proof that the challenged claims were invalid. In October 2019, the Court of Appeals affirmed the USPTO’s Patent Trial and Appeal Board. In June 2019, the parties filed cross motions for summary judgment in the district court and the parties are awaiting a decision. The district court trial is scheduled for April 2020. In November 2017, Board of Regents, The University of Texas System and TissueGen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® PDS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 (the ’603 patent) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the USPTO, seeking Inter Partes Review (IPR) of both asserted patents. Those petitions have been stayed by the USPTO pending a decision by the U.S. Supreme Court in an unrelated case. UT dismissed the ’603 patent from the suit and no longer accuses PDS ® Plus Antibacterial Sutures or STRATAFIX ® PDS ® Plus Antibacterial Sutures of infringement. The district court trial is scheduled for June 2020. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (“Intuitive”) filed a patent infringement suit against Auris Health, Inc. (“Auris”) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200 patent); 6,491,701 (’701 patent); 6,522,906 (’906 patent); 6,800,056 (’056 patent); 8,142,447 (’447 patent); 8,620,473 (’473 patent); 8,801,601 (’601 patent); and 9,452,276 (’276 patent) based on Auris’ Monarch™ Platform. Auris filed Petitions for Inter Partes Review with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. In December 2019, the USPTO instituted review of the ’601 patent and denied review of the ’056 patent. The district court trial is scheduled to begin in January 2021. In August 2019, RSB Spine LLC (“RSB Spine”) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713, 537 by one or more of the following products: ZERO-P-VA™ Spacer, ZERO-P ® Spacer, ZERO-P NATURAL™ Plate, SYNFIX ® LR Spacer and SYNFIX ® Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., Precision Spine, Inc., and Xtant Medical Holdings, Inc. Pharmaceutical In August 2016, Sandoz Ltd and Hexal AG (collectively, San

Restructuring

Restructuring	12 Months Ended
Restructuring	Dec. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring The Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 20 to the Consolidated Financial Statements. In 2019, the Company recorded a pre-tax charge of $0.6 billion , which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.2 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $0.8 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion , over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2019: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 31, 2017 229 — 38 267 2018 activity (35 ) — 10 (25 ) Reserve balance, December 30, 2018 194 — 48 242 Current year activity: Charges — 151 460 611 Cash payments (30 ) — (424 ) (454 ) Settled non cash — (151 ) (68 ) (3) (219 ) Reserve balance, December 29, 2019 (1) $ 164 — 16 180 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Relates to pension related actuarial losses associated with the transfer of employees to Jabil Inc. as part of the strategic collaboration.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 29, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Description of the Company And Business Segments	Description of the Company and Business Segments The Company has approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular) and eye health fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
New Accounting Pronouncements	New Accounting Standards Recently Adopted Accounting Standards ASU 2016-02 : Leases The Company adopted this standard as of the beginning of fiscal year 2019, on a prospective basis. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements. The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet. ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. For additional disclosures see Note 16 to the Consolidated Financial Statements. ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings. The Company has elected not to reclassify the income tax effects of this standard and therefore this standard will not impact the Company's consolidated financial statements. ASU 2018-16 : Derivatives and Hedging (Topic ASC 815) This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments. Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned below: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 ) Recently Issued Accounting Standards Not Adopted as of December 29, 2019 ASU 2018-18 : Collaborative Arrangements This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements. ASU 2016-13 : Financial Instruments - Credit Losses This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements.
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $7.0 billion and $5.8 billion as of December 29, 2019 and December 30, 2018, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal reporting years 2019 , 2018 and 2017 . Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were approximately 2.0% of the total revenues and are included in sales to customers. See Note 18 to the Consolidated Financial Statements for further disaggregation of revenue.
Shipping and Handling	Shipping and Handling Shipping and handling costs incurred were $1.0 billion , $1.1 billion and $1.0 billion in 2019 , 2018 and 2017 , respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2019 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Product Liability	Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.
Research and Development	Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S.
Advertising	Advertising
Income Taxes	Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of the global intangible low-taxed income (GILTI) in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). In fiscal 2018, the Company elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.8 billion under current enacted tax laws and regulations and at current currency exchange rates.
Net Earnings Per Share	Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Annual Closing Date	Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks , and therefore includes additional shipping days, as was the case in 2015, and will be the case again in 2020.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 29, 2019
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements	Accounting Standards adopted in the fiscal 2018 with a cumulative effect to the 2018 opening balance of Retained Earnings The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned below: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 )
Estimated Useful Lives of Assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years

Cash, Cash Equivalents and Cu_2

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Dec. 29, 2019
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalent Composition	At the end of the fiscal year 2019 and 2018 , cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2019 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,637 2,637 — Non-U.S. Sovereign Securities (1) 439 149 290 U.S. Reverse repurchase agreements 6,375 6,375 — Other Reverse repurchase agreements 375 375 — Corporate debt securities (1) 1,323 889 434 Money market funds 2,864 2,864 — Time deposits (1) 906 906 — Subtotal $ 14,919 14,195 724 U.S. Gov't Securities $ 4,102 3,095 1,007 Corporate debt securities 266 15 251 Subtotal available for sale (2) $ 4,368 3,110 1,258 Total cash, cash equivalents and current marketable securities $ 17,305 1,982 (Dollars in Millions) 2018 Carrying Amount Cash & Cash Equivalents Current Marketable Securities Cash $ 2,619 2,619 — U.S. Reverse repurchase agreements 3,009 3,009 — Other Reverse repurchase agreements 443 443 — Money market funds 3,397 3,397 — Time deposits (1) 485 485 — Subtotal $ 9,953 9,953 — Gov't Securities $ 9,474 8,144 1,330 Corporate debt securities 260 10 250 Subtotal available for sale (2) $ 9,734 8,154 1,580 Total cash, cash equivalents and current marketable securities $ 18,107 1,580 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Contractual Maturities of Available for Sale Securities	The contractual maturities of the available for sale debt securities at December 29, 2019 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 4,322 4,322 Due after one year through five years 46 46 Due after five years through ten years — — Total debt securities $ 4,368 4,368

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 29, 2019
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of 2019 and 2018 , inventories were comprised of: (Dollars in Millions) 2019 2018 Raw materials and supplies $ 1,117 1,114 Goods in process 1,832 2,109 Finished goods 6,071 5,376 Total inventories (1) $ 9,020 8,599 (1) See Note 20 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 29, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment at Cost and Accumulated Depreciation	At the end of 2019 and 2018 , property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2019 2018 Land and land improvements $ 854 807 Buildings and building equipment 11,877 11,176 Machinery and equipment 26,964 25,992 Construction in progress 3,637 3,876 Total property, plant and equipment, gross $ 43,332 41,851 Less accumulated depreciation 25,674 24,816 Total property, plant and equipment, net (1) $ 17,658 17,035 (1) See Note 20 to the Consolidated Financial Statements for details on assets held for sale and the related divestitures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
Intangible Assets and Goodwill (Tables)	Dec. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	At the end of 2019 and 2018 , the gross and net amounts of intangible assets were: (Dollars in Millions) 2019 2018 Intangible assets with definite lives: Patents and trademarks — gross $ 36,634 35,194 Less accumulated amortization 13,154 9,784 Patents and trademarks — net $ 23,480 25,410 Customer relationships and other intangibles — gross $ 22,056 21,334 Less accumulated amortization 9,462 8,323 Customer relationships and other intangibles — net* $ 12,594 13,011 Intangible assets with indefinite lives: Trademarks $ 6,922 6,937 Purchased in-process research and development (1) 4,647 2,253 Total intangible assets with indefinite lives $ 11,569 9,190 Total intangible assets — net $ 47,643 47,611 *The majority is comprised of customer relationships (1) In the fiscal year 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion . Additionally, in the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter 2018 related to the development program of AL-8176.
Goodwill	Goodwill as of December 29, 2019 and December 30, 2018 , as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Pharmaceutical Medical Devices Total Goodwill at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions 168 51 184 403 Goodwill, related to divestitures — — (1,348 ) (1) (1,348 ) Currency translation/other (373 ) (97 ) (38 ) (508 ) Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,188 75 2,018 3,281 Currency translation/other (122 ) 31 (4 ) (95 ) Goodwill at December 29, 2019 $ 9,736 9,169 14,734 33,639 (1) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business. Goodwill of $0.3 billion is related to the divestiture of the Advanced Sterilization Products business which closed in 2019, and was pending and classified as assets held for sale on the Consolidated Balance Sheet as of December 30, 2018.
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2020 2021 2022 2023 2024 $4,500 4,300 4,100 4,100 4,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 29, 2019
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 29, 2019 and December 30, 2018 , net of tax: December 29, 2019 December 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 159 — — — — 56 — Amount of gain or (loss) recognized in AOCI — — — 159 — — — — 56 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (54 ) (321 ) (105 ) — 22 47 200 (220 ) — (24 ) Amount of gain or (loss) recognized in AOCI (20 ) (606 ) (94 ) — 39 (32 ) (17 ) (193 ) — (4 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 292 — — — — 133 — Amount of gain or (loss) recognized in AOCI $ — — — 415 — — — — 117 —
Schedule of Derivatives Recorded in Consolidated Balance Sheets	For the fiscal years ended December 29, 2019 and December 30, 2018 , the following amounts were recorded on the Consolidated Balance Sheet Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) December 29, 2019 December 30, 2018 December 29, 2019 December 30, 2018 Current Portion of Long-term Debt $ — 494 — 5
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended December 29, 2019 and December 30, 2018: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Recognized In Income on Derivative Derivatives Not Designated as Hedging Instruments December 29, 2019 December 30, 2018 Foreign Exchange Contracts Other (income) expense (144 ) (68 )
Schedule of Effect of Net Investment Hedges	The following table is the effect of net investment hedges for the fiscal years ended December 29, 2019 and December 30, 2018: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) December 29, 2019 December 30, 2018 December 29, 2019 December 30, 2018 Debt $ 121 218 Interest (income) expense — — Cross Currency interest rate swaps $ 488 150 Interest (income) expense — —
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments for the fiscal years ended December 29, 2019 and December 30, 2018 : December 30, 2018 December 29, 2019 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 533 104 1,148 1,148 Equity Investments without readily determinable value $ 681 (38 ) 69 712 712 December 31, 2017 December 30, 2018 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (247 ) 7 511 511 Equity Investments without readily determinable value $ 510 13 158 681 681 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended December 29, 2019 and December 30, 2018 were as follows: 2019 2018 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 209 — 209 501 Interest rate contracts (2)(4) — 693 — 693 161 Total — 902 — 902 662 Liabilities: Forward foreign exchange contracts — 426 — 426 548 Interest rate contracts (3)(4) — 193 — 193 292 Total — 619 — 619 840 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 23 — 23 32 Liabilities: Forward foreign exchange contracts — 33 — 33 32 Available For Sale Other Investments: Equity investments (5) 1,148 — — 1,148 511 Debt securities (6) $ — 4,368 — 4,368 9,734 Other Liabilities Contingent Consideration (7) 1,715 1,715 397 Gross to Net Derivative Reconciliation 2019 2018 (Dollars in Millions) Total Gross Assets $ 925 694 Credit Support Agreement (CSA) (841 ) (423 ) Total Net Asset 84 271 Total Gross Liabilities 652 872 Credit Support Agreement (CSA) (586 ) (605 ) Total Net Liabilities $ 66 267 Summarized information about changes in liabilities for contingent consideration is as follows: 2019 2018 2017 (Dollars in Millions) Beginning Balance 397 600 378 Changes in estimated fair value (8) 151 (156 ) 87 Additions 1,246 125 160 Payments (79 ) (172 ) (25 ) Ending Balance 1,715 397 600 (1) 2018 assets and liabilities are all classified as Level 2 with the exception of equity investments of $511 million , which are classified as Level 1 and contingent consideration of $397 million , classified as Level 3. (2) Includes $1 million and $6 million of non-current assets for the fiscal years ending December 29, 2019 and December 30, 2018 , respectively. (3) Includes $3 million of non-current liabilities for the fiscal years ending December 30, 2018 . (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. (6) Classified as cash equivalents and current marketable securities. (7) Includes $1,631 million (primarily related to Auris Health), $397 million and $600 million , classified as non-current other liabilities as of December 29, 2019 , December 30, 2018 and December 31, 2017 respectively. Includes $84 million classified as current liabilities as of December 29, 2019 . (8) Amounts are recorded primarily in Research and Development expense.

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
Borrowings (Tables)	Dec. 29, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of long-term debt are as follows: (Dollars in Millions) 2019 Effective Rate % 2018 Effective Rate % 4.75% Notes due 2019 (1B Euro 1.1096) (2) /(1B Euro 1.14) (3) $ — — 1,139 (2) 5.83 1.875% Notes due 2019 — — 494 1.93 0.89% Notes due 2019 — — 300 1.32 1.125% Notes due 2019 — — 699 1.13 3% Zero Coupon Convertible Subordinated Debentures due 2020 51 3.00 51 3.00 2.95% Debentures due 2020 549 3.15 548 3.15 1.950% Notes due 2020 500 1.99 499 1.99 3.55% Notes due 2021 449 3.67 449 3.67 2.45% Notes due 2021 349 2.48 349 2.48 1.65% Notes due 2021 999 1.65 998 1.65 0.250% Notes due 2022 (1B Euro 1.1096) (2) /(1B Euro 1.14) (3) 1,108 (2) 0.26 1,137 (3) 0.26 2.25% Notes due 2022 998 2.31 996 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 804 3.17 805 3.17 2.05% Notes due 2023 498 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.1096) (2) /(750MM Euro 1.14) (3) 829 (2) 0.68 851 (3) 0.68 5.50% Notes due 2024 (500MM GBP 1.2987) (2) /(500MM GBP 1.2636) (3) 645 (2) 6.75 627 (3) 6.75 2.625% Notes due 2025 748 2.63 748 2.63 2.45% Notes due 2026 1,993 2.47 1,992 2.47 2.95% Notes due 2027 996 2.96 996 2.96 1.150% Notes due 2028 (750MM Euro 1.1096) (2) /(750MM Euro 1.14) (3) 825 (2) 1.21 847 (3) 1.21 2.900% Notes due 2028 1,494 2.91 1,493 2.91 6.95% Notes due 2029 297 7.14 297 7.14 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 855 4.24 856 4.24 1.650% Notes due 2035 (1.5B Euro 1.1096) (2) /(1.5B Euro 1.14) (3) 1,649 (2) 1.68 1,693 (3) 1.68 3.55% Notes due 2036 989 3.59 988 3.59 5.95% Notes due 2037 992 5.99 991 5.99 3.625% Notes due 2037 1,487 3.64 1,486 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 991 3.42 990 3.42 4.50% Debentures due 2040 539 4.63 538 4.63 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 495 4.52 495 4.52 3.70% Notes due 2046 1,973 3.74 1,972 3.74 3.75% Notes due 2047 991 3.76 991 3.76 3.500% Notes due 2048 742 3.52 742 3.52 Other 18 — 24 — Subtotal 27,594 (4) 3.19 % (1) 30,320 (4) 3.19 (1 ) Less current portion 1,100 2,636 Total long-term debt $ 26,494 27,684 (1) Weighted average effective rate. (2) Translation rate at December 29, 2019 . (3) Translation rate at December 30, 2018 . (4) The excess of the fair value over the carrying value of debt was $3.0 billion in 2019 and $0.3 billion in 2018 .
Aggregate Maturities of Long Term Obligations	Aggregate maturities of long-term debt obligations commencing in 2020 are: (Dollars in Millions) 2020 2021 2022 2023 2024 After 2024 $1,100 1,797 2,106 1,552 1,474 19,565

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 29, 2019
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The provision for taxes on income consists of: (Dollars in Millions) 2019 2018 2017 Currently payable: U.S. taxes $ 1,941 1,284 12,095 International taxes 2,744 2,434 1,872 Total currently payable 4,685 3,718 13,967 Deferred: U.S. taxes (814 ) 1,210 (1) (1,956 ) International taxes (1,662 ) (2,226 ) 4,362 Total deferred (2,476 ) (1,016 ) 2,406 Provision for taxes on income $ 2,209 2,702 16,373
Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate	A comparison of income tax expense at the U.S. statutory rate of 21% in 2019 and 2018 and 35% in 2017 , to the Company’s effective tax rate is as follows: (Dollars in Millions) 2019 2018 2017 U.S. $ 3,543 5,575 4,865 International 13,785 12,424 12,808 Earnings before taxes on income: $ 17,328 17,999 17,673 Tax rates: U.S. statutory rate 21.0 % 21.0 35.0 International operations (1) (5.9 ) (3.7 ) (12.8 ) U.S. taxes on international income (2) 1.8 1.4 0.7 Tax benefits on share-based compensation (0.5 ) (1.5 ) (2.1 ) All other 0.2 (0.3 ) (1.5 ) TCJA and related impacts (3.9 ) (3) (1.9 ) (3) 73.3 (4) Effective Rate 12.7 % 15.0 92.6 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2017 amount also includes tax cost related to the revaluation of deferred tax balances related to the change in the Belgian statutory tax rate increasing the tax provision by approximately 3.4% . (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to balances originally recorded as part of the 2017 TCJA provisional tax charge. Further information provided below. (4) Includes U.S. state and local taxes provisionally recorded as part TCJA provisional charge which was approximately 0.6% of the total effective tax rate.
Temporary Differences and Carryforwards	mporary differences and carryforwards for 2019 and 2018 were as follows: 2019 Deferred Tax 2018 Deferred Tax (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,393 2,398 Stock based compensation 546 639 Depreciation & amortization 1,122 1,784 Non-deductible intangibles (5,752 ) (5,967 ) International R&D capitalized for tax 1,189 1,282 Reserves & liabilities 2,384 1,647 Income reported for tax purposes 1,605 1,104 Net operating loss carryforward international 838 786 Undistributed foreign earnings 765 (1,289 ) 693 (2,240 ) Global intangible low-taxed income (2,965 ) (2,971 ) Miscellaneous international 696 (81 ) 603 (93 ) Miscellaneous U.S. 410 469 Total deferred income taxes $ 11,948 (10,087 ) 11,405 (11,271 )
Summary of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2019 2018 2017 Beginning of year $ 3,326 3,151 3,041 Increases related to current year tax positions 249 242 332 Increases related to prior period tax positions 408 145 232 Decreases related to prior period tax positions (105 ) (137 ) (416 ) (1) Settlements (9 ) (40 ) (2 ) Lapse of statute of limitations (16 ) (35 ) (36 ) End of year $ 3,853 3,326 3,151 (1) In 2017, $347 million of this decrease is related to the TCJA.

Employee Related Obligations (T

Employee Related Obligations (Tables)	12 Months Ended
Employee Related Obligations (Tables)	Dec. 29, 2019
Compensation Related Costs [Abstract]
Employee Related Obligations	At the end of 2019 and 2018 , employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2019 2018 Pension benefits $ 5,538 5,327 Postretirement benefits 2,297 2,283 Postemployment benefits 3,004 2,330 Deferred compensation 338 410 Total employee obligations 11,177 10,350 Less current benefits payable 514 399 Employee related obligations — non-current $ 10,663 9,951

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	12 Months Ended
Pensions and Other Benefit Plans (Tables)	Dec. 29, 2019
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2019 , 2018 and 2017 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2017 2019 2018 2017 Service cost $ 1,163 1,283 1,080 274 269 247 Interest cost 1,096 996 927 185 148 159 Expected return on plan assets (2,322 ) (2,212 ) (2,041 ) (6 ) (7 ) (6 ) Amortization of prior service cost (credit) 4 3 2 (31 ) (31 ) (30 ) Recognized actuarial losses 579 852 609 129 123 138 Curtailments and settlements 73 1 17 — — — Net periodic benefit cost $ 593 923 594 551 502 508
Amounts Expected to be Recognized in Net Periodic Benefit Cost	Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans: (Dollars in Millions) Amortization of net transition obligation $ — Amortization of net actuarial losses 1,022 Amortization of prior service credit 29
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2019 2018 2017 2019 2018 2017 Net Periodic Benefit Cost Service cost discount rate 3.63 % 3.20 3.59 4.45 3.85 4.63 Interest cost discount rate 4.13 % 3.60 3.98 4.25 3.62 3.94 Rate of increase in compensation levels 3.99 % 3.98 4.01 4.29 4.29 4.31 Expected long-term rate of return on plan assets 8.31 % 8.46 8.43 Benefit Obligation Discount rate 2.91 % 3.76 3.30 3.39 4.40 3.78 Rate of increase in compensation levels 4.01 % 3.97 3.99 4.29 4.29 4.30
Assumed Health Care Cost Trend Rates	The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2019 2018 Health care cost trend rate assumed for next year 5.87 % 6.12 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.50 % 4.55 % Year the rate reaches the ultimate trend rate 2040 2038
Effect of One Percentage Point Change in Assumed Health Care Cost Trend Rates	A one-percentage-point change in assumed health care cost trend rates would have the following effect: One-Percentage- One-Percentage- (Dollars in Millions) Point Increase Point Decrease Health Care Plans Total interest and service cost $ 21 (17 ) Post-retirement benefit obligation $ 296 (246 )
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2019 and 2018 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2019 2018 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 31,670 33,221 4,480 4,582 Service cost 1,163 1,283 274 269 Interest cost 1,096 996 185 148 Plan participant contributions 63 66 — — Amendments — 26 — — Actuarial (gains) losses 5,178 (2,326 ) 562 (119 ) Divestitures & acquisitions (278 ) (29 ) — — Curtailments, settlements & restructuring (172 ) (21 ) — — Benefits paid from plan assets * (1,555 ) (1,018 ) (431 ) (383 ) Effect of exchange rates 23 (528 ) 6 (17 ) Projected benefit obligation — end of year $ 37,188 31,670 5,076 4,480 Change in Plan Assets Plan assets at fair value — beginning of year $ 26,818 28,404 180 281 Actual return on plan assets 6,185 (1,269 ) 19 — Company contributions 908 1,140 347 282 Plan participant contributions 63 66 — — Settlements (16 ) (13 ) — — Divestitures & acquisitions (274 ) (17 ) — — Benefits paid from plan assets * (1,555 ) (1,018 ) (431 ) (383 ) Effect of exchange rates 72 (475 ) — — Plan assets at fair value — end of year $ 32,201 26,818 115 180 Funded status — end of year $ (4,987 ) (4,852 ) (4,961 ) (4,300 ) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 551 475 — — Current liabilities (113 ) (98 ) (397 ) (281 ) Non-current liabilities (5,425 ) (5,229 ) (4,564 ) (4,019 ) Total recognized in the consolidated balance sheet — end of year $ (4,987 ) (4,852 ) (4,961 ) (4,300 ) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 8,835 8,323 1,685 1,263 Prior service cost (credit) (8 ) 2 (75 ) (106 ) Unrecognized net transition obligation — — — — Total before tax effects $ 8,827 8,325 1,610 1,157 Accumulated Benefit Obligations — end of year $ 33,416 28,533 * In 2019, the Company offered a voluntary lump-sum payment option for certain eligible former employees who are vested participants of the U.S. Qualified Defined Benefit Pension Plan. The distribution of the lump-sums was completed by the end of fiscal 2019. The amount distributed in 2019 was approximately $514 million. Retirement Plans Other Benefit Plans (Dollars in Millions) 2019 2018 2019 2018 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 593 923 551 502 Net actuarial (gain) loss 1,084 1,153 550 (111 ) Amortization of net actuarial loss (579 ) (852 ) (129 ) (123 ) Prior service cost (credit) — 26 — — Amortization of prior service (cost) credit (4 ) (3 ) 31 31 Effect of exchange rates 1 (114 ) 1 (3 ) Total loss/(income) recognized in other comprehensive income, before tax $ 502 210 453 (206 ) Total recognized in net periodic benefit cost and other comprehensive income $ 1,095 1,133 1,004 296
Information Related to the Benefit Obligation and the Fair Value of Plan Assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2019 and December 31, 2018, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2019 2018 2019 2018 2019 2018 2019 2018 Plan Assets $ 21,398 17,725 — — 10,803 9,093 — — Projected Benefit Obligation 22,034 18,609 2,544 2,176 12,132 10,467 478 418 Accumulated Benefit Obligation 19,831 16,851 2,115 1,793 11,040 9,510 430 379 Over (Under) Funded Status Projected Benefit Obligation $ (636 ) (884 ) (2,544 ) (2,176 ) (1,329 ) (1,374 ) (478 ) (418 ) Accumulated Benefit Obligation 1,567 874 (2,115 ) (1,793 ) (237 ) (417 ) (430 ) (379 )
Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2020 2021 2022 2023 2024 2025-2029 Projected future benefit payments Retirement plans $ 1,126 1,172 1,234 1,323 1,359 7,945 Other benefit plans $ 437 450 466 479 494 2,356
Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2020 2021 2022 2023 2024 2025-2029 Projected future contributions $ 103 107 113 118 127 749
Company' Retirement Plan Asset Allocation and Target Allocations	The Company’s retirement plan asset allocation at the end of 2019 and 2018 and target allocations for 2020 are as follows: Percent of Plan Assets Target Allocation 2019 2018 2020 Worldwide Retirement Plans Equity securities 74 % 71 % 69 % Debt securities 26 29 31 Total plan assets 100 % 100 % 100 %
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2019 and December 31, 2018: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (a) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 Short-term investment funds $ 119 122 405 529 — — — — 524 651 Government and agency securities — — 4,140 3,595 — — — — 4,140 3,595 Debt instruments — — 3,452 3,105 — — — — 3,452 3,105 Equity securities 12,483 11,298 2 4 — — — — 12,485 11,302 Commingled funds — — 3,338 2,304 181 133 7,580 5,201 11,099 7,638 Insurance contracts — — — — 19 193 — — 19 193 Other assets — — 9 33 — — 473 301 482 334 Investments at fair value $ 12,602 11,420 11,346 9,570 200 326 8,053 5,502 32,201 26,818 (a) The activity for the Level 3 assets is not significant for all years presented.

Capital and Treasury Stock (Tab

Capital and Treasury Stock (Tables)	12 Months Ended
Capital and Treasury Stock (Tables)	Dec. 29, 2019
Equity [Abstract]
Changes in Treasury Stock	Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at January 1, 2017 413,332 $ 28,352 Employee compensation and stock option plans (25,508 ) (3,156 ) Repurchase of common stock 49,494 6,358 Balance at December 31, 2017 437,318 31,554 Employee compensation and stock option plans (22,082 ) (3,060 ) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 34,362 Employee compensation and stock option plans (20,053 ) (2,691 ) Repurchase of common stock 49,870 6,746 Balance at December 29, 2019 487,336 $ 38,417

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Dec. 29, 2019
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total January 1, 2017 $ (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net 2017 changes 1,696 (179 ) (170 ) 355 1,702 December 31, 2017 (7,351 ) 232 (6,150 ) 70 (13,199 ) Cumulative adjustment to retained earnings — (232 ) (1) (232 ) Net 2018 changes (1,518 ) — (8 ) (265 ) (1,791 ) December 30, 2018 (8,869 ) — (6,158 ) (195 ) (15,222 ) Net 2019 changes 164 — (733 ) (100 ) (669 ) December 29, 2019 $ (8,705 ) — (6,891 ) (295 ) (15,891 ) (1) Per the adoption of ASU 2016-01- Financial Instruments

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Dec. 29, 2019
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 29, 2019 , December 30, 2018 and December 31, 2017 : (In Millions Except Per Share Amounts) 2019 2018 2017 Basic net earnings per share $ 5.72 5.70 0.48 Average shares outstanding — basic 2,645.1 2,681.5 2,692.0 Potential shares exercisable under stock option plans 136.3 139.0 139.7 Less: shares repurchased under treasury stock method (97.8 ) (92.5 ) (87.3 ) Convertible debt shares 0.7 0.7 0.9 Adjusted average shares outstanding — diluted 2,684.3 2,728.7 2,745.3 Diluted net earnings per share $ 5.63 5.61 0.47

Lease Commitments (Tables)

Lease Commitments (Tables)	12 Months Ended
Lease Commitments (Tables)	Dec. 29, 2019
Leases, Operating [Abstract]
Maturity of Lease Liabilities related to Operating Lease	The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 29, 2019 are: (Dollars in Millions) Operating Leases 2020 $ 215 2021 254 2022 197 2023 141 2024 86 After 2024 201 Total lease payments 1,094 Less: Interest 109 Present Value of lease liabilities $ 985
Schedule of Minimum Rental Payments Under Operating Leases	As of December 30, 2018, prior to the adoption of ASU 2016-02, the approximate future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year were: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases as of December 29, 2019 were as follows : (Dollars in Millions) Non-current operating lease right-of-use assets $ 957 Current operating lease liabilities 269 Non-current Operating lease liabilities 716 Total operating lease liabilities $ 985

Common Stock, Stock Option Pl_2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Dec. 29, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule Valuation Assumptions	The average fair value of options granted was $17.80 , $17.98 and $13.38 , in 2019 , 2018 and 2017 , respectively. The fair value was estimated based on the weighted average assumptions of: 2019 2018 2017 Risk-free rate 2.56 % 2.77 % 2.25 % Expected volatility 16.27 % 15.77 % 15.30 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.80 % 2.70 % 2.90 %
Summary of Stock Option Activity	A summary of option activity under the Plan as of December 29, 2019 , December 30, 2018 and December 31, 2017 , and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Average Exercise Price Aggregate Intrinsic Value (Dollars in Millions) Shares at January 1, 2017 113,455 $ 83.16 $ 3,636 Options granted 19,287 115.67 Options exercised (18,975 ) 70.87 Options canceled/forfeited (2,461 ) 101.40 Shares at December 31, 2017 111,306 90.48 5,480 Options granted 17,115 129.51 Options exercised (16,228 ) 75.44 Options canceled/forfeited (2,541 ) 112.90 Shares at December 30, 2018 109,652 98.29 3,214 Options granted 19,745 131.94 Options exercised (14,785 ) 82.43 Options canceled/forfeited (2,975 ) 125.11 Shares at December 29, 2019 111,637 $ 105.63 $ 4,478
Summary of Options Outstanding	The following table summarizes stock options outstanding and exercisable at December 29, 2019 : (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Average Exercise Price Options Average Exercise Price $58.65-$66.07 7,752 1.3 $63.71 7,752 $63.71 $72.54-$90.44 23,837 3.6 $82.08 23,837 $82.08 $100.06-$101.87 29,586 5.6 $101.07 29,083 $101.05 $115.67-$129.51 31,810 7.6 $122.32 84 $120.76 $131.94-$141.06 18,652 9.1 $131.94 5 $131.94 111,637 6.0 $105.63 60,761 $88.88 (1) Average contractual life remaining in years.
Summary of Restricted Share Units	A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2019 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 30, 2018 18,460 2,494 Granted 5,769 932 Issued (6,261 ) (996 ) Canceled/forfeited/adjusted (1,199 ) (256 ) Shares at December 29, 2019 16,769 2,174

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	12 Months Ended
Segments of Business and Geographic Areas (Tables)	Dec. 29, 2019
Segment Reporting [Abstract]
Schedule of Sales by Segment of Business	Sales to Customers % Change (Dollars in Millions) 2019 2018 2017 ’19 vs. ’18 ’18 vs. ’17 CONSUMER Baby Care U.S. $ 362 422 449 (14.2 )% (6.0 ) International 1,313 1,436 1,467 (8.6 ) (2.1 ) Worldwide 1,675 1,858 1,916 (9.9 ) (3.0 ) Beauty U.S. 2,392 2,403 2,335 (0.4 ) 2.9 International 2,201 1,979 1,865 11.2 6.1 Worldwide 4,593 4,382 4,200 4.8 4.3 Oral Care U.S. 621 637 616 (2.5 ) 3.4 International 906 918 915 (1.2 ) 0.3 Worldwide 1,528 1,555 1,531 (1.7 ) 1.6 OTC U.S. 2,010 1,850 1,716 8.6 7.8 International 2,434 2,484 2,410 (2.0 ) 3.1 Worldwide 4,444 4,334 4,126 2.5 5.0 Women's Health U.S. 12 13 12 (5.5 ) 8.3 International 974 1,036 1,038 (6.0 ) (0.2 ) Worldwide 986 1,049 1,050 (6.0 ) (0.1 ) Wound Care/Other U.S. 441 436 437 1.2 (0.2 ) International 230 239 342 (3.9 ) (30.1 ) Worldwide 671 675 779 (0.6 ) (13.4 ) TOTAL CONSUMER U.S. 5,839 5,761 5,565 1.4 3.5 International 8,059 8,092 8,037 (0.4 ) 0.7 Worldwide 13,898 13,853 13,602 0.3 1.8 PHARMACEUTICAL Immunology U.S. 9,641 9,073 8,871 6.3 2.3 International 4,309 4,047 3,373 6.5 20.0 Worldwide 13,950 13,120 12,244 6.3 7.2 REMICADE ® U.S. 3,079 3,664 4,525 (16.0 ) (19.0 ) U.S. Exports 294 436 563 (32.7 ) (22.6 ) International 1,007 1,226 1,227 (17.8 ) (0.1 ) Worldwide 4,380 5,326 6,315 (17.8 ) (15.7 ) SIMPONI / SIMPONI ARIA ® U.S. 1,159 1,051 954 10.2 10.2 International 1,029 1,033 879 (0.4 ) 17.5 Worldwide 2,188 2,084 1,833 5.0 13.7 STELARA ® U.S. 4,346 3,469 2,767 25.3 25.4 International 2,015 1,687 1,244 19.4 35.6 Worldwide 6,361 5,156 4,011 23.4 28.5 TREMFYA ® U.S. 764 453 62 68.5 * International 248 91 1 * * Worldwide 1,012 544 63 85.9 * OTHER IMMUNOLOGY U.S. — — — — — International 10 10 22 4.5 (54.5 ) Worldwide 10 10 22 4.5 (54.5 ) Infectious Diseases U.S. 1,597 1,378 1,358 15.9 1.5 International 1,815 1,926 1,796 (5.7 ) 7.2 Worldwide 3,413 3,304 3,154 3.3 4.8 EDURANT ® / rilpivirine U.S. 50 58 58 (13.7 ) 0.0 International 812 758 656 7.1 15.5 Worldwide 861 816 714 5.6 14.3 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,422 1,169 1,109 21.6 5.4 International 689 786 712 (12.3 ) 10.4 Worldwide 2,110 1,955 1,821 8.0 7.4 OTHER INFECTIOUS DISEASES U.S. 126 151 191 (16.5 ) (20.9 ) International 315 382 428 (17.6 ) (10.7 ) Worldwide 441 533 619 (17.3 ) (13.9 ) Neuroscience U.S. 2,919 2,574 2,630 13.4 (2.1 ) International 3,409 3,503 3,356 (2.7 ) 4.4 Worldwide 6,328 6,077 5,986 4.1 1.5 CONCERTA ® / Methylphenidate U.S. 233 229 384 1.7 (40.4 ) International 463 434 407 6.6 6.6 Worldwide 696 663 791 4.9 (16.2 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 2,107 1,791 1,590 17.6 12.6 International 1,224 1,137 979 7.7 16.1 Worldwide 3,330 2,928 2,569 13.7 14.0 RISPERDAL CONSTA ® U.S. 314 315 360 (0.3 ) (12.5 ) International 374 422 445 (11.4 ) (5.2 ) Worldwide 688 737 805 (6.7 ) (8.4 ) OTHER NEUROSCIENCE U.S. 266 239 296 11.4 (19.3 ) International 1,349 1,510 1,525 (10.7 ) (1.0 ) Worldwide 1,614 1,749 1,821 (7.7 ) (4.0 ) Oncology U.S. 4,299 4,331 3,098 (0.7 ) 39.8 International 6,393 5,513 4,160 16.0 32.5 Worldwide 10,692 9,844 7,258 8.6 35.6 DARZALEX ® U.S. 1,567 1,203 884 30.3 36.1 International 1,430 822 358 73.9 * Worldwide 2,998 2,025 1,242 48.0 63.0 IMBRUVICA ® U.S. 1,555 1,129 841 37.7 34.2 International 1,856 1,486 1,052 24.9 41.3 Worldwide 3,411 2,615 1,893 30.4 38.1 VELCADE ® U.S. — — — — — International 751 1,116 1,114 (32.7 ) 0.2 Worldwide 751 1,116 1,114 (32.7 ) 0.2 ZYTIGA ® / abiraterone acetate U.S. 810 1,771 1,228 (54.3 ) 44.2 International 1,985 1,727 1,277 15.0 35.2 Worldwide 2,795 3,498 2,505 (20.1 ) 39.6 OTHER ONCOLOGY U.S. 367 228 145 61.0 57.2 International 371 362 359 2.4 0.8 Worldwide 739 590 504 25.0 17.1 Pulmonary Hypertension U.S. 1,684 1,651 773 2.0 * International 939 922 554 1.9 66.4 Worldwide 2,623 2,573 1,327 1.9 93.9 OPSUMIT ® U.S. 766 700 320 9.4 * International 562 515 253 9.0 * Worldwide 1,327 1,215 573 9.2 * TRACLEER ® / bosentan U.S. 131 268 161 (51.1 ) 66.5 International 210 278 242 (24.3 ) 14.9 Worldwide 341 546 403 (37.5 ) 35.5 UPTRAVI ® U.S. 714 598 238 19.3 * International 105 65 25 62.4 * Worldwide 819 663 263 23.5 * OTHER U.S. 74 85 54 (13.7 ) 57.4 International 62 64 34 (3.7 ) 88.2 Worldwide 135 149 88 (9.4 ) 69.3 Cardiovascular / Metabolism / Other U.S. 3,734 4,279 4,744 (12.7 ) (9.8 ) International 1,458 1,537 1,543 (5.2 ) (0.4 ) Worldwide 5,192 5,816 6,287 (10.7 ) (7.5 ) XARELTO ® U.S. 2,313 2,477 2,500 (6.6 ) (0.9 ) International — — — — — Worldwide 2,313 2,477 2,500 (6.6 ) (0.9 ) INVOKANA ® / INVOKAMET ® U.S. 536 711 944 (24.6 ) (24.7 ) International 199 170 167 17.3 1.8 Worldwide 735 881 1,111 (16.5 ) (20.7 ) PROCRIT ® / EPREX ® U.S. 505 674 675 (25.1 ) (0.1 ) International 285 314 297 (9.2 ) 5.7 Worldwide 790 988 972 (20.0 ) 1.6 OTHER U.S. 380 417 625 (9.1 ) (33.3 ) International 974 1,053 1,079 (7.6 ) (2.4 ) Worldwide 1,353 1,470 1,704 (8.0 ) (13.7 ) TOTAL PHARMACEUTICAL U.S. 23,874 23,286 21,474 2.5 8.4 International 18,324 17,448 14,782 5.0 18.0 Worldwide 42,198 40,734 36,256 3.6 12.4 MEDICAL DEVICES Diabetes Care U.S. — 371 612 * (39.4 ) International — 638 1,003 * (36.4 ) Worldwide — 1,009 1,615 * (37.5 ) Diagnostics U.S. — — — — — International — — 1 — * Worldwide — — 1 — * Interventional Solutions U.S. 1,443 1,283 1,148 12.5 11.8 International 1,554 1,363 1,148 14.0 18.7 Worldwide 2,997 2,646 2,296 13.3 15.2 Orthopaedics U.S. 5,319 5,281 5,404 0.7 (2.3 ) International 3,520 3,604 3,654 (2.3 ) (1.4 ) Worldwide 8,839 8,885 9,058 (0.5 ) (1.9 ) HIPS U.S. 863 841 827 2.6 1.7 International 575 577 567 (0.3 ) 1.8 Worldwide 1,438 1,418 1,394 1.4 1.7 KNEES U.S. 889 911 948 (2.4 ) (3.9 ) International 591 591 575 0.0 2.8 Worldwide 1,480 1,502 1,523 (1.4 ) (1.4 ) TRAUMA U.S. 1,652 1,599 1,576 3.3 1.5 International 1,068 1,100 1,040 (2.9 ) 5.8 Worldwide 2,720 2,699 2,616 0.8 3.2 SPINE & OTHER U.S. 1,915 1,930 2,053 (0.8 ) (6.0 ) International 1,286 1,336 1,472 (3.8 ) (9.2 ) Worldwide 3,201 3,266 3,525 (2.0 ) (7.3 ) Surgery U.S. 3,828 4,125 4,085 (7.2 ) 1.0 International 5,673 5,776 5,474 (1.8 ) 5.5 Worldwide 9,501 9,901 9,559 (4.0 ) 3.6 ADVANCED U.S. 1,637 1,657 1,620 (1.2 ) 2.3 International 2,458 2,345 2,136 4.8 9.8 Worldwide 4,095 4,002 3,756 2.3 6.5 GENERAL U.S. 1,762 1,751 1,728 0.6 1.3 International 2,718 2,806 2,735 (3.1 ) 2.6 Worldwide 4,480 4,557 4,463 (1.7 ) 2.1 SPECIALTY U.S. 430 717 737 (40.1 ) (2.7 ) International 497 625 603 (20.5 ) 3.6 Worldwide 926 1,342 1,340 (31.0 ) 0.1 Vision U.S. 1,794 1,777 1,575 0.9 12.8 International 2,830 2,776 2,488 2.0 11.6 Worldwide 4,624 4,553 4,063 1.6 12.1 CONTACT LENSES / OTHER U.S. 1,304 1,237 1,122 5.4 10.2 International 2,088 2,065 1,914 1.1 7.9 Worldwide 3,392 3,302 3,036 2.7 8.8 SURGICAL U.S. 490 540 453 (9.4 ) 19.2 International 742 711 574 4.4 23.9 Worldwide 1,232 1,251 1,027 (1.6 ) 21.8 TOTAL MEDICAL DEVICES U.S. 12,384 12,837 12,824 (3.5 ) 0.1 International 13,579 14,157 13,768 (4.1 ) 2.8 Worldwide 25,963 26,994 26,592 (3.8 ) 1.5 WORLDWIDE U.S. 42,097 41,884 39,863 0.5 5.1 International 39,962 39,697 36,587 0.7 8.5 Worldwide $ 82,059 81,581 76,450 0.6 % 6.7 *Percentage greater than 100% or not meaningful
Schedule of Segment Reporting Information	Income Before Tax Identifiable Assets (Dollars in Millions) 2019 (3) 2018 (4) 2017 (5) 2019 2018 Consumer $ 2,061 2,320 2,524 $ 26,618 25,877 Pharmaceutical 8,816 12,568 11,083 56,292 56,636 Medical Devices 7,286 4,397 5,392 49,462 46,254 Total 18,163 19,285 18,999 132,372 128,767 Less: Expense not allocated to segments (1) 835 1,286 1,326 General corporate (2) 25,356 24,187 Worldwide total $ 17,328 17,999 17,673 $ 157,728 152,954 Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) 2019 2018 2017 2019 2018 2017 Consumer $ 328 438 485 $ 765 688 674 Pharmaceutical 950 1,012 936 3,910 3,802 2,416 Medical Devices 1,912 1,843 1,566 2,014 2,103 2,216 Segments total 3,190 3,293 2,987 6,689 6,593 5,306 General corporate 308 377 292 320 336 336 Worldwide total $ 3,498 3,670 3,279 $ 7,009 6,929 5,642
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2019 2018 2017 2019 2018 United States $ 42,097 41,884 39,863 $ 41,528 37,117 Europe 18,466 18,753 17,126 48,015 51,433 Western Hemisphere excluding U.S. 5,941 6,113 6,041 2,862 2,752 Asia-Pacific, Africa 15,555 14,831 13,420 5,486 2,733 Segments total 82,059 81,581 76,450 97,891 94,035 General corporate 1,049 1,064 Other non long-lived assets 58,788 57,855 Worldwide total $ 82,059 81,581 76,450 $ 157,728 152,954 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In 2019, the Company utilized three wholesalers distributing products for all three segments that represented approximately 15.0% , 12.0% and 11.0% of the total consolidated revenues. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0% , 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) The Consumer segment includes a gain of $0.3 billion related to the Company's previously held equity investment in DR. CI:LABO, litigation expense of $0.4 billion and a restructuring charge of $0.1 billion . The Pharmaceutical segment includes litigation expense of $4.3 billion including $4.0 billion related to the agreement in principle to settle opioid litigation (see Note 21 to the Consolidated Financial Statements for additional information regarding the opioid litigation), an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, an unrealized gain on securities of $0.6 billion , Actelion acquisition related costs of $0.2 billion and a restructuring charge of $0.1 billion . The Medical Devices segment includes a gain of $2.0 billion from the divestiture of the ASP business, a restructuring related charge of $0.4 billion , litigation expense of $0.4 billion and Auris Health acquisition related costs of $0.1 billion . (4) The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL ® and litigation expense of $0.3 billion . The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion , Actelion acquisition related costs of $0.2 billion , unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion , a restructuring related charge of $0.6 billion , AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business. (5) The Pharmaceutical segment includes $0.8 billion for Actelion acquisition and integration related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion . The Medical Devices segment includes litigation expense of $1.1 billion , a restructuring related charge of $0.8 billion , an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED ® . (6) Long-lived assets include property, plant and equipment, net for 2019 , and 2018 of $17,658 and $17,035 , respectively, and intangible assets and goodwill, net for 2019 and 2018 of $81,282 and $78,064 , respectively.

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
Selected Quarterly Financial Data (unaudited) (Tables)	Dec. 29, 2019
Selected Quarterly Financial Information [Abstract]
Summary of Selected Quarterly Financial Data (unaudited)	Selected unaudited quarterly financial data for the years 2019 and 2018 are summarized below: 2019 2018 (Dollars in Millions Except Per Share Data) First Quarter (1) Second Quarter (2) Third Quarter (3) Fourth Quarter (4) First Quarter (5) Second Quarter (6) Third Quarter (7) Fourth Quarter (8) Segment sales to customers Consumer $ 3,318 3,544 3,469 3,567 3,398 3,504 3,415 3,536 Pharmaceutical 10,244 10,529 10,877 10,548 9,844 10,354 10,346 10,190 Medical Devices 6,459 6,489 6,383 6,632 6,767 6,972 6,587 6,668 Total sales 20,021 20,562 20,729 20,747 20,009 20,830 20,348 20,394 Gross profit 13,406 13,622 13,862 13,613 13,395 13,903 13,759 13,433 Earnings before provision for taxes on income 4,422 7,041 1,647 4,218 5,481 4,973 4,423 3,122 Net earnings 3,749 5,607 1,753 4,010 4,367 3,954 3,934 3,042 Basic net earnings per share $ 1.41 2.11 0.67 1.52 1.63 1.47 1.47 1.14 Diluted net earnings per share $ 1.39 2.08 0.66 1.50 1.60 1.45 1.44 1.12 (1) The first quarter of 2019 includes a gain of $0.3 billion after-tax ( $0.3 billion before-tax) related to the Company's previously held equity investment in DR. CI:LABO, an in-process research and development expense of $703 million after-tax ( $890 million before-tax) related to the Alios asset, a litigation expense of $342 million after-tax ( $423 million before-tax), an unrealized gain on securities of $125 million after-tax ( $158 million before-tax), a restructuring related charge of $75 million after-tax ( $90 million before-tax), and acquisition related costs of $60 million after-tax ( $67 million before-tax). (2) The second quarter of 2019 includes a gain of $1.5 billion after-tax ( $2.0 billion before-tax) from the divestiture of the ASP business, a litigation expense of $342 million after-tax ( $409 million before-tax), an unrealized gain on securities of $117 million after-tax ( $148 million before-tax), a restructuring related charge of $116 million after-tax ( $142 million before-tax) and acquisition related costs of $50 million after-tax ( $55 million before-tax). (3) The third quarter of 2019 includes a litigation expense of $3,080 million after-tax ( $4,000 million before-tax) related to the agreement in principle to settle opioid litigation, a restructuring related charge of $106 million after-tax ( $128 million before-tax), acquisition related costs of $88 million after-tax ( $107 million before-tax), a $391 million benefit after-tax from the impact of tax legislation, and an unrealized loss on securities of $71 million after-tax ( $89 million before-tax). (4) The fourth quarter of 2019 includes a litigation expense of $251 million after-tax ( $264 million before-tax), an unrealized gain on securities of $277 million after-tax ( $350 million before-tax), a restructuring related charge of $214 million after-tax ( $251 million before-tax), a $184 million benefit after-tax from the impact of tax legislation, and acquisition related costs of $82 million after-tax ( $90 million before-tax). (5) The first quarter of 2018 includes an Actelion acquisition related cost of $92 million after-tax ( $96 million before-tax) and a restructuring related charge of $81 million after-tax ( $107 million before-tax). (6) The second quarter of 2018 includes a litigation expense of $609 million after-tax ( $703 million before-tax) and a restructuring related charge of $152 million after-tax ( $176 million before-tax). (7) The third quarter of 2018 includes an in-process research and development expense of $859 million after-tax ( $1,126 million before-tax) related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $184 million after and before tax, a restructuring related charge of $162 million after-tax ( $190 million before-tax) and a $265 million benefit after-tax from the impact of tax legislation. (8) The fourth quarter of 2018 includes a litigation expense of $1,113 million after-tax ( $1,288 million before-tax), a restructuring related charge of $190 million after-tax ( $227 million before-tax) and a $137 million

Business Acquisitions and Div_2

Business Acquisitions and Divestitures (Tables)	12 Months Ended
Business Acquisitions and Divestitures (Tables)	Dec. 29, 2019
Business Combinations [Abstract]
Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	(Dollars in Millions) Cash & Cash equivalents 469 Inventory (1) 759 Accounts Receivable 485 Other current assets 93 Property, plant and equipment 104 Goodwill 6,161 Intangible assets 25,010 Deferred Taxes 99 Other non-current assets 19 Total Assets Acquired 33,199 Current liabilities 956 Deferred Taxes 1,776 Other non-current liabilities 413 Total Liabilities Assumed 3,145 Net Assets Acquired 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value.
Purchase Price Allocation of Identifiable Intangible Assets	The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks* $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010
Schedule of Pro Forma Results	The following table provides pro forma results of operations for the fiscal year ended December 31, 2017, as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) 2017 Net Sales 77,681 Net Earnings 1,509 Diluted Net Earnings per Common Share 0.55

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
Restructuring (Tables)	Dec. 29, 2019
Restructuring and Related Activities [Abstract]
Summary of Severance Charges and Associated Spending	The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2019: (Dollars in Millions) Severance Asset Write-offs Other (2) Total Reserve balance, December 31, 2017 229 — 38 267 2018 activity (35 ) — 10 (25 ) Reserve balance, December 30, 2018 194 — 48 242 Current year activity: Charges — 151 460 611 Cash payments (30 ) — (424 ) (454 ) Settled non cash — (151 ) (68 ) (3) (219 ) Reserve balance, December 29, 2019 (1) $ 164 — 16 180 (1) Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 29, 2019USD ($)EmployeeSegment	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2018USD ($)
Concentration of Credit Risk [Line Items]
Accrued Rebates Returns And Promotions		$ 10,883	$ 9,380
Number of employees \| Employee		132,200
Number of business segments \| Segment		3
Deferred taxes on income		$ 7,819	7,640
Other assets		5,695	4,182
Retained earnings		$ 110,659	$ 106,216
Minimum reverse repurchase agreement collateral (as a percent)		102.00%
Sales return reserve (as a percent)		1.00%	1.00%	1.00%
Percentage of profit share payments (less than)		2.00%	2.00%	2.00%
Cost of products sold		$ 27,556	$ 27,091	$ 25,439
Shipping and handling costs as a percent of sales		0.50%
Advertising expense		$ 2,200	2,600	2,500
Provisional toll tax charge	$ 10,100
Deferred tax liability foreign taxes	4,500	$ 1,289	2,240	4,500
Deferred tax asset offset	$ 1,100			1,100
Minimum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets		3 years
Maximum \| Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets		8 years
R&D Expense
Concentration of Credit Risk [Line Items]
Concentration risk (as a percent)		5.00%
Retained Earnings
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					$ (254)
Retained Earnings \| ASU 2014-09 - Revenue from Contracts with Customers
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					(47)
Retained Earnings \| ASU 2016-01 - Financial Instruments
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					232
Retained Earnings \| ASU 2016-16 - Income Taxes: Intra-Entity Transfers
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					$ (439)
Shipping and Handling
Concentration of Credit Risk [Line Items]
Cost of products sold		$ 1,000	1,100	$ 1,000
Pharmaceutical
Concentration of Credit Risk [Line Items]
Accrued Rebates Returns And Promotions		$ 7,000	$ 5,800

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Impact of Adoption (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers	$ 20,747	$ 20,729	$ 20,562	$ 20,021	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 82,059	$ 81,581	$ 76,450
Net earnings	4,010	$ 1,753	$ 5,607	$ 3,749	3,042	$ 3,934	$ 3,954	$ 4,367	15,119	15,297	1,300
Assets	157,728				152,954				157,728	152,954
Liabilities	98,257				93,202				98,257	93,202
Equity	$ 59,471				$ 59,752				$ 59,471	$ 59,752	$ 60,160	$ 70,418

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Adjustments for Accounting Standards Update 2017-07 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cost of products sold									$ 27,556	$ 27,091	$ 25,439
Selling, marketing and administrative expenses									22,178	22,540	21,520
Research and development expense									11,355	10,775	10,594
Other (income) expense, net									2,525	1,405	(42)
Earnings before provision for taxes on income	$ 4,218	$ 1,647	$ 7,041	$ 4,422	$ 3,122	$ 4,423	$ 4,973	$ 5,481	$ 17,328	$ 17,999	$ 17,673

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount	$ 800
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment		$ (254)
ASU 2014-09 - Revenue from Contracts with Customers \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment		(47)
ASU 2016-01 - Financial Instruments \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment		232
ASU 2016-16 - Income Taxes: Intra-Entity Transfers \| Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment		$ (439)

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Dec. 29, 2019
Minimum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Minimum \| Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum \| Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum \| Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum \| Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Cash, Cash Equivalents and Cu_3

Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	$ 17,305	$ 18,107
Current Marketable Securities	1,982	1,580
Held-to-maturity Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	14,919	9,953
Cash & Cash Equivalents	14,195	9,953
Current Marketable Securities	724	0
Held-to-maturity Securities \| Cash
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,637	2,619
Cash & Cash Equivalents	2,637	2,619
Current Marketable Securities	0	0
Held-to-maturity Securities \| Other Sovereign Securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	439
Cash & Cash Equivalents	149
Current Marketable Securities	290
Held-to-maturity Securities \| U.S. Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	6,375	3,009
Cash & Cash Equivalents	6,375	3,009
Current Marketable Securities	0	0
Held-to-maturity Securities \| Other Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	375	443
Cash & Cash Equivalents	375	443
Current Marketable Securities	0	0
Held-to-maturity Securities \| Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,323
Cash & Cash Equivalents	889
Current Marketable Securities	434
Held-to-maturity Securities \| Money market funds
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	2,864	3,397
Cash & Cash Equivalents	2,864	3,397
Current Marketable Securities	0	0
Held-to-maturity Securities \| Time deposits(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	906	485
Cash & Cash Equivalents	906	485
Current Marketable Securities	0	0
Available-for-sale Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	4,368	9,734
Cash & Cash Equivalents	3,110	8,154
Current Marketable Securities	1,258	1,580
Available-for-sale Securities \| U.S. Gov't Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	4,102	9,474
Cash & Cash Equivalents	3,095	8,144
Current Marketable Securities	1,007	1,330
Available-for-sale Securities \| Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	266	260
Cash & Cash Equivalents	15	10
Current Marketable Securities	$ 251	$ 250

Cash, Cash Equivalents and Cu_4

Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details) $ in Millions	Dec. 29, 2019USD ($)
Cost Basis
Due within one year	$ 4,322
Due after one year through five years	46
Due after five years through ten years	0
Total debt securities	4,368
Fair Value
Due within one year	4,322
Due after one year through five years	46
Due after five years through ten years	0
Total debt securities	$ 4,368

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Summary of Inventories
Raw materials and supplies	$ 1,117	$ 1,114
Goods in process	1,832	2,109
Finished goods	6,071	5,376
Total inventories (1)	9,020	8,599
Discontinued Operations, Held-for-sale or Disposed of by Sale \| AdvancedSterilizationProducts
Inventory [Line Items]
Disposal Group, Including Discontinued Operation, Inventory, Current		200
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Supply Chain
Inventory [Line Items]
Disposal Group, Including Discontinued Operation, Inventory, Current	$ 100	$ 300

Property, Plant and Equipment

Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Property, Plant and Equipment, Net [Abstract]
Land and land improvements	$ 854	$ 807
Buildings and building equipment	11,877	11,176
Machinery and equipment	26,964	25,992
Construction in progress	3,637	3,876
Total property, plant and equipment, gross	43,332	41,851
Less accumulated depreciation	25,674	24,816
Total property, plant and equipment, net(1)	$ 17,658	$ 17,035

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Interest expense capitalized	$ 70	$ 86	$ 94
Depreciation expense, including the amortization of capitalized interest	$ 2,500	2,600	$ 2,600
AdvancedSterilizationProducts \| Discontinued Operations, Held-for-sale or Disposed of by Sale
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment		100
Supply Chain \| Discontinued Operations, Held-for-sale or Disposed of by Sale
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment		$ 100

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process	$ 890	$ 1,126	$ 890	$ 1,126	$ 408
Intangible assets with indefinite lives:
Indefinite lived intangible assets			11,569	9,190
Total intangible assets - net			47,643	47,611
Trademarks
Intangible assets with indefinite lives:
Indefinite lived intangible assets			6,922	6,937
Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets			4,647	2,253
Patents And Trademarks
Intangible assets with definite lives:
Finite lived intangible assets gross			36,634	35,194
Less accumulated amortization			13,154	9,784
Finite lived intangible assets net			23,480	25,410
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite lived intangible assets gross			22,056	21,334
Less accumulated amortization			9,462	8,323
Finite lived intangible assets net			12,594	$ 13,011
Auris Health \| Purchased in-process research and development
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Research and Development in Process			$ 2,900
Alios Biopharma Inc \| Purchased in-process research and development
Intangible assets with indefinite lives:
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 900	$ 800

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Goodwill [Roll Forward]
Goodwill beginning of period	$ 30,453	$ 31,906
Goodwill, related to acquisitions	3,281	403
Goodwill, related to divestitures		(1,348)
Currency translation/other	(95)	(508)
Goodwill end of period	33,639	30,453
Consumer
Goodwill [Roll Forward]
Goodwill beginning of period	8,670	8,875
Goodwill, related to acquisitions	1,188	168
Goodwill, related to divestitures		0
Currency translation/other	(122)	(373)
Goodwill end of period	9,736	8,670
Pharmaceutical
Goodwill [Roll Forward]
Goodwill beginning of period	9,063	9,109
Goodwill, related to acquisitions	75	51
Goodwill, related to divestitures		0
Currency translation/other	31	(97)
Goodwill end of period	9,169	9,063
Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	12,720	13,922
Goodwill, related to acquisitions	2,018	184
Goodwill, related to divestitures		(1,348)
Currency translation/other	(4)	(38)
Goodwill end of period	$ 14,734	$ 12,720

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Apr. 01, 2019
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)			$ 11,569	$ 9,190
Amortization expense of amortizable intangible assets			4,500	4,400	$ 3,000
Goodwill			$ 33,639	30,453	31,906
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life			12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life			21 years
Auris Health
Finite-Lived Intangible Assets [Line Items]
Goodwill						$ 2,000
Consumer
Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 9,736	8,670	8,875
Medical Devices
Finite-Lived Intangible Assets [Line Items]
Goodwill			14,734	12,720	13,922
Pharmaceutical
Finite-Lived Intangible Assets [Line Items]
Goodwill			9,169	9,063	$ 9,109
Goodwill \| AdvancedSterilizationProducts \| Medical Devices
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent				300
Goodwill \| LifeScan \| Medical Devices
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent				1,000
Purchased in-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)			$ 4,647	$ 2,253
Purchased in-process research and development \| Alios Biopharma Inc
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 900	$ 800

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Amortization of Intangible Assets (Details) $ in Millions	Dec. 29, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived intangibles, amortization expense next twelve months	$ 4,500
Finite lived intangibles, amortization expense, year two	4,300
Finite lived intangibles, amortization expense, year three	4,100
Finite lived intangibles, amortization expense, year four	4,100
Finite lived intangibles, amortization expense, year five	$ 4,000

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2018	Jan. 01, 2017
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,715	$ 397
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	1,715	397	$ 600		$ 378
Other Assets, Noncurrent	5,695	4,182
Foreign currency translation	164	(1,518)	1,696
Deferred net losses (gains) on derivatives included in accumulated other comprehensive income	$ 295
Description of Reclassification of Cash Flow Hedge Gain (Loss)	next 12 months
Maximum length of time for hedging transaction exposure	18 months
Unrealized holding gain (loss) arising during period	$ 0	(1)	159
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	151	(156)	87
Business Combination, Consideration Transferred, Liabilities Incurred	1,246	125	160
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	(79)	(172)	(25)
Foreign exchange contracts
Derivative [Line Items]
Collateral paid	255
Derivative, notional amount	45,300	41,100
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount	20,100	7,300
Interest rate swaps contracts:
Derivative [Line Items]
Derivative, notional amount		500
Equity securities \| Equity Investments with Readily Determinable Value
Derivative [Line Items]
Marketable Securities, Noncurrent	1,148	511	751
Other Assets, Noncurrent	1,148	511
Equity, Fair Value Adjustment	533	(247)
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	104	7
Equity securities \| Equity Investments without Readily Determinable Value
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss	(57)	(54)
Other Assets, Noncurrent	712	681
Equity, Fair Value Adjustment	(38)	13
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	69	158
Equity, Fair Value Adjustment, Change in Observable Prices	19	67
Equity Securities without Readily Determinable Fair Value, Amount	712	681	510
Retained Earnings
Derivative [Line Items]
Cumulative effect adjustment				$ (254)
ASU 2016-01 - Financial Instruments \| Retained Earnings
Derivative [Line Items]
Cumulative effect adjustment				$ 232
Fair Value, Inputs, Level 3
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	1,715	397
Other Current Liabilities
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	84
Other Noncurrent Liabilities
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,631	$ 397	$ 600

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Sales \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	$ 0	$ 0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Sales \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0
Sales \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(54)	47
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(20)	(32)
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cost of Products Sold \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0
Cost of Products Sold \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(321)	200
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(606)	(17)
R&D Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
R&D Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0
R&D Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(105)	(220)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(94)	(193)
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	159	56
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	159	56
Interest (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	292	133
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	415	117
Interest (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Other (Income) Expense \| Cross currency interest rate swaps contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	0	0
Other (Income) Expense \| Forward foreign exchange contracts: \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	22	(24)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	$ 39	$ (4)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Liability	$ 66	$ 267
Current Portion of Long-term Debt
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Liability	0	494
Deferred (Gain) Loss on Discontinuation of Fair Value Hedge	$ 0	$ 5

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Forward foreign exchange contracts: \| Not Designated as Hedging Instrument \| Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ (144)	$ (68)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	$ 121	$ 218
Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	488	150
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	0	0
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Equity Investment [Roll Forward]
Other Assets, Noncurrent	$ 5,695	$ 4,182
Equity securities \| Equity Investments with Readily Determinable Value
Other Investment Not Readily Marketable [Line Items]
Marketable Securities, Noncurrent	1,148	511	$ 751
Equity Investment [Roll Forward]
Equity, Fair Value Adjustment	533	(247)
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	104	7
Other Assets, Noncurrent	1,148	511
Equity securities \| Equity Investments without Readily Determinable Value
Equity Investment [Roll Forward]
Equity, Fair Value Adjustment	(38)	13
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	69	158
Other Assets, Noncurrent	712	681
Equity Securities without Readily Determinable Fair Value, Amount	$ 712	$ 681	$ 510

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 925	$ 694
Derivative Asset, Fair Value, Gross Liability	(841)	(423)
Financial assets and liabilities at fair value
Derivative assets	84	271
Derivative Instruments in Hedges, Assets, at Fair Value	902
Derivative liabilities	66	267
Derivative Instruments in Hedges, Liabilities, at Fair Value	619
Equity Securities, FV-NI	1,148	511
Debt securities	4,368	9,734
Derivative Liability, Fair Value, Gross Liability	652	872
Derivative Liability, Fair Value, Gross Asset	(586)	(605)
Business Combination, Contingent Consideration, Liability	1,715	397
Level 1
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Equity Securities, FV-NI	1,148	511
Debt securities	0
Level 2
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	902	662
Derivative Instruments in Hedges, Liabilities, at Fair Value	619	840
Equity Securities, FV-NI	0
Debt securities	4,368
Level 3
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Equity Securities, FV-NI	0
Debt securities	0
Business Combination, Contingent Consideration, Liability	1,715	397
Interest rate swaps contracts:
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	693
Derivative Instruments in Hedges, Liabilities, at Fair Value	193
Non-current assets included in interest rate contracts	1	6
Non-current liabilities included in interest rate contracts		3
Interest rate swaps contracts: \| Level 1
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Interest rate swaps contracts: \| Level 2
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	693	161
Derivative Instruments in Hedges, Liabilities, at Fair Value	193	292
Interest rate swaps contracts: \| Level 3
Financial assets and liabilities at fair value
Derivative Instruments in Hedges, Assets, at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Foreign exchange contracts
Financial assets and liabilities at fair value
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	23
Derivative Instruments in Hedges, Assets, at Fair Value	209
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	33
Derivative Instruments in Hedges, Liabilities, at Fair Value	426
Foreign exchange contracts \| Level 1
Financial assets and liabilities at fair value
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	0
Derivative Instruments in Hedges, Assets, at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	0
Foreign exchange contracts \| Level 2
Financial assets and liabilities at fair value
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	23	32
Derivative Instruments in Hedges, Assets, at Fair Value	209	501
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	33	32
Derivative Instruments in Hedges, Liabilities, at Fair Value	426	$ 548
Foreign exchange contracts \| Level 3
Financial assets and liabilities at fair value
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value	0
Derivative Instruments in Hedges, Assets, at Fair Value	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value	0
Derivative Instruments in Hedges, Liabilities, at Fair Value	$ 0

Borrowings - Schedule of Long-t

Borrowings - Schedule of Long-term Debt Instruments (Details) € in Millions, $ in Millions, £ in Billions	Dec. 29, 2019USD ($)	Dec. 29, 2019GBP (£)	Dec. 29, 2019EUR (€)	Dec. 30, 2018USD ($)	Dec. 30, 2018GBP (£)	Dec. 30, 2018EUR (€)
Debt Instrument [Line Items]
Effective interest rate	3.19%	3.19%	3.19%	3.19%	3.19%	3.19%
Borrowed under the commercial paper program	$ 1,100			$ 2,600
Total long-term debt	26,494			27,684
Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Long-term Debt	27,594			30,320
Less current portion	1,100			2,636
Total long-term debt	$ 26,494			$ 27,684
4.75% Notes due 2019 (1B Euro 1.1096)(2)/(1B Euro 1.14)(3)
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	5.83%	5.83%	5.83%
Long-term Debt	$ 0			$ 1,139
Stated interest rate (as a percent)				4.75%	4.75%	4.75%
Debt Instrument, Face Amount \| €			€ 1,000			€ 1,000
Foreign Currency Exchange Rate, Translation	1.1096	1.1096	1.1096	1.14	1.14	1.14
1.875% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	1.93%	1.93%	1.93%
Long-term Debt	$ 0			$ 494
Stated interest rate (as a percent)				1.875%	1.875%	1.875%
0.89% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	1.32%	1.32%	1.32%
Long-term Debt	$ 0			$ 300
Stated interest rate (as a percent)				0.89%	0.89%	0.89%
1.125% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	1.13%	1.13%	1.13%
Long-term Debt	$ 0			$ 699
Stated interest rate (as a percent)				1.125%	1.125%	1.125%
3% Zero Coupon Convertible Subordinated Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%
Long-term Debt	$ 51			$ 51
Stated interest rate (as a percent)	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%
2.95% Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	3.15%	3.15%	3.15%	3.15%	3.15%	3.15%
Long-term Debt	$ 549			$ 548
Stated interest rate (as a percent)	2.95%	2.95%	2.95%	2.95%	2.95%	2.95%
1.950% Notes due 2020
Debt Instrument [Line Items]
Effective interest rate	1.99%	1.99%	1.99%	1.99%	1.99%	1.99%
Long-term Debt	$ 500			$ 499
Stated interest rate (as a percent)	1.95%	1.95%	1.95%	1.95%	1.95%	1.95%
3.55% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	3.67%	3.67%	3.67%	3.67%	3.67%	3.67%
Long-term Debt	$ 449			$ 449
Stated interest rate (as a percent)	3.55%	3.55%	3.55%	3.55%	3.55%	3.55%
2.45% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	2.48%	2.48%	2.48%	2.48%	2.48%	2.48%
Long-term Debt	$ 349			$ 349
Stated interest rate (as a percent)	2.45%	2.45%	2.45%	2.45%	2.45%	2.45%
1.65% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
Long-term Debt	$ 999			$ 998
Stated interest rate (as a percent)	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
0.250% Notes due 2022 (1B Euro 1.1096)(2)/(1B Euro 1.14)(3)
Debt Instrument [Line Items]
Effective interest rate	0.26%	0.26%	0.26%	0.26%	0.26%	0.26%
Long-term Debt	$ 1,108			$ 1,137
Stated interest rate (as a percent)	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%
Debt Instrument, Face Amount \| €			€ 1,000			€ 1,000
Foreign Currency Exchange Rate, Translation	1.1096	1.1096	1.1096	1.14	1.14	1.14
2.25% Notes due 2022
Debt Instrument [Line Items]
Effective interest rate	2.31%	2.31%	2.31%	2.31%	2.31%	2.31%
Long-term Debt	$ 998			$ 996
Stated interest rate (as a percent)	2.25%	2.25%	2.25%	2.25%	2.25%	2.25%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Effective interest rate	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
Long-term Debt	$ 250			$ 250
Stated interest rate (as a percent)	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	3.17%	3.17%	3.17%	3.17%	3.17%	3.17%
Long-term Debt	$ 804			$ 805
Stated interest rate (as a percent)	3.375%	3.375%	3.375%	3.375%	3.375%	3.375%
2.05% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	2.09%	2.09%	2.09%	2.09%	2.09%	2.09%
Long-term Debt	$ 498			$ 498
Stated interest rate (as a percent)	2.05%	2.05%	2.05%	2.05%	2.05%	2.05%
0.650% Notes due 2024 (750MM Euro 1.1096)(2)/(750MM Euro 1.14)(3)
Debt Instrument [Line Items]
Effective interest rate	0.68%	0.68%	0.68%	0.68%	0.68%	0.68%
Long-term Debt	$ 829			$ 851
Stated interest rate (as a percent)	0.65%	0.65%	0.65%	0.65%	0.65%	0.65%
Debt Instrument, Face Amount \| €			€ 750			€ 750
Foreign Currency Exchange Rate, Translation	1.1096	1.1096	1.1096	1.14	1.14	1.14
5.50% Notes due 2024 (500MM GBP 1.2987)(2)/(500MM GBP 1.2636)(3)
Debt Instrument [Line Items]
Effective interest rate	6.75%	6.75%	6.75%	6.75%	6.75%	6.75%
Long-term Debt	$ 645			$ 627
Stated interest rate (as a percent)	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%
Debt Instrument, Face Amount \| £		£ 0.5			£ 0.5
Foreign Currency Exchange Rate, Translation	1.2987	1.2987	1.2987	1.2636	1.2636	1.2636
2.625% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	2.63%	2.63%	2.63%	2.63%	2.63%	2.63%
Long-term Debt	$ 748			$ 748
Stated interest rate (as a percent)	2.625%	2.625%	2.625%	2.625%	2.625%	2.625%
2.45% Notes due 2026
Debt Instrument [Line Items]
Effective interest rate	2.47%	2.47%	2.47%	2.47%	2.47%	2.47%
Long-term Debt	$ 1,993			$ 1,992
Stated interest rate (as a percent)	2.45%	2.45%	2.45%	2.45%	2.45%	2.45%
2.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	2.96%	2.96%	2.96%	2.96%	2.96%	2.96%
Long-term Debt	$ 996			$ 996
Stated interest rate (as a percent)	2.95%	2.95%	2.95%	2.95%	2.95%	2.95%
1.150% Notes due 2028 (750MM Euro 1.1096)(2)/(750MM Euro 1.14)(3)
Debt Instrument [Line Items]
Effective interest rate	1.21%	1.21%	1.21%	1.21%	1.21%	1.21%
Long-term Debt	$ 825			$ 847
Stated interest rate (as a percent)	1.15%	1.15%	1.15%	1.15%	1.15%	1.15%
Debt Instrument, Face Amount \| €			€ 750			€ 750
Foreign Currency Exchange Rate, Translation	1.1096	1.1096	1.1096	1.14	1.14	1.14
2.900% Notes due 2028
Debt Instrument [Line Items]
Effective interest rate	2.91%	2.91%	2.91%	2.91%	2.91%	2.91%
Long-term Debt	$ 1,494			$ 1,493
Stated interest rate (as a percent)	2.90%	2.90%	2.90%	2.90%	2.90%	2.90%
6.95% Notes due 2029
Debt Instrument [Line Items]
Effective interest rate	7.14%	7.14%	7.14%	7.14%	7.14%	7.14%
Long-term Debt	$ 297			$ 297
Stated interest rate (as a percent)	6.95%	6.95%	6.95%	6.95%	6.95%	6.95%
4.95% Debentures due 2033
Debt Instrument [Line Items]
Effective interest rate	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
Long-term Debt	$ 498			$ 498
Stated interest rate (as a percent)	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Effective interest rate	4.24%	4.24%	4.24%	4.24%	4.24%	4.24%
Long-term Debt	$ 855			$ 856
Stated interest rate (as a percent)	4.375%	4.375%	4.375%	4.375%	4.375%	4.375%
1.650% Notes due 2035 (1.5B Euro 1.1096)(2)/(1.5B Euro 1.14)(3)
Debt Instrument [Line Items]
Effective interest rate	1.68%	1.68%	1.68%	1.68%	1.68%	1.68%
Long-term Debt	$ 1,649			$ 1,693
Stated interest rate (as a percent)	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
Debt Instrument, Face Amount \| €			€ 1,500			€ 1,500
Foreign Currency Exchange Rate, Translation	1.1096	1.1096	1.1096	1.14	1.14	1.14
3.55% Notes due 2036
Debt Instrument [Line Items]
Effective interest rate	3.59%	3.59%	3.59%	3.59%	3.59%	3.59%
Long-term Debt	$ 989			$ 988
Stated interest rate (as a percent)	3.55%	3.55%	3.55%	3.55%	3.55%	3.55%
5.95% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	5.99%	5.99%	5.99%	5.99%	5.99%	5.99%
Long-term Debt	$ 992			$ 991
Stated interest rate (as a percent)	5.95%	5.95%	5.95%	5.95%	5.95%	5.95%
3.625% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	3.64%	3.64%	3.64%	3.64%	3.64%	3.64%
Long-term Debt	$ 1,487			$ 1,486
Stated interest rate (as a percent)	3.625%	3.625%	3.625%	3.625%	3.625%	3.625%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Effective interest rate	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
Long-term Debt	$ 696			$ 696
Stated interest rate (as a percent)	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
3.400% Notes due 2038
Debt Instrument [Line Items]
Effective interest rate	3.42%	3.42%	3.42%	3.42%	3.42%	3.42%
Long-term Debt	$ 991			$ 990
Stated interest rate (as a percent)	3.40%	3.40%	3.40%	3.40%	3.40%	3.40%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Effective interest rate	4.63%	4.63%	4.63%	4.63%	4.63%	4.63%
Long-term Debt	$ 539			$ 538
Stated interest rate (as a percent)	4.50%	4.50%	4.50%	4.50%	4.50%	4.50%
4.85% Notes due 2041
Debt Instrument [Line Items]
Effective interest rate	4.89%	4.89%	4.89%	4.89%	4.89%	4.89%
Long-term Debt	$ 297			$ 297
Stated interest rate (as a percent)	4.85%	4.85%	4.85%	4.85%	4.85%	4.85%
4.50% Notes due 2043
Debt Instrument [Line Items]
Effective interest rate	4.52%	4.52%	4.52%	4.52%	4.52%	4.52%
Long-term Debt	$ 495			$ 495
Stated interest rate (as a percent)	4.50%	4.50%	4.50%	4.50%	4.50%	4.50%
3.70% Notes due 2046
Debt Instrument [Line Items]
Effective interest rate	3.74%	3.74%	3.74%	3.74%	3.74%	3.74%
Long-term Debt	$ 1,973			$ 1,972
Stated interest rate (as a percent)	3.70%	3.70%	3.70%	3.70%	3.70%	3.70%
3.75% Notes due 2047
Debt Instrument [Line Items]
Effective interest rate	3.76%	3.76%	3.76%	3.76%	3.76%	3.76%
Long-term Debt	$ 991			$ 991
Stated interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%	3.75%
3.500% Notes due 2048
Debt Instrument [Line Items]
Effective interest rate	3.52%	3.52%	3.52%	3.52%	3.52%	3.52%
Long-term Debt	$ 742			$ 742
Stated interest rate (as a percent)	3.50%	3.50%	3.50%	3.50%	3.50%	3.50%
Other
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-term Debt	$ 18			$ 24

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
Borrowings - Narrative (Details) - USD ($) $ in Billions	Dec. 29, 2019	Dec. 30, 2018
Debt Disclosure [Abstract]
Excess of fair value over carrying value of debt	$ 3	$ 0.3
Line of Credit Facility, Initiation Date	Sep. 12, 2019
Borrowing capacity under credit facility	$ 10
Line of Credit Facility, Expiration Date	Sep. 10, 2020
Short-term borrowings and the current portion of long-term debt	$ 1.2	2.8
Borrowed under the commercial paper program	$ 1.1	$ 2.6

Borrowings - Aggregate Maturiti

Borrowings - Aggregate Maturities of Long Term Obligations (Details) $ in Millions	Dec. 29, 2019USD ($)
Aggregate maturities of long-term obligations
2019	$ 1,100
2020	1,797
2021	2,106
2022	1,552
2023	1,474
After 2024	$ 19,565

Income Taxes - Provision for I

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	35.00%
Increase in effective tax rate (as a percent)		(77.60%)
Currently payable:
U.S. taxes	$ 1,941	$ 1,284	$ 12,095
International taxes	2,744	2,434	1,872
Total currently payable	4,685	3,718	13,967
Deferred:
U.S. taxes	(814)	1,210	(1,956)
International taxes	(1,662)	(2,226)	4,362
Total deferred	(2,476)	(1,016)	2,406
Provision for taxes on income	$ 2,209	$ 2,702	$ 16,373

Income Taxes - Comparison of I

Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.									$ 3,543	$ 5,575	$ 4,865
International									13,785	12,424	12,808
Earnings before provision for taxes on income	$ 4,218	$ 1,647	$ 7,041	$ 4,422	$ 3,122	$ 4,423	$ 4,973	$ 5,481	$ 17,328	$ 17,999	$ 17,673
Tax Rates:
U.S. statutory rate									21.00%	21.00%	35.00%
International operations (1)									(5.90%)	(3.70%)	(12.80%)
U.S. taxes on international income (2)									1.80%	1.40%	0.70%
Tax benefits on share-based compensation									(0.50%)	(1.50%)	(2.10%)
All other									0.20%	(0.30%)	(1.50%)
TCJA and related impacts									(3.90%)	(1.90%)	73.30%
Effective tax rate									12.70%	15.00%	92.60%
Increase in effective tax rate (as a percent)										(77.60%)
State and Local Jurisdiction
Tax Rates:
Increase in effective tax rate (as a percent)									0.60%
Administration of the Treasury, Belgium
Tax Rates:
Increase in effective tax rate (as a percent)									3.40%		3.40%

Income Taxes - Temporary Diffe

Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred Tax Assets, Employee related obligations	$ 2,393	$ 2,398
Deferred Tax Assets, Stock based compensation	546	639
Deferred Tax Assets, Property, Plant and Equipment	1,122	1,784
Deferred Tax Assets, International R&D capitalized for tax	1,189	1,282
Deferred Tax Assets, Reserves & liabilities	2,384	1,647
Deferred Tax Assets, Income reported for tax purposes	1,605	1,104
Deferred Tax Assets, Net operating loss carryforward international	838	786
Deferred Tax Assets, Undistributed Foreign Earnings	765	693
Deferred Tax Liabilities, Non-deductible intangibles	(5,752)	(5,967)
Deferred Tax Liabilities, Undistributed Foreign Earnings	(1,289)	(2,240)	$ (4,500)
Deferred Tax Liability, Global Intangible Low-Taxed Income	(2,965)	(2,971)
Deferred Tax Assets, Miscellaneous international	696	603
Deferred Tax Assets Other Domestic	410	469
Deferred Tax Assets, Total deferred income taxes	11,948	11,405
Deferred Tax Liabilities, Miscellaneous international	(81)	(93)
Deferred Tax Liabilities, Total deferred income taxes	$ (10,087)	$ (11,271)

Income Taxes - Summary of Acti

Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Summary of unrecognized tax benefits
Beginning of year	$ 3,326	$ 3,151	$ 3,041
Increases related to current year tax positions	249	242	332
Increases related to prior period tax positions	408	145	232
Decreases related to prior period tax positions	(105)	(137)	(416)
Settlements	(9)	(40)	(2)
Lapse of statute of limitations	(16)	(35)	(36)
End of year	$ 3,853	3,326	$ 3,151
Unrecognized tax benefits decrease from TCJA		$ 347

Income Taxes - Narrative (Deta

Income Taxes - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	2 Months Ended	3 Months Ended				12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Feb. 18, 2020	Dec. 29, 2019	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Oct. 31, 2019	Jan. 01, 2017
Tax Credit Carryforward [Line Items]
U.S. statutory rate							21.00%	21.00%	35.00%
Net decrease in tax rate							2.30%
Reversal of deferred tax liability			$ 600					$ 2,800
Reversal of deferred tax asset			200					900
TJCA foreign tax credits, net deferred tax expense (benefit)			$ (400)					1,900
TJCA, foreign tax credit percent	1.70%		2.20%
Increase (decrease) in earnings before taxes, percent				23.50%
Effective tax rate reconciliation, litigation settlement, percent				2.10%
TCJA, increase (decrease) in deferred tax asset	$ 300
Increase (decrease) in unrecognized tax benefits							$ 300
Effective tax rate reconciliation, unrecognized tax benefits, percent							1.50%
Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent							1.20%
TCJA, provisional liability	8,200		$ 8,200	$ 8,200			$ 8,200
TJCA , provisional liability, non-current	7,700		7,700	7,700			7,700
Provisional tax cost						$ 13,000		200
Provisional toll tax charge						10,100
Deferred tax liability foreign taxes	1,289		1,289	1,289	$ 2,240	4,500	$ 1,289	$ 2,240	$ 4,500
Deferred tax asset offset						1,100			$ 1,100
Remeasurement of deferred tax assets and liabilities						600
GILTI, deferred tax cost					1,400
Increase (decrease) in effective tax rate (as a percent)								(77.60%)
Effective income tax rate reconciliation, deduction								1.70%
Effective income tax rate reconciliation, TCJA							3.90%	1.90%	(73.30%)
Effective income tax rate reconciliation, GILTI								1.60%
Effective income tax rate reconciliation, stock-based compensation								1.50%	2.00%
Effective income tax rate reconciliation, divestiture of business								0.80%
Unrecognized tax benefits	3,853		3,853	3,853	3,326	3,151	$ 3,853	$ 3,326	$ 3,151		$ 3,041
Unrecognized tax benefits, interest on income tax expense							50	53	$ 60
Unrecognized tax benefits, interest on income taxes accrued	559		559	559	$ 503		559	$ 503
Income tax expense recorded related to TRAF							$ 100
TRAF effect on tax rate							0.60%
Income tax expense related to change in tax rate from TRAF							$ 600
Deferred tax asset recorded related to TRAF							900
Deferred tax expense related to TRAF							$ 450
Increase (decrease) to federal tax basis step-up			300
TCJA, undistributed foreign earnings percent related to cash and cash equivalents									15.50%
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents									8.00%
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Deferred tax liability foreign taxes						$ 100			$ 100
Increase (decrease) in effective tax rate (as a percent)							0.60%
Administration of the Treasury, Belgium
Tax Credit Carryforward [Line Items]
Increase (decrease) in effective tax rate (as a percent)							3.40%		3.40%
Accrued Taxes On Income
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits	$ 900		$ 900	$ 900			$ 900
Minimum
Tax Credit Carryforward [Line Items]
TRAF, expected benefit on transitional provision							200
Maximum
Tax Credit Carryforward [Line Items]
TRAF, expected benefit on transitional provision							$ 500
Pending Litigation
Tax Credit Carryforward [Line Items]
Loss contingency, estimate of possible loss										$ 4,000
Subsequent Event \| Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Payment on unrecognized tax benefit liability		$ 600

Employee Related Obligations -

Employee Related Obligations - Employee Related Obligations (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Employee-related Liabilities [Abstract]
Pension benefits	$ 5,538	$ 5,327
Postretirement benefits	2,297	2,283
Postemployment benefits	3,004	2,330
Deferred compensation	338	410
Total employee obligations	11,177	10,350
Less current benefits payable	514	399
Employee related obligations — non-current	$ 10,663	$ 9,951

Employee Related Obligations _2

Employee Related Obligations - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Compensation Related Costs [Abstract]
Prepaid employee related obligations	$ 551	$ 475

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 1,163	$ 1,283	$ 1,080
Interest cost	1,096	996	927
Expected return on plan assets	(2,322)	(2,212)	(2,041)
Amortization of prior service cost (credit)	4	3	2
Recognized actuarial losses	579	852	609
Curtailments and settlements	73	1	17
Net periodic benefit cost	593	923	594
Other Benefit Plans
Components of net periodic benefit cost
Service cost	274	269	247
Interest cost	185	148	159
Expected return on plan assets	(6)	(7)	(6)
Amortization of prior service cost (credit)	(31)	(31)	(30)
Recognized actuarial losses	129	123	138
Curtailments and settlements	0	0	0
Net periodic benefit cost	$ 551	$ 502	$ 508

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans - Amounts Expected to be Recognized in Net Periodic Benefit Cost (Details) $ in Millions	Dec. 29, 2019USD ($)
Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year [Abstract]
Amortization of net transition obligation	$ 0
Amortization of net actuarial losses	1,022
Amortization of prior service credit	$ 29

Pensions and Other Benefit Pl_5

Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Retirement Plans
Net Periodic Benefit Cost
Service cost discount rate	3.63%	3.20%	3.59%
Interest cost discount rate	4.13%	3.60%	3.98%
Rate of increase in compensation levels	3.99%	3.98%	4.01%
Expected long-term rate of return on plan assets	8.31%	8.46%	8.43%
Benefit Obligation
Discount rate	2.91%	3.76%	3.30%
Rate of increase in compensation levels	4.01%	3.97%	3.99%
Other Benefit Plans
Net Periodic Benefit Cost
Service cost discount rate	4.45%	3.85%	4.63%
Interest cost discount rate	4.25%	3.62%	3.94%
Rate of increase in compensation levels	4.29%	4.29%	4.31%
Benefit Obligation
Discount rate	3.39%	4.40%	3.78%
Rate of increase in compensation levels	4.29%	4.29%	4.30%

Pensions and Other Benefit Pl_6

Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Health care cost trend rate assumed for next year	5.87%	6.12%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	4.50%	4.55%

Pensions and Other Benefit Pl_7

Pensions and Other Benefit Plans - Effect of One Percentage Point Change in Assumed Health Care Cost Trend Rates (Details) $ in Millions	12 Months Ended
	Dec. 29, 2019USD ($)
Effect of one percentage point change in assumed health care cost trend rates
Effect of one percentage point increase on total interest and service cost	$ 21
Effect of one percentage point decrease on total interest and service cost	(17)
Effect of one percentage point increase on post-retirement benefit obligation	296
Effect of one percentage point decrease on post-retirement benefit obligation	$ (246)

Pensions and Other Benefit Pl_8

Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	$ 551	$ 475
Current liabilities	(514)	(399)
Non-current liabilities	(10,663)	(9,951)
Retirement Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	31,670	33,221
Service cost	1,163	1,283	$ 1,080
Interest cost	1,096	996	927
Plan participant contributions	63	66
Amendments	0	26
Actuarial (gains) losses	5,178	(2,326)
Divestitures & acquisitions	(278)	(29)
Curtailments, settlements & restructuring	(172)	(21)
Benefits paid from plan assets	(1,555)	(1,018)
Effect of exchange rates	23	(528)
Projected benefit obligation - end of year	37,188	31,670	33,221
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	26,818	28,404
Actual return on plan assets	6,185	(1,269)
Company contributions	908	1,140
Plan participant contributions	63	66
Settlements	(16)	(13)
Divestitures & acquisitions	(274)	(17)
Benefits paid from plan assets	(1,555)	(1,018)
Effect of exchange rates	72	(475)
Plan assets at fair value - End of year	32,201	26,818	28,404
Funded status - end of year	(4,987)	(4,852)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	551	475
Current liabilities	(113)	(98)
Non-current liabilities	(5,425)	(5,229)
Total recognized in the consolidated balance sheet — end of year	(4,987)	(4,852)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	8,835	8,323
Prior service cost (credit)	(8)	2
Unrecognized net transition obligation	0	0
Total before tax effects	8,827	8,325
Accumulated Benefit Obligation	33,416	28,533
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	593	923	594
Net actuarial (gain) loss	1,084	1,153
Amortization of net actuarial loss	(579)	(852)
Prior service cost (credit)	0	26
Amortization of prior service (cost) credit	(4)	(3)
Effect of exchange rates	1	(114)
Total loss/(income) recognized in other comprehensive income, before tax	502	210
Total recognized in net periodic benefit cost and other comprehensive income	1,095	1,133
Other Benefit Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	4,480	4,582
Service cost	274	269	247
Interest cost	185	148	159
Plan participant contributions	0	0
Amendments	0	0
Actuarial (gains) losses	562	(119)
Divestitures & acquisitions	0	0
Curtailments, settlements & restructuring	0	0
Benefits paid from plan assets	(431)	(383)
Effect of exchange rates	6	(17)
Projected benefit obligation - end of year	5,076	4,480	4,582
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	180	281
Actual return on plan assets	19	0
Company contributions	347	282
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	(431)	(383)
Effect of exchange rates	0	0
Plan assets at fair value - End of year	115	180	281
Funded status - end of year	(4,961)	(4,300)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	0	0
Current liabilities	(397)	(281)
Non-current liabilities	(4,564)	(4,019)
Total recognized in the consolidated balance sheet — end of year	(4,961)	(4,300)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	1,685	1,263
Prior service cost (credit)	(75)	(106)
Unrecognized net transition obligation	0	0
Total before tax effects	1,610	1,157
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	551	502	$ 508
Net actuarial (gain) loss	550	(111)
Amortization of net actuarial loss	(129)	(123)
Prior service cost (credit)	0	0
Amortization of prior service (cost) credit	31	31
Effect of exchange rates	1	(3)
Total loss/(income) recognized in other comprehensive income, before tax	453	(206)
Total recognized in net periodic benefit cost and other comprehensive income	$ 1,004	$ 296

Pensions and Other Benefit Pl_9

Pensions and Other Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Percentage of corridor of greater of market value of assets	10.00%
Accumulated benefit obligation unfunded plans	$ 4,300	$ 7,500
Projected benefit obligation, unfunded plans	5,200	8,800
Plan Assets	900	4,300
Fair value of company's common stock directly held in plan assets	$ 984	$ 876
Percentage of company's common stock to plan asset	3.10%	3.30%
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 32,201	$ 26,818	$ 28,404
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	115	180	$ 281
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	489
International Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	419
Commingled funds \| Level 2 \| Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	84	72
Short-term Investments \| Level 2 \| Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 31	$ 108
Minimum \| Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	3 years
Maximum \| Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	5 years

Pensions and Other Benefit P_10

Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018
Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 21,398	$ 17,725
Projected Benefit Obligation	22,034	18,609
Accumulated Benefit Obligation	19,831	16,851
Projected Benefit Obligation	(636)	(884)
Accumulated Benefit Obligation	1,567	874
Non-Qualified Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	2,544	2,176
Accumulated Benefit Obligation	2,115	1,793
Projected Benefit Obligation	(2,544)	(2,176)
Accumulated Benefit Obligation	(2,115)	(1,793)
Funded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	10,803	9,093
Projected Benefit Obligation	12,132	10,467
Accumulated Benefit Obligation	11,040	9,510
Projected Benefit Obligation	(1,329)	(1,374)
Accumulated Benefit Obligation	(237)	(417)
Unfunded Plans \| International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	478	418
Accumulated Benefit Obligation	430	379
Projected Benefit Obligation	(478)	(418)
Accumulated Benefit Obligation	$ (430)	$ (379)

Pensions and Other Benefit P_11

Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) $ in Millions	Dec. 29, 2019USD ($)
Retirement plans
Defined Benefit Plan Disclosure [Line Items]
2020	$ 1,126
2021	1,172
2022	1,234
2023	1,323
2024	1,359
2025-2029	7,945
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
2020	437
2021	450
2022	466
2023	479
2024	494
2025-2029	$ 2,356

Pensions and Other Benefit P_12

Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) $ in Millions	Dec. 29, 2019USD ($)
Retirement Benefits [Abstract]
2020	$ 103
2021	107
2022	113
2023	118
2024	127
2025-2029	$ 749

Pensions and Other Benefit P_13

Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)	Dec. 29, 2019	Dec. 30, 2018
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	100.00%	100.00%
Target Allocation	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	74.00%	71.00%
Target Allocation	69.00%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	26.00%	29.00%
Target Allocation	31.00%

Pensions and Other Benefit P_14

Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 32,201	$ 26,818	$ 28,404
Fair Value, Measurements, Recurring
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	32,201	26,818
Investments Measured at Net Asset Value	8,053	5,502
Fair Value, Measurements, Recurring \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	12,602	11,420
Fair Value, Measurements, Recurring \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,346	9,570
Fair Value, Measurements, Recurring \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	200	326
Fair Value, Measurements, Recurring \| Short-term investment funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	524	651
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	119	122
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	405	529
Fair Value, Measurements, Recurring \| Short-term investment funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	4,140	3,595
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	4,140	3,595
Fair Value, Measurements, Recurring \| Government and agency securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,452	3,105
Fair Value, Measurements, Recurring \| Debt instruments \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Debt instruments \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,452	3,105
Fair Value, Measurements, Recurring \| Debt instruments \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	12,485	11,302
Fair Value, Measurements, Recurring \| Equity securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	12,483	11,298
Fair Value, Measurements, Recurring \| Equity securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2	4
Fair Value, Measurements, Recurring \| Equity securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,099	7,638
Investments Measured at Net Asset Value	7,580	5,201
Fair Value, Measurements, Recurring \| Commingled funds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Commingled funds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,338	2,304
Fair Value, Measurements, Recurring \| Commingled funds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	181	133
Fair Value, Measurements, Recurring \| Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	19	193
Investments Measured at Net Asset Value	0	0
Fair Value, Measurements, Recurring \| Insurance contracts \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Insurance contracts \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Insurance contracts \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	19	193
Fair Value, Measurements, Recurring \| Other assets
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	482	334
Investments Measured at Net Asset Value	473	301
Fair Value, Measurements, Recurring \| Other assets \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring \| Other assets \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	9	33
Fair Value, Measurements, Recurring \| Other assets \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 0	$ 0

Savings Plan - Narrative (Deta

Savings Plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
Savings Plan - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Savings Plan [Abstract]
Matching contributions	$ 235	$ 242	$ 214

Capital and Treasury Stock - Ch

Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Treasury Stock, Balance, Shares	457,519	437,318	413,332
Employee compensation and stock option plans, Shares	(20,053)	(22,082)	(25,508)
Treasury Stock, Ending Balance, Shares	487,336	457,519	437,318
Changes in treasury stock
Treasury Stock, Balance	$ 34,362	$ 31,554	$ 28,352
Employee compensation and stock option plans related to treasury stock	(2,691)	(3,060)	(3,156)
Repurchase of common stock, Amounts	6,746	5,868	6,358
Treasury Stock, Ending Balance	$ 38,417	$ 34,362	$ 31,554
Treasury Stock
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Repurchase of common stock, Shares	49,870	42,283	49,494
Changes in treasury stock
Repurchase of common stock, Amounts	$ 6,746	$ 5,868	$ 6,358

Capital and Treasury Stock - Na

Capital and Treasury Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Dec. 17, 2018	Oct. 13, 2015
Equity, Class of Treasury Stock [Line Items]
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000	3,119,843,000
Cash dividends paid (in dollars per share)	$ 3.75	$ 3.54	$ 3.32
Payments for Repurchase of Common Stock	$ 6,746	$ 5,868	$ 6,358
December 17, 2018 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount				$ 5,000
October 13, 2015 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 10,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		$ 59,752	$ 60,160	$ 70,418
Net change		(669)	(1,791)	1,702
Cumulative adjustment	[1]		(486)
Ending Balance		59,471	59,752	60,160
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(8,869)	(7,351)	(9,047)
Net change		164	(1,518)	1,696
Ending Balance		(8,705)	(8,869)	(7,351)
Gain/(Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		0	232	411
Net change		0	0	(179)
Cumulative adjustment			(232)
Ending Balance		0	0	232
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(6,158)	(6,150)	(5,980)
Net change		(733)	(8)	(170)
Ending Balance		(6,891)	(6,158)	(6,150)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(195)	70	(285)
Net change		(100)	(265)	355
Ending Balance		(295)	(195)	70
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(15,222)	(13,199)	(14,901)
Net change		(669)	(1,791)	1,702
Cumulative adjustment	[1]		(232)
Ending Balance		$ (15,891)	$ (15,222)	$ (13,199)

[1]	(1) See Note 1 to Consolidated Financial Statements for additional details on the effect of cumulative adjustments to retained earnings.

International Currency Transl_2

International Currency Translation - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Foreign Currency Translation [Abstract]
Foreign currency transaction gain (loss), before tax	$ (267)	$ (265)	$ (216)

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares shares in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share (in dollars per share)	$ 1.52	$ 0.67	$ 2.11	$ 1.41	$ 1.14	$ 1.47	$ 1.47	$ 1.63	$ 5.72	$ 5.70	$ 0.48
Average shares outstanding — basic (in shares)									2,645.1	2,681.5	2,692
Potential shares exercisable under stock option plans (in shares)									136.3	139	139.7
Less: shares repurchased under treasury stock method (in shares)									(97.8)	(92.5)	(87.3)
Convertible debt shares (in shares)									0.7	0.7	0.9
Average shares outstanding - diluted (in shares)									2,684.3	2,728.7	2,745.3
Diluted net earnings per share (in dollars per share)	$ 1.50	$ 0.66	$ 2.08	$ 1.39	$ 1.12	$ 1.44	$ 1.45	$ 1.60	$ 5.63	$ 5.61	$ 0.47

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Interest expense convertible debt	$ 1	$ 1	$ 1

Lease Commitments - Narrative (

Lease Commitments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 307	$ 332	$ 372
Cash paid for operating leases	$ 308
Weighted average remaining lease term	5 years 9 months 18 days
Weighted average discount rate	3.00%
Minimum
Lessee, Lease, Description [Line Items]
Lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term	55 years

Lease Commitments - Schedule of

Lease Commitments - Schedule of Operating Lease Payments Under Topic 842 (Details) $ in Millions	Dec. 29, 2019USD ($)
Leases [Abstract]
2020	$ 215
2021	254
2022	197
2023	141
2024	86
After 2024	201
Total lease payments	1,094
Less: Interest	109
Present Value of lease liabilities	$ 985

Lease Commitments - Schedule _2

Lease Commitments - Schedule of Minimum Rental Payments Under Operating Leases Under Topic 840 (Details) $ in Millions	Dec. 30, 2018USD ($)
Leases, Operating [Abstract]
2019	$ 223
2020	188
2021	154
2022	116
2023	76
After 2023	139
Total	$ 896

Lease Commitments - Supplementa

Lease Commitments - Supplemental Balance Sheet Information (Details) $ in Millions	Dec. 29, 2019USD ($)
Leases [Abstract]
Non-current operating lease right-of-use assets	$ 957
Current operating lease liabilities	269
Non-current Operating lease liabilities	716
Total operating lease liabilities	$ 985

Common Stock, Stock Option Pl_3

Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 29, 2019USD ($)StockBasedCompensationPlans$ / sharesshares	Dec. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans \| StockBasedCompensationPlans	2
Compensation cost charged for Long term incentive plan	$ 977	$ 978	$ 962
Total income tax benefit recognized	227	192	275
Total compensation cost not yet recognized for option	$ 823	$ 827	$ 798
Weighted average period for total compensation cost not yet recognized	1 year 8 months 15 days	1 year 8 months 23 days	1 year 9 months 3 days
Average fair value of option granted (in dollars per share) \| $ / shares	$ 17.80	$ 17.98	$ 13.38
Total intrinsic value of options exercised	$ 807	$ 1,028	$ 1,060
Stock options outstanding (in shares) \| shares	111,637	109,652	111,306
Stock option average life	6 years	6 years 2 months 12 days	6 years 3 months 18 days
Stock options exercisable \| shares		54,862	52,421
Stock options average price \| $ / shares		$ 82.03	$ 73.61
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average fair value of RSU's and PSU's granted \| $ / shares	$ 121.31	$ 119.67	$ 107.69
Fair Value of RSU or PSU units settled	$ 585.9	$ 613.7	$ 596.5
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Average fair value of RSU's and PSU's granted \| $ / shares	$ 124.67	$ 120.64	$ 114.13
Fair Value of RSU or PSU units settled	$ 119.1	$ 128.8	$ 132.5
Minimum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Vesting percentage	0.00%
Maximum \| Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Maximum \| Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Vesting percentage	200.00%
2012 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under long-term incentive plan \| shares	650,000
Shares available for future grants under long-term incentive plan \| shares	315,000

Common Stock, Stock Option Pl_4

Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Weighted average assumptions of fair value of options
Risk-free rate	2.56%	2.77%	2.25%
Expected volatility	16.27%	15.77%	15.30%
Expected life (in years)	7 years	7 years	7 years
Expected dividend yield	2.80%	2.70%	2.90%

Common Stock, Stock Option Pl_5

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Outstanding Shares
Options outstanding beginning of period	109,652	111,306	113,455
Options granted	19,745	17,115	19,287
Options exercised	(14,785)	(16,228)	(18,975)
Options canceled/forfeited	(2,975)	(2,541)	(2,461)
Options outstanding end of period	111,637	109,652	111,306
Weighted Average Exercise Price
Options exercise price beginning of period	$ 98.29	$ 90.48	$ 83.16
Options granted, average exercise price (in dollars per share)	131.94	129.51	115.67
Options exercised, average exercise price (in dollars per share)	82.43	75.44	70.87
Options canceled/forfeited, average exercise price (in dollars per share)	125.11	112.90	101.40
Options exercise price end of period	$ 105.63	$ 98.29	$ 90.48
Aggregate intrinsic value	$ 4,478	$ 3,214	$ 5,480	$ 3,636

Common Stock, Stock Option Pl_6

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Stock options outstanding and exercisable
Outstanding number of Options (in shares)	111,637	109,652	111,306
Outstanding, Average Life	6 years	6 years 2 months 12 days	6 years 3 months 18 days
Outstanding Average Exercise Price (in dollars per share)	$ 105.63
Exercisable number of Options (in shares)	60,761
Exercisable, Average Exercise Price (in dollars per share)	$ 88.88
$58.65-$66.07
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	58.65
Price Range, Maximum (in dollars per share)	$ 66.07
Outstanding number of Options (in shares)	7,752
Outstanding, Average Life	1 year 3 months 18 days
Outstanding Average Exercise Price (in dollars per share)	$ 63.71
Exercisable number of Options (in shares)	7,752
Exercisable, Average Exercise Price (in dollars per share)	$ 63.71
$72.54-$90.44
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	72.54
Price Range, Maximum (in dollars per share)	$ 90.44
Outstanding number of Options (in shares)	23,837
Outstanding, Average Life	3 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 82.08
Exercisable number of Options (in shares)	23,837
Exercisable, Average Exercise Price (in dollars per share)	$ 82.08
$100.06-$101.87
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	100.06
Price Range, Maximum (in dollars per share)	$ 101.87
Outstanding number of Options (in shares)	29,586
Outstanding, Average Life	5 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 101.07
Exercisable number of Options (in shares)	29,083
Exercisable, Average Exercise Price (in dollars per share)	$ 101.05
$115.67-$129.51
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	115.67
Price Range, Maximum (in dollars per share)	$ 129.51
Outstanding number of Options (in shares)	31,810
Outstanding, Average Life	7 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 122.32
Exercisable number of Options (in shares)	84
Exercisable, Average Exercise Price (in dollars per share)	$ 120.76
$131.94-$141.06
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	131.94
Price Range, Maximum (in dollars per share)	$ 141.06
Outstanding number of Options (in shares)	18,652
Outstanding, Average Life	9 years 1 month 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 131.94
Exercisable number of Options (in shares)	5
Exercisable, Average Exercise Price (in dollars per share)	$ 131.94

Common Stock, Stock Option Pl_7

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details) shares in Thousands	12 Months Ended
	Dec. 29, 2019shares
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	2,494
Shares, granted	932
Shares, issued	(996)
Shares, canceled/forfeited/adjusted	(256)
Shares, Ending balance	2,174
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	18,460
Shares, granted	5,769
Shares, issued	(6,261)
Shares, canceled/forfieted	(1,199)
Shares, Ending balance	16,769

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017	Oct. 31, 2019
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs	$ 90	$ 107	$ 55	$ 67
Sales to Customers	20,747	20,729	20,562	20,021	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 82,059	$ 81,581	$ 76,450
Percentage Change In Sales By Segment Of Business									0.60%	6.70%
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	3,567	3,469	3,544	3,318	3,536	3,415	3,504	3,398	$ 13,898	$ 13,853	13,602
Percentage Change In Sales By Segment Of Business									0.30%	1.80%
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,548	$ 10,877	$ 10,529	$ 10,244	$ 10,190	$ 10,346	$ 10,354	$ 9,844	$ 42,198	$ 40,734	36,256
Percentage Change In Sales By Segment Of Business									3.60%	12.40%
Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 13,950	$ 13,120	12,244
Percentage Change In Sales By Segment Of Business									6.30%	7.20%
Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,413	$ 3,304	3,154
Percentage Change In Sales By Segment Of Business									3.30%	4.80%
Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 6,328	$ 6,077	5,986
Percentage Change In Sales By Segment Of Business									4.10%	1.50%
Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 10,692	$ 9,844	7,258
Percentage Change In Sales By Segment Of Business									8.60%	35.60%
Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,623	$ 2,573	1,327
Percentage Change In Sales By Segment Of Business									1.90%	93.90%
Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,192	$ 5,816	6,287
Percentage Change In Sales By Segment Of Business									(10.70%)	(7.50%)
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 25,963	$ 26,994	26,592
Percentage Change In Sales By Segment Of Business									(3.80%)	1.50%
Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 1,009	1,615
Percentage Change In Sales By Segment Of Business										(37.50%)
Medical Devices \| Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	1
Percentage Change In Sales By Segment Of Business									0.00%
Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,997	$ 2,646	2,296
Percentage Change In Sales By Segment Of Business									13.30%	15.20%
Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 8,839	$ 8,885	9,058
Percentage Change In Sales By Segment Of Business									(0.50%)	(1.90%)
Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 9,501	$ 9,901	9,559
Percentage Change In Sales By Segment Of Business									(4.00%)	3.60%
Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,624	$ 4,553	4,063
Percentage Change In Sales By Segment Of Business									1.60%	12.10%
Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,675	$ 1,858	1,916
Percentage Change In Sales By Segment Of Business									(9.90%)	(3.00%)
Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,593	$ 4,382	4,200
Percentage Change In Sales By Segment Of Business									4.80%	4.30%
Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,528	$ 1,555	1,531
Percentage Change In Sales By Segment Of Business									(1.70%)	1.60%
OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,444	$ 4,334	4,126
Percentage Change In Sales By Segment Of Business									2.50%	5.00%
Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 986	$ 1,049	1,050
Percentage Change In Sales By Segment Of Business									(6.00%)	(0.10%)
Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 671	$ 675	779
Percentage Change In Sales By Segment Of Business									(0.60%)	(13.40%)
Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,380	$ 5,326	6,315
Percentage Change In Sales By Segment Of Business									(17.80%)	(15.70%)
Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,188	$ 2,084	1,833
Percentage Change In Sales By Segment Of Business									5.00%	13.70%
Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 6,361	$ 5,156	4,011
Percentage Change In Sales By Segment Of Business									23.40%	28.50%
Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,012	$ 544	63
Percentage Change In Sales By Segment Of Business									85.90%
Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 10	$ 10	22
Percentage Change In Sales By Segment Of Business									4.50%	(54.50%)
EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 861	$ 816	714
Percentage Change In Sales By Segment Of Business									5.60%	14.30%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,110	$ 1,955	1,821
Percentage Change In Sales By Segment Of Business									8.00%	7.40%
Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 441	$ 533	619
Percentage Change In Sales By Segment Of Business									(17.30%)	(13.90%)
CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 696	$ 663	791
Percentage Change In Sales By Segment Of Business									4.90%	(16.20%)
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,330	$ 2,928	2,569
Percentage Change In Sales By Segment Of Business									13.70%	14.00%
RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 688	$ 737	805
Percentage Change In Sales By Segment Of Business									(6.70%)	(8.40%)
OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,614	$ 1,749	1,821
Percentage Change In Sales By Segment Of Business									(7.70%)	(4.00%)
DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,998	$ 2,025	1,242
Percentage Change In Sales By Segment Of Business									48.00%	63.00%
IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,411	$ 2,615	1,893
Percentage Change In Sales By Segment Of Business									30.40%	38.10%
VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 751	$ 1,116	1,114
Percentage Change In Sales By Segment Of Business									(32.70%)	0.20%
ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,795	$ 3,498	2,505
Percentage Change In Sales By Segment Of Business									(20.10%)	39.60%
Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 739	$ 590	504
Percentage Change In Sales By Segment Of Business									25.00%	17.10%
OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,327	$ 1,215	573
Percentage Change In Sales By Segment Of Business									9.20%
TRACLEER \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 341	$ 546	403
Percentage Change In Sales By Segment Of Business									(37.50%)	35.50%
UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 819	$ 663	263
Percentage Change In Sales By Segment Of Business									23.50%
Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 135	$ 149	88
Percentage Change In Sales By Segment Of Business									(9.40%)	69.30%
Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,353	$ 1,470	1,704
Percentage Change In Sales By Segment Of Business									(8.00%)	(13.70%)
Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,313	$ 2,477	2,500
Percentage Change In Sales By Segment Of Business									(6.60%)	(0.90%)
INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 735	$ 881	1,111
Percentage Change In Sales By Segment Of Business									(16.50%)	(20.70%)
PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 790	$ 988	972
Percentage Change In Sales By Segment Of Business									(20.00%)	1.60%
HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,438	$ 1,418	1,394
Percentage Change In Sales By Segment Of Business									1.40%	1.70%
KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,480	$ 1,502	1,523
Percentage Change In Sales By Segment Of Business									(1.40%)	(1.40%)
TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,720	$ 2,699	2,616
Percentage Change In Sales By Segment Of Business									0.80%	3.20%
SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,201	$ 3,266	3,525
Percentage Change In Sales By Segment Of Business									(2.00%)	(7.30%)
ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,095	$ 4,002	3,756
Percentage Change In Sales By Segment Of Business									2.30%	6.50%
GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,480	$ 4,557	4,463
Percentage Change In Sales By Segment Of Business									(1.70%)	2.10%
SPECIALTY \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 926	$ 1,342	1,340
Percentage Change In Sales By Segment Of Business									(31.00%)	0.10%
CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,392	$ 3,302	3,036
Percentage Change In Sales By Segment Of Business									2.70%	8.80%
SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,232	$ 1,251	1,027
Percentage Change In Sales By Segment Of Business									(1.60%)	21.80%
United States
Segment Reporting Information [Line Items]
Sales to Customers									$ 42,097	$ 41,884	39,863
Percentage Change In Sales By Segment Of Business									0.50%	5.10%
United States \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,839	$ 5,761	5,565
Percentage Change In Sales By Segment Of Business									1.40%	3.50%
United States \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									$ 23,874	$ 23,286	21,474
Percentage Change In Sales By Segment Of Business									2.50%	8.40%
United States \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 9,641	$ 9,073	8,871
Percentage Change In Sales By Segment Of Business									6.30%	2.30%
United States \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,597	$ 1,378	1,358
Percentage Change In Sales By Segment Of Business									15.90%	1.50%
United States \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,919	$ 2,574	2,630
Percentage Change In Sales By Segment Of Business									13.40%	(2.10%)
United States \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,299	$ 4,331	3,098
Percentage Change In Sales By Segment Of Business									(0.70%)	39.80%
United States \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,684	$ 1,651	773
Percentage Change In Sales By Segment Of Business									2.00%
United States \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,734	$ 4,279	4,744
Percentage Change In Sales By Segment Of Business									(12.70%)	(9.80%)
United States \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 12,384	$ 12,837	12,824
Percentage Change In Sales By Segment Of Business									(3.50%)	0.10%
United States \| Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 371	612
Percentage Change In Sales By Segment Of Business										(39.40%)
United States \| Medical Devices \| Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
United States \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,443	$ 1,283	1,148
Percentage Change In Sales By Segment Of Business									12.50%	11.80%
United States \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,319	$ 5,281	5,404
Percentage Change In Sales By Segment Of Business									0.70%	(2.30%)
United States \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,828	$ 4,125	4,085
Percentage Change In Sales By Segment Of Business									(7.20%)	1.00%
United States \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,794	$ 1,777	1,575
Percentage Change In Sales By Segment Of Business									0.90%	12.80%
United States \| Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 362	$ 422	449
Percentage Change In Sales By Segment Of Business									(14.20%)	(6.00%)
United States \| Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,392	$ 2,403	2,335
Percentage Change In Sales By Segment Of Business									(0.40%)	2.90%
United States \| Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 621	$ 637	616
Percentage Change In Sales By Segment Of Business									(2.50%)	3.40%
United States \| OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,010	$ 1,850	1,716
Percentage Change In Sales By Segment Of Business									8.60%	7.80%
United States \| Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 12	$ 13	12
Percentage Change In Sales By Segment Of Business									(5.50%)	8.30%
United States \| Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 441	$ 436	437
Percentage Change In Sales By Segment Of Business									1.20%	(0.20%)
United States \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,079	$ 3,664	4,525
Percentage Change In Sales By Segment Of Business									(16.00%)	(19.00%)
United States \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,159	$ 1,051	954
Percentage Change In Sales By Segment Of Business									10.20%	10.20%
United States \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,346	$ 3,469	2,767
Percentage Change In Sales By Segment Of Business									25.30%	25.40%
United States \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 764	$ 453	62
Percentage Change In Sales By Segment Of Business									68.50%
United States \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
United States \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 50	$ 58	58
Percentage Change In Sales By Segment Of Business									(13.70%)	0.00%
United States \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,422	$ 1,169	1,109
Percentage Change In Sales By Segment Of Business									21.60%	5.40%
United States \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 126	$ 151	191
Percentage Change In Sales By Segment Of Business									(16.50%)	(20.90%)
United States \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 233	$ 229	384
Percentage Change In Sales By Segment Of Business									1.70%	(40.40%)
United States \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,107	$ 1,791	1,590
Percentage Change In Sales By Segment Of Business									17.60%	12.60%
United States \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 314	$ 315	360
Percentage Change In Sales By Segment Of Business									(0.30%)	(12.50%)
United States \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 266	$ 239	296
Percentage Change In Sales By Segment Of Business									11.40%	(19.30%)
United States \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,567	$ 1,203	884
Percentage Change In Sales By Segment Of Business									30.30%	36.10%
United States \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,555	$ 1,129	841
Percentage Change In Sales By Segment Of Business									37.70%	34.20%
United States \| VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
United States \| ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 810	$ 1,771	1,228
Percentage Change In Sales By Segment Of Business									(54.30%)	44.20%
United States \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 367	$ 228	145
Percentage Change In Sales By Segment Of Business									61.00%	57.20%
United States \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 766	$ 700	320
Percentage Change In Sales By Segment Of Business									9.40%
United States \| TRACLEER \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 131	$ 268	161
Percentage Change In Sales By Segment Of Business									(51.10%)	66.50%
United States \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 714	$ 598	238
Percentage Change In Sales By Segment Of Business									19.30%
United States \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 74	$ 85	54
Percentage Change In Sales By Segment Of Business									(13.70%)	57.40%
United States \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 380	$ 417	625
Percentage Change In Sales By Segment Of Business									(9.10%)	(33.30%)
United States \| Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,313	$ 2,477	2,500
Percentage Change In Sales By Segment Of Business									(6.60%)	(0.90%)
United States \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 536	$ 711	944
Percentage Change In Sales By Segment Of Business									(24.60%)	(24.70%)
United States \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 505	$ 674	675
Percentage Change In Sales By Segment Of Business									(25.10%)	(0.10%)
United States \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 863	$ 841	827
Percentage Change In Sales By Segment Of Business									2.60%	1.70%
United States \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 889	$ 911	948
Percentage Change In Sales By Segment Of Business									(2.40%)	(3.90%)
United States \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,652	$ 1,599	1,576
Percentage Change In Sales By Segment Of Business									3.30%	1.50%
United States \| SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,915	$ 1,930	2,053
Percentage Change In Sales By Segment Of Business									(0.80%)	(6.00%)
United States \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,637	$ 1,657	1,620
Percentage Change In Sales By Segment Of Business									(1.20%)	2.30%
United States \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,762	$ 1,751	1,728
Percentage Change In Sales By Segment Of Business									0.60%	1.30%
United States \| SPECIALTY \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 430	$ 717	737
Percentage Change In Sales By Segment Of Business									(40.10%)	(2.70%)
United States \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,304	$ 1,237	1,122
Percentage Change In Sales By Segment Of Business									5.40%	10.20%
United States \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 490	$ 540	453
Percentage Change In Sales By Segment Of Business									(9.40%)	19.20%
Non-US
Segment Reporting Information [Line Items]
Sales to Customers									$ 39,962	$ 39,697	36,587
Percentage Change In Sales By Segment Of Business									0.70%	8.50%
Non-US \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 8,059	$ 8,092	8,037
Percentage Change In Sales By Segment Of Business									(0.40%)	0.70%
Non-US \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									$ 18,324	$ 17,448	14,782
Percentage Change In Sales By Segment Of Business									5.00%	18.00%
Non-US \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,309	$ 4,047	3,373
Percentage Change In Sales By Segment Of Business									6.50%	20.00%
Non-US \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,815	$ 1,926	1,796
Percentage Change In Sales By Segment Of Business									(5.70%)	7.20%
Non-US \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,409	$ 3,503	3,356
Percentage Change In Sales By Segment Of Business									(2.70%)	4.40%
Non-US \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 6,393	$ 5,513	4,160
Percentage Change In Sales By Segment Of Business									16.00%	32.50%
Non-US \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 939	$ 922	554
Percentage Change In Sales By Segment Of Business									1.90%	66.40%
Non-US \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,458	$ 1,537	1,543
Percentage Change In Sales By Segment Of Business									(5.20%)	(0.40%)
Non-US \| Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 13,579	$ 14,157	13,768
Percentage Change In Sales By Segment Of Business									(4.10%)	2.80%
Non-US \| Medical Devices \| Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 638	1,003
Percentage Change In Sales By Segment Of Business										(36.40%)
Non-US \| Medical Devices \| Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	1
Percentage Change In Sales By Segment Of Business									0.00%
Non-US \| Medical Devices \| Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,554	$ 1,363	1,148
Percentage Change In Sales By Segment Of Business									14.00%	18.70%
Non-US \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,520	$ 3,604	3,654
Percentage Change In Sales By Segment Of Business									(2.30%)	(1.40%)
Non-US \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,673	$ 5,776	5,474
Percentage Change In Sales By Segment Of Business									(1.80%)	5.50%
Non-US \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,830	$ 2,776	2,488
Percentage Change In Sales By Segment Of Business									2.00%	11.60%
Non-US \| Baby Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,313	$ 1,436	1,467
Percentage Change In Sales By Segment Of Business									(8.60%)	(2.10%)
Non-US \| Beauty \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,201	$ 1,979	1,865
Percentage Change In Sales By Segment Of Business									11.20%	6.10%
Non-US \| Oral Care \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 906	$ 918	915
Percentage Change In Sales By Segment Of Business									(1.20%)	0.30%
Non-US \| OTC \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,434	$ 2,484	2,410
Percentage Change In Sales By Segment Of Business									(2.00%)	3.10%
Non-US \| Women's Health \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 974	$ 1,036	1,038
Percentage Change In Sales By Segment Of Business									(6.00%)	(0.20%)
Non-US \| Wound Care and Other \| Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 230	$ 239	342
Percentage Change In Sales By Segment Of Business									(3.90%)	(30.10%)
Non-US \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,007	$ 1,226	1,227
Percentage Change In Sales By Segment Of Business									(17.80%)	(0.10%)
Non-US \| Simponi/Simponi Aria \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,029	$ 1,033	879
Percentage Change In Sales By Segment Of Business									(0.40%)	17.50%
Non-US \| Stelara \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,015	$ 1,687	1,244
Percentage Change In Sales By Segment Of Business									19.40%	35.60%
Non-US \| Tremfya \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 248	$ 91	1
Non-US \| Other Immunology \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 10	$ 10	22
Percentage Change In Sales By Segment Of Business									4.50%	(54.50%)
Non-US \| EDURANT/rilpivirine \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 812	$ 758	656
Percentage Change In Sales By Segment Of Business									7.10%	15.50%
Non-US \| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 689	$ 786	712
Percentage Change In Sales By Segment Of Business									(12.30%)	10.40%
Non-US \| Other Infectious Diseases \| Pharmaceutical \| Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 315	$ 382	428
Percentage Change In Sales By Segment Of Business									(17.60%)	(10.70%)
Non-US \| CONCERTA/Methylphenidate \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 463	$ 434	407
Percentage Change In Sales By Segment Of Business									6.60%	6.60%
Non-US \| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,224	$ 1,137	979
Percentage Change In Sales By Segment Of Business									7.70%	16.10%
Non-US \| RISPERDAL CONSTA \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 374	$ 422	445
Percentage Change In Sales By Segment Of Business									(11.40%)	(5.20%)
Non-US \| OTHER NEUROSCIENCE \| Pharmaceutical \| Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,349	$ 1,510	1,525
Percentage Change In Sales By Segment Of Business									(10.70%)	(1.00%)
Non-US \| DARZALEX \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,430	$ 822	358
Percentage Change In Sales By Segment Of Business									73.90%
Non-US \| IMBRUVICA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,856	$ 1,486	1,052
Percentage Change In Sales By Segment Of Business									24.90%	41.30%
Non-US \| VELCADE \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 751	$ 1,116	1,114
Percentage Change In Sales By Segment Of Business									(32.70%)	0.20%
Non-US \| ZYTIGA \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,985	$ 1,727	1,277
Percentage Change In Sales By Segment Of Business									15.00%	35.20%
Non-US \| Other Oncology \| Pharmaceutical \| Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 371	$ 362	359
Percentage Change In Sales By Segment Of Business									2.40%	0.80%
Non-US \| OPSUMIT \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 562	$ 515	253
Percentage Change In Sales By Segment Of Business									9.00%
Non-US \| TRACLEER \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 210	$ 278	242
Percentage Change In Sales By Segment Of Business									(24.30%)	14.90%
Non-US \| UPTRAVI \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 105	$ 65	25
Percentage Change In Sales By Segment Of Business									62.40%
Non-US \| Other \| Pharmaceutical \| Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 62	$ 64	34
Percentage Change In Sales By Segment Of Business									(3.70%)	88.20%
Non-US \| Other \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 974	$ 1,053	1,079
Percentage Change In Sales By Segment Of Business									(7.60%)	(2.40%)
Non-US \| Xarelto \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
Non-US \| INVOKANA/INVOKAMET \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 199	$ 170	167
Percentage Change In Sales By Segment Of Business									17.30%	1.80%
Non-US \| PROCRIT/EPREX \| Pharmaceutical \| Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 285	$ 314	297
Percentage Change In Sales By Segment Of Business									(9.20%)	5.70%
Non-US \| HIPS \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 575	$ 577	567
Percentage Change In Sales By Segment Of Business									(0.30%)	1.80%
Non-US \| KNEES \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 591	$ 591	575
Percentage Change In Sales By Segment Of Business									0.00%	2.80%
Non-US \| TRAUMA \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,068	$ 1,100	1,040
Percentage Change In Sales By Segment Of Business									(2.90%)	5.80%
Non-US \| SPINE & OTHER \| Medical Devices \| Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,286	$ 1,336	1,472
Percentage Change In Sales By Segment Of Business									(3.80%)	(9.20%)
Non-US \| ADVANCED \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,458	$ 2,345	2,136
Percentage Change In Sales By Segment Of Business									4.80%	9.80%
Non-US \| GENERAL \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,718	$ 2,806	2,735
Percentage Change In Sales By Segment Of Business									(3.10%)	2.60%
Non-US \| SPECIALTY \| Medical Devices \| Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 497	$ 625	603
Percentage Change In Sales By Segment Of Business									(20.50%)	3.60%
Non-US \| CONTACT LENSES/OTHER \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,088	$ 2,065	1,914
Percentage Change In Sales By Segment Of Business									1.10%	7.90%
Non-US \| SURGICAL \| Medical Devices \| Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 742	$ 711	574
Percentage Change In Sales By Segment Of Business									4.40%	23.90%
UNITED STATES Exports \| Remicade \| Pharmaceutical \| Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 294	$ 436	$ 563
Percentage Change In Sales By Segment Of Business									(32.70%)	(22.60%)
Auris Health \| Pharmaceutical
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs									$ 100
Pending Litigation
Segment Reporting Information [Line Items]
Loss contingency, estimate of possible loss												$ 4,000

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Sales to Customers	$ 20,747	$ 20,729	$ 20,562	$ 20,021	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 82,059	$ 81,581	$ 76,450
Earnings before provision for taxes on income	4,218	1,647	7,041	4,422	3,122	4,423	4,973	5,481	17,328	17,999	17,673
Identifiable Assets	157,728				152,954				157,728	152,954
Additions to Property, Plant & Equipment									3,498	3,670	3,279
Depreciation and Amortization									7,009	6,929	5,642
United States
Segment Reporting Information [Line Items]
Sales to Customers									42,097	41,884	39,863
Non-US
Segment Reporting Information [Line Items]
Sales to Customers									39,962	39,697	36,587
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	3,567	3,469	3,544	3,318	3,536	3,415	3,504	3,398	13,898	13,853	13,602
Consumer \| United States
Segment Reporting Information [Line Items]
Sales to Customers									5,839	5,761	5,565
Consumer \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers									8,059	8,092	8,037
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	10,548	$ 10,877	$ 10,529	$ 10,244	10,190	$ 10,346	$ 10,354	$ 9,844	42,198	40,734	36,256
Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers									23,874	23,286	21,474
Pharmaceutical \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers									18,324	17,448	14,782
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									25,963	26,994	26,592
Medical Devices \| United States
Segment Reporting Information [Line Items]
Sales to Customers									12,384	12,837	12,824
Medical Devices \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers									13,579	14,157	13,768
Operating Segments
Segment Reporting Information [Line Items]
Identifiable Assets	132,372				128,767				132,372	128,767
Additions to Property, Plant & Equipment									3,190	3,293	2,987
Depreciation and Amortization									6,689	6,593	5,306
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments									835	1,286	1,326
Corporate, Non-Segment \| General Corporate
Segment Reporting Information [Line Items]
Identifiable Assets	25,356				24,187				25,356	24,187
Additions to Property, Plant & Equipment									308	377	292
Depreciation and Amortization									320	336	336
Operating Segments
Segment Reporting Information [Line Items]
Sales to Customers									82,059	81,581	76,450
Earnings before provision for taxes on income									18,163	19,285	18,999
Operating Segments \| United States
Segment Reporting Information [Line Items]
Sales to Customers									42,097	41,884	39,863
Operating Segments \| Consumer
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									2,061	2,320	2,524
Identifiable Assets	26,618				25,877				26,618	25,877
Additions to Property, Plant & Equipment									328	438	485
Depreciation and Amortization									765	688	674
Operating Segments \| Pharmaceutical
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									8,816	12,568	11,083
Identifiable Assets	56,292				56,636				56,292	56,636
Additions to Property, Plant & Equipment									950	1,012	936
Depreciation and Amortization									3,910	3,802	2,416
Operating Segments \| Medical Devices
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									7,286	4,397	5,392
Identifiable Assets	$ 49,462				$ 46,254				49,462	46,254
Additions to Property, Plant & Equipment									1,912	1,843	1,566
Depreciation and Amortization									2,014	2,103	2,216
Immunology \| Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									13,950	13,120	12,244
Immunology \| Pharmaceutical \| United States
Segment Reporting Information [Line Items]
Sales to Customers									9,641	9,073	8,871
Immunology \| Pharmaceutical \| Non-US
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,309	$ 4,047	$ 3,373

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019USD ($)	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)Segment	Dec. 31, 2017USD ($)Segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 20,747	$ 20,729	$ 20,562	$ 20,021	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 82,059	$ 81,581	$ 76,450
Identifiable Assets	157,728				152,954				157,728	152,954
Gain (Loss) on Disposition of Assets										1,200	1,300
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									151	$ (156)	$ 87
Number of segments \| Segment										3	3
Acquisition related costs	90	107	55	67
Restructuring charges	251	128	142	90	227		176		266	$ 251	$ 309
After Tax Restructuring Charge	214	106	116	75	190	162	152	81
Asset write-downs									1,096	1,258	795
In-process research and development (Note 5)				890		1,126			890	1,126	408
Litigation expense	264	4,000	409	423	1,288		703
Gain from divestiture									2,154	1,217	1,307
Unrealized Gain (Loss) on Securities	350	89	148	158
Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									25,963	26,994	26,592
Restructuring charges						190		107	400
Asset write-downs											200
Litigation expense									400	1,700	1,100
Restructuring Charge, Net of Accrual Adjustment										600	800
Gain from divestiture											700
Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	3,567	3,469	3,544	3,318	3,536	3,415	3,504	3,398	13,898	13,853	13,602
Restructuring charges									100
Litigation expense									400	300
Gain from divestiture											500
Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	10,548	$ 10,877	$ 10,529	10,244	10,190	10,346	$ 10,354	$ 9,844	42,198	40,734	36,256
Unrealized loss on securities										200
Restructuring charges									100
In-process research and development (Note 5)									900		400
Litigation expense									4,300		100
Research and Development Expense									300
Property, Plant and Equipment
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	17,658				17,035				17,658	17,035
Other Intangible Assets
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	81,282				78,064				81,282	78,064
Ci:z Holdings Co. Ltd. \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Sale of Equity Investments				$ 300					300
Alios Biopharma Inc and XO1 Limited \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
In-process research and development (Note 5)										1,100
XO1
Revenues from External Customers and Long-Lived Assets [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability						$ (184)				(200)
Actelion
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs									200	200	800
Actelion \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs									200	200	800
AMO \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs										100	100
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									42,097	41,884	39,863
United States \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									12,384	12,837	12,824
United States \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									5,839	5,761	5,565
United States \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									23,874	23,286	21,474
Corporate, Non-Segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Other Non Long Lived Assets	58,788				57,855				58,788	57,855
Corporate, Non-Segment \| General Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	1,049				1,064				1,049	1,064
Identifiable Assets	25,356				24,187				25,356	24,187
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									82,059	81,581	76,450
Long-Lived Assets	97,891				94,035				97,891	94,035
Operating Segments \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	49,462				46,254				49,462	46,254
Operating Segments \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	26,618				25,877				26,618	25,877
Operating Segments \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	56,292				56,636				56,292	56,636
Unrealized Gain (Loss) on Securities									600
Operating Segments \| NIZORAL \| Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets										300
Operating Segments \| PANCREASE \| Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets										200
Operating Segments \| LifeScan \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business										500
Operating Segments \| United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									42,097	41,884	39,863
Long-Lived Assets	41,528				37,117				41,528	37,117
Operating Segments \| Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									18,466	18,753	17,126
Long-Lived Assets	48,015				51,433				48,015	51,433
Operating Segments \| Western Hemisphere excluding U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									5,941	6,113	6,041
Long-Lived Assets	2,862				2,752				2,862	2,752
Operating Segments \| Asia-Pacific, Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									15,555	14,831	$ 13,420
Long-Lived Assets	$ 5,486				$ 2,733				$ 5,486	$ 2,733
Wholesaler 1 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									15.00%	14.00%	14.00%
Wholesaler 2 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									12.00%	11.00%	10.00%
Wholesaler 3 \| Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									11.00%	11.00%
AdvancedSterilizationProducts
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business									$ 2,000
AdvancedSterilizationProducts \| Operating Segments \| Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Business									$ 2,000

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$ 20,747	$ 20,729	$ 20,562	$ 20,021	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 82,059	$ 81,581	$ 76,450
Gross profit	13,613	13,862	13,622	13,406	13,433	13,759	13,903	13,395	54,503	54,490	51,011
Earnings before provision for taxes on income	4,218	1,647	7,041	4,422	3,122	4,423	4,973	5,481	17,328	17,999	17,673
Net earnings	$ 4,010	$ 1,753	$ 5,607	$ 3,749	$ 3,042	$ 3,934	$ 3,954	$ 4,367	$ 15,119	$ 15,297	$ 1,300
Basic net earnings per share (in dollars per share)	$ 1.52	$ 0.67	$ 2.11	$ 1.41	$ 1.14	$ 1.47	$ 1.47	$ 1.63	$ 5.72	$ 5.70	$ 0.48
Diluted net earnings per share (in dollars per share)	$ 1.50	$ 0.66	$ 2.08	$ 1.39	$ 1.12	$ 1.44	$ 1.45	$ 1.60	$ 5.63	$ 5.61	$ 0.47
Restructuring charge, after tax	$ 214	$ 106	$ 116	$ 75	$ 190	$ 162	$ 152	$ 81
Restructuring charges	251	128	142	90	227		176		$ 266	$ 251	$ 309
Litigation income (expense) net after-tax	251	3,080	342	342	1,113		609
Litigation expense	264	4,000	409	423	1,288		703
Unrealized Gain (Loss) on Securities, After-tax	277	71	117	125
Unrealized Gain (Loss) on Securities	350	89	148	158
Acquisition related costs after tax	82	88	50	60
Acquisition related costs	90	107	55	67
In-process research and development, after tax				703		859
In-process research and development (Note 5)				890		1,126			890	1,126	408
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									151	(156)	87
Asset Impairment Charges									1,096	1,258	795
Provisional charge	184	391			(137)	(265)
Actelion
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs								96
Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers									25,963	26,994	26,592
Restructuring charges						190		107	400
Litigation expense									400	1,700	1,100
Asset Impairment Charges											200
Consumer
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	3,567	3,469	3,544	3,318	3,536	3,415	3,504	3,398	13,898	13,853	13,602
Restructuring charges									100
Litigation expense									400	300
Med Devices
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$ 6,632	$ 6,383	6,489	6,459	$ 6,668	6,587	$ 6,972	6,767
Ci:z Holdings Co. Ltd. \| Consumer
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Equity Investments, After-tax				300
Gain (Loss) on Sale of Equity Investments				$ 300					300
XO1
Summary of Selected Quarterly Financial Data (unaudited)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability						$ (184)				(200)
AMO \| Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs										100	100
Actelion
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs after tax								$ 92
Acquisition related costs									200	200	800
Operating Segments
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers									82,059	81,581	76,450
Earnings before provision for taxes on income									18,163	19,285	18,999
Operating Segments \| Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Earnings before provision for taxes on income									7,286	4,397	5,392
Operating Segments \| Consumer
Summary of Selected Quarterly Financial Data (unaudited)
Earnings before provision for taxes on income									$ 2,061	$ 2,320	$ 2,524
ADVANCED \| Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Gain (Loss) on Disposition of Business, After-tax			1,500
Gain (Loss) on Disposition of Business			$ 2,000

Business Acquisitions and Div_3

Business Acquisitions and Divestitures - Narrative (Details) ¥ / shares in Units, $ / shares in Units, ¥ in Billions	Dec. 30, 2019USD ($)	Apr. 01, 2019USD ($)	Jan. 17, 2019USD ($)	Jan. 17, 2019JPY (¥)¥ / shares	Jun. 16, 2017USD ($)$ / shares	Dec. 29, 2019USD ($)	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jul. 01, 2018USD ($)	Oct. 01, 2017USD ($)	Dec. 29, 2019USD ($)	Dec. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 30, 2012USD ($)	Jan. 16, 2019	Oct. 22, 2018
Business Acquisition [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 10,000,000,000						$ 10,000,000,000
Goodwill						33,639,000,000						33,639,000,000	$ 30,453,000,000	$ 31,906,000,000
Current liabilities						1,400,000,000						1,400,000,000
Acquisition payments												5,810,000,000	899,000,000	35,151,000,000
Other Nonoperating Income (Expense)												(2,525,000,000)	(1,405,000,000)	42,000,000
Acquisition related costs						90,000,000	$ 107,000,000	$ 55,000,000	$ 67,000,000
Liabilities assumed												1,418,000,000	148,000,000	1,786,000,000
Contingent consideration						1,715,000,000						1,715,000,000	397,000,000
Indefinite lived intangible assets						11,569,000,000						11,569,000,000	9,190,000,000
Purchase price												5,810,000,000	899,000,000	35,151,000,000
Asset write-downs												1,096,000,000	1,258,000,000	795,000,000
Gain on divestitures, pre-tax													1,200,000,000	1,300,000,000
Auris Health
Business Acquisition [Line Items]
Goodwill		$ 2,000,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities		200,000,000
Current liabilities		1,800,000,000
Business Combination, Contingent Consideration, Liability, Noncurrent		$ 1,100,000,000
Business Acquisition, Discount Rate		10.00%
Acquisition payments		$ 3,400,000,000
Contingent consideration		2,350,000,000
Intangible assets		$ 3,000,000,000
XBiotech
Business Acquisition [Line Items]
Acquisition payments	$ 800,000,000
Ci:z Holdings Co. Ltd.
Business Acquisition [Line Items]
Goodwill						1,200,000,000						1,200,000,000
Current liabilities						400,000,000						400,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Adjustments Made To Intangible Assets, Other than Goodwill						100,000,000						$ 100,000,000
Business Acquisition, Percentage of Voting Interests Acquired																	20.00%
Other Nonoperating Income (Expense)									$ 300,000,000
Acquisition price (in dollars per share) \| ¥ / shares				¥ 5,900
Business Combination, Consideration Transferred			$ 2,100,000,000	¥ 230
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life												15 years 3 months 18 days
Foreign Currency Exchange Rate, Translation																109.06
Intangible assets						$ 1,500,000,000						$ 1,500,000,000
2017 Acquisitions
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired														34,400,000,000
Actelion
Business Acquisition [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory					$ 642,000,000
Goodwill, Subsequent Recognition of Deferred Tax Asset											$ 200,000,000
Business Combination, Initial Accounting Incomplete, Adjustment, Current Liabilities											$ 400,000,000
Goodwill										$ 6,161,000,000			6,200,000,000
Current liabilities										956,000,000
Acquisition payments														29,600,000,000
Acquisition price (in dollars per share) \| $ / shares					$ 280
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life					9 years
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual														1,400,000,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual														(1,400,000,000)
Acquisition related costs												$ 200,000,000	200,000,000	$ 800,000,000
Intangible assets										25,010,000,000
Idorsia
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired					9.90%	9.00%						9.00%
Convertible Note, Equity Interest, Percentage					22.10%							20.80%
AMO
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life														14 years 4 months 24 days
Synthes, Inc
Business Acquisition [Line Items]
Purchase price															$ 20,200,000,000
Purchased in-process research and development
Business Acquisition [Line Items]
Indefinite lived intangible assets						$ 4,647,000,000						$ 4,647,000,000	2,253,000,000
Medical Devices
Business Acquisition [Line Items]
Goodwill						14,734,000,000						14,734,000,000	12,720,000,000	$ 13,922,000,000
Asset write-downs														200,000,000
Medical Devices \| AMO
Business Acquisition [Line Items]
Goodwill														1,700,000,000
Acquisition payments														4,300,000,000
Finite-lived Intangible Assets Acquired														2,300,000,000
Acquisition related costs													100,000,000	100,000,000
Consumer
Business Acquisition [Line Items]
Goodwill						9,736,000,000						9,736,000,000	8,670,000,000	8,875,000,000
Maximum \| Auris Health
Business Acquisition [Line Items]
Business Combination, Probability Of Success Factor		95.00%
Maximum \| Actelion
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life					10 years
Minimum \| Auris Health
Business Acquisition [Line Items]
Business Combination, Probability Of Success Factor		55.00%
Minimum \| Actelion
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life					4 years
Intellectual Property \| Actelion
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired					$ 24,230,000,000
Intellectual Property \| Valchlor
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired										$ 400,000,000
In Process Research and Development \| 2019 Acquisitions
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired						6,800,000,000						6,800,000,000
In Process Research and Development \| 2018 Acquisitions
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired													1,000,000,000
In Process Research and Development \| 2017 Acquisitions
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired														$ 1,100,000,000
Line of Credit \| Idorsia
Business Acquisition [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					250,000,000
Convertible Debt \| Idorsia
Business Acquisition [Line Items]
Long-term Debt					$ 500,000,000	500,000,000						$ 500,000,000
Debt Instrument, Term					10 years
Debt Instrument, Redemption, Period One \| Convertible Debt \| Idorsia
Business Acquisition [Line Items]
Debt Instrument, Restrictive Covenants, Shareholder Ownership Threshold, Percent					20.00%
Convertible Note, Equity Interest, Percentage					16.00%
R&D Expense
Business Acquisition [Line Items]
Concentration risk (as a percent)												5.00%
AdvancedSterilizationProducts
Business Acquisition [Line Items]
Gain (Loss) on Disposition of Business												$ 2,000,000,000
Discontinued Operations, Held-for-sale or Disposed of by Sale \| LifeScan
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Consideration													2,100,000,000
Discontinued Operations, Held-for-sale or Disposed of by Sale \| AdvancedSterilizationProducts
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Consideration						2,800,000,000						2,800,000,000
Disposal Group, Including Discontinued Operation, Cash						2,700,000,000						2,700,000,000
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment													100,000,000
Disposal Group, Including Discontinued Operation, Goodwill													300,000,000
Disposal Group, Including Discontinued Operation, Receivables Retained						100,000,000						100,000,000
Disposal Group, Including Discontinued Operation, Inventory, Current													200,000,000
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Supply Chain
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment													100,000,000
Disposal Group, Including Discontinued Operation, Inventory, Current						$ 100,000,000						$ 100,000,000	$ 300,000,000
Discount Rate \| In Process Research and Development \| Actelion
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate (Deprecated 2018-01-31)					0.09

Business Acquisitions and Div_4

Business Acquisitions and Divestitures - Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 29, 2019	Dec. 30, 2018	Jul. 01, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 33,639	$ 30,453		$ 31,906
Current liabilities	$ 1,400
Actelion
Business Acquisition [Line Items]
Cash & Cash equivalents			$ 469
Inventory(1)			759
Accounts Receivable			485
Other current assets			93
Property, plant and equipment			104
Goodwill		$ 6,200	6,161
Intangible assets			25,010
Deferred Taxes			99
Other non-current assets			19
Total Assets Acquired			33,199
Current liabilities			956
Deferred Taxes			1,776
Other non-current liabilities			413
Total Liabilities Assumed			3,145
Net Assets Acquired			$ 30,054

Business Acquisitions and Div_5

Business Acquisitions and Divestitures - Purchase Price Allocation of Identifiable Intangible Assets (Details) - Actelion $ in Millions	Jun. 16, 2017USD ($)
Business Acquisition [Line Items]
Finite-lived and Indefinite-lived Intangible Assets Acquired	$ 25,010
In Process Research and Development
Business Acquisition [Line Items]
Indefinite-lived Intangible Assets Acquired	780
Intellectual Property
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 24,230

Business Acquisitions and Div_6

Business Acquisitions and Divestitures - Schedule of Pro Forma Results (Details) - Actelion $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares
Business Acquisition [Line Items]
Net Sales	$ 77,681
Net Earnings	$ 1,509
Diluted Net Earnings per Common Share \| $ / shares	$ 0.55

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	Jan. 20, 2020USD ($)	Dec. 29, 2019USD ($)patientclaimant	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 29, 2019USD ($)patientclaimant	Oct. 31, 2019USD ($)
Loss Contingencies [Line Items]
Restructuring charge, after tax \| $		$ 214	$ 106	$ 116	$ 75	$ 190	$ 162	$ 152	$ 81
Litigation expense \| $		$ 264	$ 4,000	$ 409	$ 423	$ 1,288		$ 703
Xarelto
Loss Contingencies [Line Items]
Number of plaintiffs		29,000								29,000
ASR
Loss Contingencies [Line Items]
Number of plaintiffs		1,100								1,100
Pinnacle Acetabular Cup System
Loss Contingencies [Line Items]
Number of plaintiffs		10,300								10,300
Risperdal
Loss Contingencies [Line Items]
Number of plaintiffs		11,900								11,900
Pelvic Meshes
Loss Contingencies [Line Items]
Number of plaintiffs		17,600								17,600
Invokana
Loss Contingencies [Line Items]
Number of plaintiffs		400								400
Physiomesh
Loss Contingencies [Line Items]
Number of plaintiffs		3,300								3,300
Talc
Loss Contingencies [Line Items]
Number of plaintiffs		17,900								17,900
Opiods [Member]
Loss Contingencies [Line Items]
Number of plaintiffs		2,800								2,800
Pending Litigation
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss \| $											$ 4,000
Judicial Ruling
Loss Contingencies [Line Items]
Loss Contingency, Damages Awarded, Value \| $		$ 8,000
Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] \| Settled Litigation
Loss Contingencies [Line Items]
Loss Contingency, Damages Awarded, Value \| $										$ 465
Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member] \| Judicial Ruling
Loss Contingencies [Line Items]
Loss Contingency, Damages Awarded, Value \| $										$ 572
DePuy ASR U.S. \| Settled Litigation
Loss Contingencies [Line Items]
Number of patients in settlement \| patient		10,000								10,000
Baby Powder \| Judicial Ruling \| Damages from Product Defects
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value \| $										$ 4,700
Subsequent Event \| Judicial Ruling
Loss Contingencies [Line Items]
Loss Contingency, Damages Awarded, Value \| $	$ 344

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
Restructuring - Narrative (Details) - USD ($) $ in Millions	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Cost, Expected Period Of Cash Outlays For Severance Paid									2 years
Restructuring charges	$ 251	$ 128	$ 142	$ 90	$ 227		$ 176		$ 266	$ 251	$ 309
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges						$ 190		$ 107	400
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges									611
Restructuring Reserve					242					242
Restructuring costs incurred since announced	800								800
Supply Chain \| Restructuring Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges									300
Supply Chain \| Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges									100
Supply Chain \| Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges									200
Supply Chain \| Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges									0
Restructuring Reserve					194					194
Supply Chain \| Asset Write-offs
Restructuring Cost and Reserve [Line Items]
Restructuring charges									151
Restructuring Reserve					0					0
Supply Chain \| Other(2)
Restructuring Cost and Reserve [Line Items]
Restructuring charges									460
Restructuring Reserve					$ 48					$ 48
Supply Chain \| Minimum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	1,900								1,900
Restructuring and Related Cost, Expected Future Savings	600								$ 600
Supply Chain \| Minimum \| Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Duration of Restructuring Plan									4 years
Supply Chain \| Maximum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	2,300								$ 2,300
Restructuring and Related Cost, Expected Future Savings	$ 800								$ 800
Supply Chain \| Maximum \| Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Duration of Restructuring Plan									5 years
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve											267
Medical Devices \| Severance
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve											229
Medical Devices \| Asset Write-offs
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve											0
Medical Devices \| Other(2)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve											$ 38

Restructuring - Summary of Seve

Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 29, 2019	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 29, 2019	Dec. 30, 2018	Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Restructuring charges	$ (251)	$ (128)	$ (142)	$ (90)	$ (227)		$ (176)		$ (266)	$ (251)	$ (309)
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	180								180
Supply Chain \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance ending	164								164
Supply Chain \| Asset Write-offs
Restructuring Reserve [Roll Forward]
Reserve balance ending	0								0
Supply Chain \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance ending	$ 16								16
Medical Devices
Restructuring Reserve [Roll Forward]
Restructuring charges						$ (190)		$ (107)	(400)
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning				242					242
Activity during the period										(25)
Restructuring charges									(611)
Cash payments									(454)
Settled non cash									(219)
Reserve balance ending					242					242
Supply Chain \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning				194					194
Activity during the period										(35)
Restructuring charges									0
Cash payments									(30)
Settled non cash									0
Reserve balance ending					194					194
Supply Chain \| Asset Write-offs
Restructuring Reserve [Roll Forward]
Reserve balance beginning				0					0
Activity during the period										0
Restructuring charges									(151)
Cash payments									0
Settled non cash									(151)
Reserve balance ending					0					0
Supply Chain \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance beginning				$ 48					48
Activity during the period										10
Restructuring charges									(460)
Cash payments									(424)
Settled non cash									$ (68)
Reserve balance ending					$ 48					48
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning								267		267
Reserve balance ending											267
Medical Devices \| Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning								229		229
Reserve balance ending											229
Medical Devices \| Asset Write-offs
Restructuring Reserve [Roll Forward]
Reserve balance beginning								0		0
Reserve balance ending											0
Medical Devices \| Other(2)
Restructuring Reserve [Roll Forward]
Reserve balance beginning								$ 38		$ 38
Reserve balance ending											$ 38